UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark one)
|
☒ |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the fiscal year ended December 31, 2020
OR
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number: 001-38318
Odonate Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
|
|
82-2493065 |
|
(State or other jurisdiction of incorporation or organization) |
|
|
|
(I.R.S. Employer Identification Number) |
3 East 28th Street, 10th Floor
New York, New York 10016
(332) 206-0935
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class |
Trading Symbol |
Name of Each Exchange on Which Registered |
|
Common Stock, $0.01 par value per share |
ODT |
Nasdaq Global Select Market |
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to the filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer |
☐ |
|
Accelerated filer |
☐ |
|
Non-accelerated filer |
☒ |
|
Smaller reporting company |
☒ |
|
|
|
|
Emerging growth company |
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes ☐ No ☒
The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Company as of June 30, 2020 was $566,422,191, based on the closing price on the Nasdaq Global Select Market reported for such date. Shares of common stock held by each officer and director and by each person who is known to own 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates of the Company. This determination of affiliate status is not necessarily a conclusive determination for other purposes.
As of February 8, 2021, there were 38,603,588 shares of common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
None.
TABLE OF CONTENTS
|
|
|
|
|
Page |
|
||
|
|
1 |
|
|
||||
|
|
|||||||
|
|
|||||||
|
Item 1. |
|
|
2 |
|
|
||
|
Item 1A. |
|
|
41 |
|
|
||
|
Item 1B. |
|
|
64 |
|
|
||
|
Item 2. |
|
|
64 |
|
|
||
|
Item 3. |
|
|
64 |
|
|
||
|
Item 4. |
|
|
64 |
|
|
||
|
|
|||||||
|
|
|||||||
|
Item 5. |
|
|
65 |
|
|
||
|
Item 6. |
|
|
65 |
|
|
||
|
Item 7. |
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
|
66 |
|
|
|
|
Item 7A. |
|
|
71 |
|
|
||
|
Item 8. |
|
|
71 |
|
|
||
|
Item 9. |
|
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure |
|
71 |
|
|
|
|
Item 9A. |
|
|
72 |
|
|
||
|
Item 9B. |
|
|
72 |
|
|
||
|
|
|||||||
|
|
|||||||
|
Item 10. |
|
|
73 |
|
|
||
|
Item 11. |
|
|
76 |
|
|
||
|
Item 12. |
|
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters |
|
82 |
|
|
|
|
Item 13. |
|
Certain Relationships and Related Transactions, and Director Independence |
|
84 |
|
|
|
|
Item 14. |
|
|
85 |
|
|
||
|
|
|||||||
|
|
|||||||
|
Item 15. |
|
|
86 |
|
|
||
|
Item 16. |
|
|
88 |
|
|
||
|
|
|
|
89 |
|
|
||
i
FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K contains forward-looking statements within the meaning of the federal securities laws. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. You can identify forward-looking statements by the use of the words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project,” “will,” “should,” “may,” “plan,” “assume” and other expressions that predict or indicate future events and trends and that do not relate to historical matters. You should not unduly rely on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, some of which are beyond our control. These risks, uncertainties and other factors may cause our actual results, performance or achievements to be materially different from the anticipated future results, performance or achievements expressed or implied by the forward-looking statements.
These forward-looking statements include, but are not limited to, statements regarding:
|
|
• |
whether results from CONTESSA will be sufficient to obtain regulatory approval to market tesetaxel; |
|
|
• |
our plans to develop and commercialize tesetaxel and any other product candidates; |
|
|
• |
our ongoing and planned clinical studies; |
|
|
• |
the relationship between earlier study results (preclinical and clinical) and later clinical study results; |
|
|
• |
the timing of and our ability to obtain regulatory approvals for tesetaxel and any other product candidates; |
|
|
• |
our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; |
|
|
• |
our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; |
|
|
• |
the rate and degree of market acceptance and clinical utility of tesetaxel and any other product candidates, if approved; |
|
|
• |
our commercialization, marketing and manufacturing capabilities and strategy; |
|
|
• |
significant competition in our industry; |
|
|
• |
our intellectual property position; |
|
|
• |
our ability to retain key members of management; |
|
|
• |
our ability to execute our growth strategy; and |
|
|
• |
our ability to maintain effective internal controls. |
These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from the anticipated future results, performance or achievements expressed or implied by any forward-looking statements, including the factors described under the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” You should evaluate all forward-looking statements made in this Annual Report on Form 10-K, including the documents we incorporate by reference, in the context of these risks, uncertainties and other factors.
We caution you that the risks, uncertainties and other factors referred to above may not contain all of the risks, uncertainties and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. All forward-looking statements in this Annual Report on Form 10-K apply only as of the date made and are expressly qualified in their entirety by the cautionary statements included in this Annual Report on Form
1
10-K. We undertake no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances.
PART I
In this Annual Report on Form 10-K, unless context requires otherwise, references to “we,” “us,” “our,” “Odonate” or the “Company” refer to Odonate Therapeutics, Inc.
Item 1. Business
Company Overview
We are a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several properties that make it unique among taxanes, including:
|
|
• |
oral administration with a low pill burden; |
|
|
• |
a long (~8-day) terminal plasma half-life (“t1/2”) in humans, enabling the maintenance of adequate drug levels with relatively infrequent dosing; |
|
|
• |
no history of hypersensitivity (allergic) reactions; and |
|
|
• |
significant activity against chemotherapy-resistant tumors. |
In patients with metastatic breast cancer (“MBC”), tesetaxel was shown to have significant, single-agent antitumor activity in two multicenter, Phase 2 studies. Tesetaxel currently is the subject of three studies in MBC, including a multinational, multicenter, randomized, Phase 3 study in patients with MBC, known as CONTESSA. Positive results of CONTESSA were presented at the 2020 San Antonio Breast Cancer Symposium (“SABCS”). We plan to submit a New Drug Application (“NDA”) for tesetaxel to the U.S. Food and Drug Administration (“FDA”) in mid-2021. Our goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
Breast Cancer and Its Treatment
Breast cancer is the most common cancer worldwide, with an estimated 2.3 million new cases diagnosed per year (World Health Organization). In Europe, an estimated 531,000 new cases are diagnosed and approximately 142,000 women will die of the disease each year, making it the leading cause of cancer death in women (World Health Organization). In the U.S., an estimated 279,000 new cases are diagnosed and approximately 42,000 women will die of the disease each year, making it the second-leading cause of cancer death in women (American Cancer Society).
2
Breast Cancer Incidence and Deaths Remain High
|
|
|
(1) World Health Organization (2) American Cancer Society |
Breast cancer typically is staged (Stage 0-IV) based on the size of the tumor, whether or not the tumor is invasive, whether or not the cancer is in the lymph nodes and whether or not the cancer has spread (metastasized) to other parts of the body beyond the breast. The prognosis for women with MBC remains poor; the 5-year survival rate for metastatic disease is about 28% (American Cancer Society), making this an area of continued, high unmet medical need. Therefore, treatment that balances efficacy, tolerability and quality of life is preferred.
Clinical Benefit Is a Balance of Efficacy, Tolerability and Quality of Life
|
|
3
Breast cancer is a heterogeneous disease comprised of several molecular subtypes, which are commonly grouped into clinical subtypes based on receptor status (Perou et al., Nature 2000;406:747-752). Receptors that are assessed in standard clinical practice include the estrogen receptor (“ER”) and progesterone receptor (“PgR”), collectively the hormone receptors (“HRs”), and human epidermal growth factor receptor 2 (“HER2”). Breast cancers generally are categorized by the presence or absence of these receptors. The most common type of breast cancer is HR positive and HER2 negative, accounting for approximately 64% of newly diagnosed cases (Howlader et al., Journal of the National Cancer Institute 2014;106(5):1-8). HER2-positive breast cancer and triple-negative breast cancer (“TNBC”), the latter of which lacks all three receptors, are less common, accounting for approximately 13% and 11% of breast cancers, respectively (Howlader et al., Journal of the National Cancer Institute 2014;106(5):1-8).
Estimated U.S. Breast Cancer Incidence by Receptor Status and
MBC Treatments by Receptor Status
|
|
|
CDK=cyclin-dependent kinase (1) Howlader et al., Journal of the National Cancer Institute 2014;106(5):1-8 (2) Caldeira et al., Oncology and Therapy 2016;4:189-197 |
Treatment of HR-Positive, HER2-Negative MBC
HR-positive, HER2-negative disease, which represents the majority of all MBC cases, remains an area of high unmet medical need. Over the past two decades, only modest survival benefits have been achieved in this patient population; hence, treatment goals emphasize controlling disease-related symptoms, minimizing toxicity and maximizing quality-of-life: “…therapeutic goals for those with advanced disease include disease control, preservation or improvement in quality of life and prolongation of survival, with symptom palliation…” (Di Leo A et al., The Breast 2015;24:321-330). Patients with HR-positive, HER2-negative disease are typically treated with endocrine therapy (with or without a CDK 4/6 inhibitor), chemotherapy or both.
Endocrine Therapy
Endocrine agents, with or without targeted agents such as a CDK 4/6 inhibitor, are preferred as initial treatment prior to chemotherapy for most patients with HR-positive, HER2-negative MBC (National Comprehensive Cancer Network). These agents, which typically are used sequentially, include aromatase inhibitors (e.g., anastrozole, exemestane and letrozole), selective ER modulators (e.g., tamoxifen) and ER downregulators (e.g., fulvestrant). As initial therapy in post-menopausal women with ER-positive, HER2-negative disease, letrozole plus the recently approved CDK 4/6 inhibitor, palbociclib, resulted in median progression-free survival (“PFS”) of 24.8 months, compared to 14.5 months with letrozole alone (Finn et al., New England Journal of Medicine 2016;375(20):1925-1936). As second-line
4
endocrine therapy in women with HR-positive, HER2-negative disease, fulvestrant plus palbociclib resulted in median PFS of 9.5 months, compared to 4.6 months with fulvestrant alone (Cristofanilli et al., The Lancet 2016;17(4):425-439). However, despite these recent advances in endocrine therapy, virtually all patients will progress and require subsequent treatment, typically with chemotherapy.
Chemotherapy
In HR-positive, HER2-negative MBC, chemotherapy generally is used following progression on endocrine therapy or in women for whom endocrine therapy is not indicated. Chemotherapy should be “…continued until progression of disease as tolerated because it modestly improves overall survival and substantially improves PFS, but this has to be balanced against toxicity and quality of life” (Partridge et al., Journal of Clinical Oncology 2014;32:3307-3329).
While endocrine therapy is most often the first-line treatment for women with HR-positive, HER2-negative MBC, a significant percentage of women receive chemotherapy as their first treatment for advanced disease. In a recent analysis of a large patient record database (n=1,272-1,640 in Europe and n=2,225-2,760 in the U.S.), chemotherapy-only regimens were given as the first therapy following a diagnosis of advanced disease 33%-35% of the time in Europe and 34%-42% of the time in the U.S. (Caldeira et al., Oncology and Therapy 2016;4:189-197). This suggests that a significant percentage of women are not indicated for endocrine therapy in the advanced setting due to: (i) a short relapse-free interval while on adjuvant endocrine therapy (endocrine resistance); (ii) rapidly progressing disease/visceral crisis; or (iii) endocrine intolerance.
There are several approved chemotherapy agents for the treatment of HER2-negative MBC. These include: paclitaxel, nab-paclitaxel and docetaxel (taxanes); capecitabine (a fluoropyrimidine); doxorubicin and epirubicin (anthracyclines); gemcitabine (a nucleoside inhibitor); ixabepilone (an epothilone; approved in the U.S.); and eribulin (a non-taxane microtubule dynamics inhibitor). The taxanes and eribulin are approved as monotherapy, capecitabine is approved as both monotherapy and combination therapy (with docetaxel), gemcitabine is approved as combination therapy only (with paclitaxel) and ixabepilone is approved in the U.S. as both monotherapy and combination therapy (with capecitabine).
While sequential monotherapy is appropriate for many patients, chemotherapy combinations are considered useful in patients with high tumor burden, rapidly progressing disease and visceral crisis (the National Comprehensive Cancer Network [“NCCN”] Guidelines for Invasive Breast Cancer [V1.2021]). No optimal sequence of chemotherapies is known, and choice of individual regimens and agents depends on physician preferences, as well as previous therapies, residual toxic effects, tumor burden and symptoms (Harbeck et al., Breast Cancer Research and Treatment 2017;161:63-72; Schwartzberg et al., Clinical Breast Cancer 2012;12:87-93). However, capecitabine, an oral chemotherapy and taxanes are the preferred first-line chemotherapy agents in HR-positive, HER2-negative MBC (Lin et al., Cancer Medicine 2016;5(2):209-220).
5
Taxanes and capecitabine are commonly used chemotherapy options in MBC.
Physician-reported Preferences for First-line Chemotherapy for
Patients with HR-Positive, HER2-Negative MBC(1)
|
|
|
Recent survey of 201 U.S. community-based oncologists (1) Lin et al., Cancer Medicine 2016;5(2):209-220 |
Taxanes
Taxanes are an established class of anticancer agents that are broadly used in various cancers, including breast cancer. Taxanes destroy cancer cells by preventing them from entering mitosis, a process of cell division, and thereby leading to apoptosis, or cell death. Taxanes are one of the most widely used classes of chemotherapy agents in both Europe and the U.S., with more than 2.8 million cycles administered in 2016 (Symphony Health Solutions 2016; IMS Health 2016).
>2.8 Million Cycles of Paclitaxel, Nab-paclitaxel and Docetaxel
Administered in 2016 in Europe and the U.S.(1)
|
|
|
(1) Symphony Health Solutions 2016; IMS Health 2016 |
6
While paclitaxel and docetaxel, the first two taxanes approved for the treatment of breast cancer, possess robust antitumor activity, they have low oral bioavailability and low solubility. Therefore, these pharmaceutical agents must be delivered intravenously, typically at an infusion center, and also are formulated with solubilizing agents that are known to cause hypersensitivity reactions. Nab-paclitaxel, a different formulation of paclitaxel that also is approved for the treatment of breast cancer, has a greatly reduced risk of hypersensitivity reactions, but must still be delivered intravenously.
Therapies that must be given intravenously at an infusion center often are associated with(1):
|
• fear of needles and complications associated with venous access; • anxiety, including institutional-triggered side effects such as nausea and vomiting; • heightened awareness of life-threatening disease presence; and • disruption of daily activities |
|
|
(1) Gornas et al., European Journal of Cancer Care 2010;19(1):131-136; Schott et al., BMC Cancer 2011;11:129 |
|
7
Capecitabine
Capecitabine is an oral chemotherapy agent that is considered a standard-of-care treatment in MBC (the NCCN Guidelines for Invasive Breast Cancer [V1.2021] indicate that capecitabine is a preferred regimen for HER2-negative disease). The approved dosing regimen for capecitabine in the treatment of MBC is 1,250 mg/m² dosed orally twice per day (for a total daily dose of 2,500 mg/m²) for 14 days of a 21-day cycle.
Capecitabine Is Administered Orally
with a Significant Pill Burden
|
|
|
(1) Illustration for patients with body surface area of 1.66-1.77 m2 (most common body surface area range) based on Xeloda (capecitabine) FDA Prescribing Information |
Tesetaxel: An Orally Administered Taxane with Improved Pharmacologic Properties
Tesetaxel is an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several properties that make it unique among taxanes, including:
|
|
• |
oral administration with a low pill burden; |
|
|
• |
a long (~8-day) t1/2 in humans, enabling the maintenance of adequate drug levels with relatively infrequent dosing; |
|
|
• |
no history of hypersensitivity (allergic) reactions; and |
|
|
• |
significant activity against chemotherapy-resistant tumors. |
8
Tesetaxel, which we believe will qualify as a New Chemical Entity (“NCE”), retains the same taxane core as the approved taxanes, but includes the addition of two novel, nitrogen-containing functional groups. Tesetaxel is chemically designed to:
|
|
• |
not be substantially effluxed by the P-glycoprotein (“P-gp”) pump, with the intent of retaining activity against chemotherapy-resistant tumor cells; |
|
|
• |
have high oral bioavailability; |
|
|
• |
have high solubility; and |
|
|
• |
have a long t1/2 in humans. |
Chemical and Pharmacologic Properties of Paclitaxel, Docetaxel and Tesetaxel
|
|
|
* The P-gp efflux pump mediates gastric absorption as well as chemotherapy resistance (1) Shanmugam et al., Drug Development and Industrial Pharmacy 2015;41(11):1864-1876 (2) McEntee et al., Veterinary and Comparative Oncology 2003;1(2):105-112 (3) At pH conditions similar to gastric fluid (4) Montaseri, Taxol: Solubility, Stability and Bioavailability 1997 (5) Bharate et al., Bioorganic & Medicinal Chemistry Letters 2015;25(7):1561-1567 (6) Tan et al., British Journal of Cancer 2014;110(11):2647-54 (7) Taxotere (docetaxel) FDA Prescribing Information (8) Pharmacokinetic data from Studies 927A-PRT001, 927E-PRT003, 927E-PRT005, 927A-PRT006 and 927E-PRT007 |
9
In patients with MBC, tesetaxel, administered orally as 2-5 capsules at a dose of 27 mg/m² on Day 1 of a 21-day cycle, was shown to have significant, single-agent antitumor activity in two multicenter, Phase 2 studies. Tesetaxel currently is the subject of three studies in MBC, including a multinational, multicenter, randomized, Phase 3 study in patients with MBC, known as CONTESSA. Positive results of CONTESSA were presented at the 2020 SABCS. We plan to submit an NDA for tesetaxel to the FDA in mid-2021. Our goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
Tesetaxel Dosing and Administration
|
|
|
GI50=concentration of drug required to inhibit growth by 50%; Q3/4W=once per week for 3 of 4 weeks; Q3W=once every 3 weeks (1) Shionoya et al., Cancer Science 2003;94(5):459-66 (2) Trock et al., Journal of the NCI 1997;89(13):917-31 (3) Tan et al., British Journal of Cancer 2014;110(11):2647-54 (4) Pharmacokinetic data from Studies 927A-PRT001, 927E-PRT003, 927E-PRT005, 927A-PRT006 and 927E-PRT007 (5) National Comprehensive Cancer Network (“NCCN”), Clinical Practice Guidelines in Oncology 2020 (6) Corticosteroid + antihistamine + H2 antagonist as per prescribing label |
10
Tesetaxel Is Administered Orally as
2-5 Capsules Once Every 3 Weeks
|
|
|
(1) Illustration for patients with body surface area of 1.57-1.75 m2 (most common body surface area range) based on CONTESSA, CONTESSA 2 and CONTESSA TRIO |
11
Nonclinical Studies
Tesetaxel has exhibited potent antitumor activity in both in vitro (in a test tube) and in vivo (in a live organism) nonclinical studies (Shionoya et al., Cancer Science 2003;94(5):459-466). Tesetaxel retains potent antitumor activity against chemotherapy-resistant tumor cells, including tumor cells over-expressing the P-gp efflux pump. A defense mechanism of tumor cells, this efflux pump functions to expel toxins, including many chemotherapy agents.
Tesetaxel has exhibited potent antitumor activity in in vitro nonclinical studies, with an overall GI50 of less than 1 nM. GI50 is a commonly used nonclinical measurement of antitumor potency; lower GI50 numbers connote higher potency (1 nM is 1/1,000th of 1 µM). In human tumor cell lines, tesetaxel largely retained antitumor cytotoxic (cell-killing) potency against taxane-resistant (P-gp positive) and other chemotherapy-resistant tumors, while paclitaxel and docetaxel lost considerable antitumor potency (Shionoya et al., Cancer Science 2003;94(5):459-466). Consistent with this finding, the uptake and accumulation of tesetaxel in both P-gp negative and P-gp positive tumor cells were greater than that of either paclitaxel or docetaxel.
Tesetaxel Retained Activity against Chemotherapy-resistant Tumors In Vitro(1)
|
|
|
(1) Shionoya et al., Cancer Science 2003;94(5):459-466 (2) The P-gp efflux pump mediates gastric absorption as well as chemotherapy resistance |
Clinical Studies
As of December 31, 2020, more than 1,200 patients have been treated with tesetaxel in 26 clinical studies. Tesetaxel was administered as monotherapy in 19 studies and in combination with other agents in 7 studies. Studies have been completed in MBC, gastric cancer, colorectal cancer, non-small cell lung cancer and other solid tumors as first-line, second-line or salvage therapy.
Study TOB203: A Phase 2 Study of Tesetaxel as First-line Chemotherapy for MBC
Study TOB203 was a multicenter, Phase 2 study in patients with HER2-negative MBC who had not been previously treated with chemotherapy for metastatic disease. Thirty-eight (38) patients with HR-positive, HER2-negative MBC were treated with tesetaxel monotherapy at a starting dose of 27 mg/m2 with the potential to escalate to 35 mg/m2 dosed orally on Day 1 of a 21-day cycle. Objective response rate (“ORR”) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 was the primary endpoint (Seidman et al., 2018 ASCO Annual Meeting).
12
Median age was 58 years (range: 36-80 years). Eighty-seven percent (87%) of patients had visceral disease, 74% of patients were previously treated with at least one endocrine therapy, 68% of patients were previously treated with neoadjuvant or adjuvant chemotherapy and 53% of patients were previously treated with a taxane-containing regimen.
Exposure and Patient Characteristics
|
|
|
|
|
ECOG=Eastern Cooperative Oncology Group |
||
In all 38 patients, the confirmed response rate was 45%. The confirmed response rate was consistent across subgroups. Forty-four percent (44%) of patients who had not been previously treated with a taxane-containing regimen achieved a confirmed response, compared to 45% of patients who were previously treated with a taxane-containing regimen. Median duration of response (“DoR”) was 10.9 months, and median PFS was 5.4 months.
Tumor Change from Baseline in Target Lesions(1)
|
|
|
(1) Nadir change based on sum of the diameters |
13
Response
|
|
|
(1) Includes one patient who was not evaluated for response |
Adverse Event Profile
The adverse event (“AE”) profile of 187 patients treated with tesetaxel monotherapy at 27 mg/m2 Q3W is shown in the following table.
AE Profile of Patients Treated with Tesetaxel Monotherapy at the Dose Used in CONTESSA
|
|
14
Ongoing Clinical Studies
Tesetaxel currently is the subject of three studies in MBC, including a multinational, multicenter, randomized, Phase 3 study in patients with MBC, known as CONTESSA.
Ongoing Clinical Studies of Tesetaxel in Patients with MBC
|
|
|
(1) Planned |
15
CONTESSA
In CONTESSA, 685 patients with HR-positive, HER2-negative MBC were randomized to be treated with either tesetaxel dosed orally at 27 mg/m² on Day 1 of a 21-day cycle plus a reduced dose of capecitabine (1,650 mg/m²/day dosed orally for 14 days of a 21-day cycle) or the approved dose of capecitabine alone (2,500 mg/m²/day dosed orally for 14 days of a 21-day cycle) (O’Shaughnessy et al., 2020 SABCS).
CONTESSA Study Design
|
|
|
BID=twice per day; PO=oral dosing |
|
|
• |
Primary endpoint |
|
|
o |
PFS as assessed by the Independent Radiologic Review Committee (the “IRC”) |
|
|
o |
90% power to detect a hazard ratio of 0.71 (median PFS difference of 2.5 months) |
|
|
• |
Secondary endpoints |
|
|
o |
Overall survival (“OS”) |
|
|
o |
ORR as assessed by the IRC (in patients with measurable disease) |
|
|
o |
Disease control rate (“DCR”) [ORR or stable disease of ≥24 weeks] as assessed by the IRC (in patients with measurable disease) |
16
Six hundred eighty-five (685) patients were enrolled in CONTESSA, including 45% in North America, 37% in Europe and 18% in Asia‑Pacific. One hundred percent (100%) of patients had been previously treated with a taxane, approximately 86% had been previously treated with an anthracycline and approximately 50% had been previously treated with a CDK 4/6 inhibitor. Approximately 80% of patients had visceral disease.
Baseline Characteristics
|
|
17
CONTESSA met the primary endpoint of improved PFS as assessed by the IRC. Median PFS was 9.8 months for tesetaxel plus a reduced dose of capecitabine versus 6.9 months for the approved dose of capecitabine alone, an improvement of 2.9 months. The risk of disease progression or death was reduced by 28.4% [hazard ratio=0.716 (95% confidence interval [“CI”]: 0.573-0.895); p=0.003] for patients who were treated with tesetaxel plus a reduced dose of capecitabine versus patients who were treated with the approved dose of capecitabine alone.
PFS as Assessed by IRC
|
|
18
The treatment effect was similar across protocol-specified subgroups, including patients who had rapid disease recurrence following neoadjuvant or adjuvant taxane therapy, patients who had been previously treated with a CDK 4/6 inhibitor and patients in each geographic region.
PFS as Assessed by IRC by Protocol-Specified Subgroups
|
|
|
CNS=central nervous system; ROW=rest of world |
19
ORR by the IRC and DCR by the IRC were significantly higher for tesetaxel plus a reduced dose of capecitabine versus the approved dose of capecitabine alone.
Secondary Endpoints
|
|
|
|
1) In patients with measurable disease |
1) DCR=ORR or stable disease of ≥24 weeks |
While OS data are immature, a protocol-specified interim analysis indicated the absence of an adverse effect on OS for tesetaxel plus a reduced dose of capecitabine. A protocol-specified final analysis of OS is expected in 2022.
20
The most common Grade ≥3 treatment-emergent adverse events (“TEAEs”) associated with tesetaxel plus capecitabine was neutropenia. The most common Grade ≥3 TEAE associated with capecitabine alone was hand-foot syndrome. Rates of Grade ≥3 neuropathy and Grade 2 alopecia (hair loss) were low. There were no treatment-related hypersensitivity reactions.
Grade ≥3 TEAEs That Occurred in ≥5% of Patients in Either Arm
|
|
|
(1) Pooled term includes: paraesthesia, peripheral sensory neuropathy, polyneuropathy, neuropathy peripheral and peripheral motor neuropathy for all tables Note: Safety population includes 674 patients who were randomized and treated |
21
Treatment discontinuation due to any AE occurred in 23.1% of patients treated with tesetaxel plus capecitabine versus 11.9% of patients treated with capecitabine alone.
AEs Resulting in Treatment Discontinuation in ≥1% of Patients in Either Arm
|
|
|
(1) Includes 1.8% (6 patients) treatment-related deaths (5 sepsis, 1 cardiorespiratory arrest) in the tesetaxel plus capecitabine arm and 0.9% (3 patients) treatment-related deaths (2 septic shock, 1 colitis) in the capecitabine alone arm Note: Patients may have discontinued treatment for multiple AEs. One patient discontinued treatment for both febrile neutropenia and sepsis in the tesetaxel plus capecitabine arm and one patient discontinued treatment for both diarrhea and febrile neutropenia in the capecitabine alone arm. Note: Safety population includes 674 patients who were randomized and treated |
22
The median relative delivered dose intensity, which accounts for dose reductions (both frequency and magnitude), dose delays and treatment adherence, was higher in patients treated with tesetaxel plus capecitabine.
Relative Delivered Dose Intensity
|
|
|
G-CSF=granulocyte colony-stimulating factor (1) G-CSF allowed only after occurrence of Grade ≥3 neutropenia or febrile neutropenia and only on capecitabine off days |
23
CONTESSA 2
In CONTESSA 2, 150 patients with HR-positive, HER2-negative MBC not previously treated with a taxane were enrolled and treated with tesetaxel dosed orally at 27 mg/m2 on Day 1 of a 21-day cycle plus a reduced dose of capecitabine (1,650 mg/m2/day dosed orally for 14 days of a 21-day cycle). Capecitabine is an oral chemotherapy agent that is considered a standard-of-care treatment in MBC. Where indicated, patients must have been treated with endocrine therapy with or without a CDK 4/6 inhibitor. The primary endpoint is ORR as assessed by the IRC. The secondary efficacy endpoints are DoR as assessed by the IRC, PFS as assessed by the IRC, DCR as assessed by the IRC and OS. Enrollment was complete in August 2020, and the study is ongoing.
CONTESSA 2 Study Design
|
|
|
PK=pharmacokinetic |
24
CONTESSA TRIO
CONTESSA TRIO is a multi-cohort, multicenter, Phase 2 study of tesetaxel, an investigational, orally administered taxane, in patients with MBC.
|
|
• |
In Cohort 1, approximately 200 patients with triple-negative MBC who have not been treated with prior chemotherapy for advanced disease will be randomized 1:1:1 to be treated with tesetaxel dosed orally at 27 mg/m2 on Day 1 of a 21-day cycle plus either: (i) nivolumab at 360 mg by intravenous (“IV”) infusion on Day 1 of a 21-day cycle; (ii) pembrolizumab at 200 mg by IV infusion on Day 1 of a 21-day cycle; or (iii) atezolizumab at 1,200 mg by IV infusion on Day 1 of a 21-day cycle. Nivolumab and pembrolizumab (programmed cell death protein 1 [“PD-1”] inhibitors) and atezolizumab (a programmed death-ligand 1 [“PD-L1”] inhibitor) are immuno-oncology (“IO”) agents approved for the treatment of multiple types of cancer. Two of these agents, atezolizumab and pembrolizumab, have been approved by the FDA as a first-line treatment for patients with triple-negative MBC. The primary endpoints for Cohort 1 are ORR and PFS in patients with PD-L1 positive status. The secondary endpoints are ORR and PFS in all patients, DoR and OS. Efficacy results for each of the three PD-(L)1 inhibitor combinations will be assessed for correlation with the results of each of the three approved PD-L1 diagnostic assays. Enrollment is ongoing. |
CONTESSA TRIO Study Design: Cohort 1
|
|
25
|
|
• |
In Cohort 2, 69 elderly patients with HER2-negative MBC who had not been treated with prior chemotherapy for advanced disease were enrolled and treated with tesetaxel monotherapy dosed orally at 27 mg/m2 on Day 1 of a 21-day cycle. The primary endpoints for Cohort 2 are ORR and PFS in patients with HR-positive, HER2-negative disease. The secondary endpoints are ORR and PFS in patients with triple-negative disease, DoR and OS. Enrollment was complete in November 2020, and the study is ongoing. |
CONTESSA TRIO Study Design: Cohort 2
|
|
|
|
• |
In Cohort 3, approximately 60 non-elderly adult patients with HER2-negative MBC who have not been treated with prior chemotherapy for advanced disease will be treated with tesetaxel monotherapy dosed orally at 27 mg/m2 on Day 1 of a 21-day cycle. The primary endpoints for Cohort 3 are ORR and PFS in patients with HR-positive, HER2-negative disease. The secondary endpoints are ORR and PFS in patients with triple-negative disease, DoR and OS. Enrollment is ongoing. |
CONTESSA TRIO Study Design: Cohort 3
|
|
26
Competition
The biotechnology and pharmaceutical industries are extremely competitive. Our potential competitors in the field are many in number and include major and mid-sized pharmaceutical and biotechnology companies. Many of our potential competitors have significantly more financial, technical and other resources than we do, which may give them a competitive advantage. In addition, they may have substantially more experience in effecting strategic combinations, in-licensing technology, developing drugs, obtaining regulatory approvals and manufacturing and marketing products. We cannot give any assurances that we can compete effectively with these other biotechnology and pharmaceutical companies. Any products that we may develop or discover will compete in highly competitive markets. Our potential competitors in these markets may succeed in developing products that could render our product candidates obsolete or non-competitive.
Tesetaxel faces significant competition. Multiple chemotherapies are currently available to physicians and patients for the treatment of HR-positive, HER2-negative MBC. These include: paclitaxel, nab-paclitaxel and docetaxel (taxanes); capecitabine (a fluoropyrimidine); doxorubicin and epirubicin (anthracyclines); gemcitabine (a nucleoside inhibitor); and eribulin (a non-taxane microtubule dynamics inhibitor). The taxanes and eribulin are approved as monotherapy, capecitabine is approved as both monotherapy and combination therapy (with docetaxel) and gemcitabine is approved as combination therapy only (with paclitaxel). In addition, there are novel oral paclitaxel formulations in development, such as Athenex, Inc.’s Oral Paclitaxel and Daehwa Pharmaceutical Co., Ltd.’s DHP107. We believe that the extent to which tesetaxel is adopted by the marketplace, if it is approved, will depend on factors such as its safety and tolerability, efficacy, convenience, effect on quality-of-life and cost-effectiveness relative to other treatment alternatives.
Daiichi Sankyo License Agreement
In 2013, we licensed rights to tesetaxel in all major markets from Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), the original inventor of the product. Tesetaxel had previously been licensed to Genta Incorporated.
Under the Daiichi Sankyo license agreement, we currently hold exclusive rights to 15 issued patents worldwide covering our tesetaxel program. See “Business—Patents and Proprietary Rights.” We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize tesetaxel in the following countries: France, Germany, Italy, Spain, the United Kingdom and the U.S. We are required to make aggregate future milestone payments of up to $31.0 million, contingent on attainment of certain regulatory milestones, none of which have been achieved. Additionally, we are obligated to pay Daiichi Sankyo a tiered royalty that ranges from the low to high single digits, depending on annual net sales of tesetaxel. To date, no payments have been made to Daiichi Sankyo under the license agreement. The license agreement and accompanying royalty obligation terminate on a country-by-country basis on the last-to-expire patent in each such country, which we expect will be between 2026 and 2031 in the U.S., 2025 and 2030 in European countries and 2025 and 2030 in Japan, depending on the availability and application of patent term extensions.
NCE Exclusivity
We believe that tesetaxel will qualify as an NCE. If tesetaxel qualifies as an NCE, NCE market exclusivity and analogous regulatory exclusivities in Europe and Japan will provide exclusivity for tesetaxel in the U.S., Europe and Japan for specified periods of time. Separate from patent protection, exclusivity refers to certain delays and prohibitions on approval of competitor drugs available under the statute that attach on approval of a drug.
Exclusivity in the U.S.
In the U.S., NCEs approved by the FDA are eligible for market exclusivity under the Federal Food, Drug, and Cosmetic Act (“FDCA”), which can delay the approval of generic versions of the NCE by up to
27
7.5 years from the date of the initial approval of the NCE. Specifically, the FDCA provides a 5-year period of non-patent marketing exclusivity within the U.S. to the first applicant to gain approval of an NDA for an NCE. An NCE is a drug that contains no active moiety that has been approved by the FDA in any other full NDA or 505(b)(2) NDA. An active moiety is the molecule or ion (excluding those appended portions of the molecule that cause the drug to be an ester, salt or other noncovalent derivative of the molecule) responsible for the action of the drug substance. During the first 4 years of the 5-year market exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2) NDA that relies on the original NDA as a reference. At the end of four years of market exclusivity, an ANDA or 505(b)(2) NDA may be submitted to the FDA if it contains a “paragraph IV” certification, which refers to a certification of invalidity or non-infringement of a patent that covers the reference NCE drug or its approved use and is listed in the FDA’s publication of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book. The ANDA or 505(b)(2) applicant must notify each patent holder and the NDA holder of the “paragraph IV” certification within 20 days after the postmark on the FDA letter acknowledging receipt of the ANDA. If the patented drug product is an NCE and a patent holder or its representative or an exclusive patent licensee brings suit for patent infringement within 45 days after receipt of the notice of a “paragraph IV” certification, market exclusivity for the patented drug may extend to 7.5 years from the date of approval of the NDA for the patented drug product. The period of market exclusivity may be shortened if a court enters a judgment, settlement order or consent decree stating that the patent has been infringed, is invalid or is unenforceable before the end of the 7.5 years, at which time the ANDA or 505(b)(2) NDA may be approved.
NCE market exclusivity will not preclude the submission or approval of a full NDA for the same or similar drug. An applicant submitting a full NDA for the same drug as the NCE drug would be required to conduct or sponsor nonclinical studies and adequate and well-controlled clinical studies, or obtain a right of reference to data from such studies conducted or owned by a third party, necessary to demonstrate the safety and effectiveness of the drug for its intended use and meet all other criteria for marketing approval.
Exclusivity in Europe
In Europe, new active substances qualify for 8 years of data exclusivity upon marketing authorization and an additional two years of market exclusivity, for a total of 10 years of regulatory exclusivity. This exclusivity, if granted, prevents regulatory authorities in the EU from referring to the innovator’s data to assess a generic application for 8 years, after which generic marketing authorization can be submitted, and the innovator’s data may be referenced, but the generic product may not be approved for two years. This 10-year period can be extended to a maximum of 11 years if, during the first 8 years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications that, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.
However, even if a compound is considered to be a new active substance and the sponsor is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the drug if such company can complete a full Marketing Authorization Application with a complete database of pharmaceutical tests, nonclinical studies and clinical studies and obtain marketing approval of its product.
Exclusivity in Japan
In Japan, new active substances are eligible for at least 8 years of regulatory exclusivity. Specifically, under the Pharmaceutical Affairs Law, the regulatory authority re-examines the safety and efficacy of drugs after drug approval. The data submitted to the regulatory authority is not available to generic drug companies during the re-examination period. This effectively makes the re-examination system a regulatory exclusivity system in Japan. The re-examination period is 10 years following approval for an orphan drug and 8 years for a new active substance. Innovators may also benefit from an additional 4- to 10-month waiting period for generic pricing approval. There may be an additional 4 years of market protection granted if a new indication for a drug is registered in the first 8 years of the re-examination period.
28
Patents and Proprietary Rights
The proprietary nature of, and protection for, our product candidates, processes and know-how are important to our business. Our success depends in part on our ability to protect the proprietary nature of our product candidates, processes and know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. We seek and maintain patent protection in the U.S. and internationally for our product candidates and other technology. We endeavor to patent or in-license technology, inventions and improvements that we consider important to the development of our business. In addition to patent protection, we intend to use other means to protect our proprietary rights, including pursuing periods of marketing or data exclusivity, orphan drug status (if applicable) and similar rights that are available under regulatory provisions in certain jurisdictions, including the U.S., Europe and Japan. We also rely on trade secrets, know-how and continuing innovation to develop and maintain our competitive position.
The intellectual property portfolio protecting our tesetaxel program includes 8 U.S., 4 European and 5 Japanese patents, as well as 2 pending international patent applications, 1 pending U.S. patent application, 1 pending European patent application and 1 pending Japanese patent application. Of these, 4 U.S., 3 European and 3 Japanese patents are exclusively licensed to us by Daiichi Sankyo. The 17 issued patents consist of the following:
|
|
• |
Eight (8) U.S. patents, including: (i) 1 composition-of-matter patent expiring in 2026, without taking into account any potential patent term restoration; (ii) 5 patents with claims to manufacturing methods and/or manufacturing intermediates expiring between 2023 and 2032, without taking into account any potential patent term restoration; and (iii) 2 patents with composition-of-matter, method of manufacture and/or method of use claims relating to alternate salt forms of tesetaxel expiring in 2031, without taking into account any potential patent term restoration. |
|
|
• |
Four (4) European patents, including: (i) 1 composition-of-matter patent expiring in 2022, without taking into account any potential patent term restoration; and (ii) 3 patents with claims to manufacturing methods and/or manufacturing intermediates expiring in 2022, 2025 and 2031, without taking into account any potential patent term restoration. |
|
|
• |
Five (5) Japanese patents, including: (i) 1 composition-of-matter patent expiring in 2022, without taking into account any potential patent term restoration; and (ii) 4 patents with claims to manufacturing methods and/or manufacturing intermediates expiring in 2022, 2025, 2025 and 2031, without taking into account any potential patent term restoration. |
Among these patents, one issued U.S. composition-of-matter patent (U.S. Patent No. 7,410,980) covers the crystal form of tesetaxel used in our clinical formulation and will expire in 2026. If tesetaxel is approved by the FDA, we will be entitled to request patent term restoration that could extend the protection of this patent into 2031. The exact duration of the extension depends on the time we spend in clinical studies as well as the time the FDA spends reviewing our NDA. See “Business—Government Regulation—U.S. Patent Term Restoration.” We do not anticipate that the European and Japanese patents that correspond to this U.S. patent will receive corresponding patent term restorations.
Our success depends on an intellectual property portfolio that will support our future revenue streams. We intend to maintain and build our patent portfolio through filing new patent applications and prosecuting existing applications. We cannot be certain that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications that we may file in the future, nor can we be sure that any of our existing patents or any patents granted to us in the future will be commercially useful in protecting our technology. Any of our intellectual property and proprietary rights could be challenged, invalidated, circumvented, infringed or misappropriated, or such intellectual property and proprietary rights may not be sufficient to permit us to take advantage of current market trends or otherwise to provide competitive advantages. For more information, see “Risk Factors—Risks Relating to Intellectual Property.”
29
Manufacturing
We currently contract with third-party contract development and manufacturing organizations (“CDMOs”) for the manufacture of tesetaxel and intend to do so in the future. We do not own or operate manufacturing facilities and currently have no plans to build our own clinical- or commercial-scale manufacturing capabilities. Although we rely on CDMOs, we have personnel with extensive manufacturing experience to oversee these contract service providers.
We conduct our manufacturing activities under individual purchase orders with multiple CDMOs. To date, our third-party manufacturers have met our manufacturing requirements. We expect third-party manufacturers to be capable of providing sufficient quantities of tesetaxel to meet anticipated full-scale commercial demands. To meet our projected needs for commercial manufacturing, third parties with whom we currently work with might need to increase their scale of production, or we will need to secure alternate suppliers. We believe that there are alternate sources of supply that can satisfy our anticipated clinical and commercial requirements, although we cannot be certain that identifying and establishing relationships with such sources, if necessary, would not result in significant delay or material additional costs.
Sales and Marketing
In order to commercialize tesetaxel, if approved, or any other product candidates that we may develop, we must build marketing, sales and distribution capabilities or make arrangements with third parties to perform these services. The commercial infrastructure for oncology products typically consists of a sales force that calls on oncologists, supported by sales management, medical liaisons, internal sales and marketing support and distribution support.
Additional capabilities important to the oncology marketplace include the management of key accounts such as managed care organizations, integrated delivery networks, group-purchasing organizations, specialty pharmacies and government accounts. To develop the appropriate commercial infrastructure, we will have to invest significant amounts of financial and management resources, some of which will be committed prior to any confirmation that any of our product candidates will be approved.
Where appropriate, we may elect in the future to utilize marketing partners, distributors or contract sales forces to assist in the commercialization of tesetaxel.
Government Regulation
Governmental authorities in the U.S., Europe, Japan and other countries where we may seek approval to commercialize tesetaxel extensively regulate the research, development, testing, manufacture, approval and marketing of pharmaceutical products. Our product candidates must be approved by these regulatory authorities before they may be legally marketed in the applicable jurisdictions. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Below is a general summary of applicable government regulations affecting our current and planned business activities in the U.S., Europe and Japan.
U.S. Government Regulation
In the U.S., the FDA regulates drugs under the FDCA and its implementing regulations. Failure to comply with the applicable U.S. requirements at any time during the product development or approval process, or after approval, may subject an applicant to administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions could include:
|
|
• |
refusal to approve pending applications; |
|
|
• |
withdrawal of an approval; |
30
|
|
• |
imposition of a clinical hold; |
|
|
• |
warning or untitled letters; |
|
|
• |
seizures or administrative detention of product; |
|
|
• |
total or partial suspension of production or distribution; |
|
|
• |
injunctions, fines, restitution, disgorgement, refusal of government contracts or civil or criminal penalties; or |
|
|
• |
criminal prosecution. |
U.S. Drug Approval Process
The process required by the FDA before a pharmaceutical product may be marketed in the U.S. generally involves the following:
|
|
• |
completion of extensive nonclinical laboratory tests, in vivo nonclinical studies and formulation studies conducted according to Good Laboratory Practices and other applicable regulations; |
|
|
• |
submission to the FDA of an investigational new drug (“IND”) application, which must become effective before human clinical studies may begin; |
|
|
• |
performance of adequate and well-controlled human clinical studies according to current Good Clinical Practices (“cGCPs”) and other applicable regulations to establish the safety and efficacy of the product candidate for its intended use; |
|
|
• |
submission to the FDA of an NDA or other applications for approval; |
|
|
• |
satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities to assess compliance with current Good Manufacturing Practices (“cGMPs”) and conformance with the manufacturing-related elements of the application to assure consistent production of the product within required specifications; |
|
|
• |
potential FDA audit of the study sites that generated the data in support of the NDA; |
|
|
• |
FDA review and approval of the NDA; and |
|
|
• |
compliance with any post-approval requirements, such as post-approval studies required by the FDA. |
Once a pharmaceutical candidate is identified for development, it enters the nonclinical testing stage. Nonclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the nonclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. The IND will also include a protocol detailing the objectives of the clinical study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated.
All clinical studies must be conducted under the supervision of one or more qualified investigators in accordance with FDA requirements. An institutional review board (“IRB”) must review and approve the protocol and will monitor the study until completion. Clinical studies must be conducted under protocols detailing the objectives of the study, dosing procedures, research subject selection, inclusion and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol, and any material amendments to the protocol, must be submitted to the FDA as part of the IND, and sponsors must report to the FDA serious and unexpected adverse reactions in a timely manner. Sponsors also must make certain financial disclosures to the FDA regarding any financial relationships with study investigators.
Human clinical studies are typically conducted in three sequential phases that may overlap or be combined.
31
|
|
• |
Phase 1—The product candidate is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and elimination. Initial human testing is often conducted in patients for product candidates intended to treat severe or life-threatening diseases, such as cancer, especially when the product candidate may be inherently too toxic to ethically administer to healthy volunteers. |
|
|
• |
Phase 2—Clinical studies are performed on a limited patient population intended to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. |
|
|
• |
Phase 3—Clinical studies are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the product and provide an adequate basis for product approval and labeling. A pivotal study is a clinical study that is intended to meet regulatory authority requirements for the evaluation of a product candidate’s efficacy and safety such that it can be used to justify the approval of the product. In certain instances, the FDA may require the completion of post-approval studies, sometimes referred to as Phase 4 studies, which are conducted after initial regulatory approval to collect additional information from the treatment of patients for the intended indication or to meet other regulatory requirements. |
Human clinical studies are inherently uncertain, and Phase 1, Phase 2, Phase 3 or post-approval studies may not be successfully completed or may not be completed at all. The FDA or the sponsor may suspend a clinical study at any time for a variety of reasons, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical study if the clinical study is not being conducted in accordance with the IRB’s requirements or if the product candidate has been associated with unexpected serious harm to patients.
The results of product development, nonclinical studies and clinical studies, along with descriptions of the manufacturing process, analytical tests and other control mechanisms, direction for use, proposed labeling, patent information and other relevant information, are submitted to the FDA as part of an NDA requesting approval to market the product. Within 60 days following submission of the application, the FDA reviews the NDA to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to accept any NDA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. Once the submission is accepted for filing, the FDA begins an in-depth, substantive review of the NDA, which includes an assessment of the nonclinical and clinical data, the product’s formulation and manufacturing and whether the product is safe and effective for the proposed intended use. The FDA’s review goal for NDAs for new molecular entities is 10 months from the date the application is accepted for filing for a standard review and 6 months from the date the application is accepted for filing for a priority review. The FDA does not always meet these goal dates for standard and priority review NDAs, and the review process can be significantly extended by requests from the FDA for additional information or clarification.
Under the Prescription Drug User Fee Act, each NDA must be accompanied by a user fee, which for Fiscal Year 2021 runs at approximately $2.88 million for NDAs requiring clinical trials, as well as a program fee for prescription human drugs of approximately $336,000. Fee waivers or reductions are available, such as for the first application by a small business or for certain products designated as Orphan Drugs under the Orphan Drug Act.
FDA Expedited Review and Approval
The FDA has various programs, including fast-track designation, breakthrough therapy designation, accelerated approval and priority review, each of which are intended to facilitate and expedite the development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening conditions. Different qualifying criteria apply to each program, and each program offers different mechanisms to expedite the development or approval process, such as additional opportunities to meet with the FDA regarding the product candidate’s clinical development program, the opportunity for
32
rolling review of a marketing application, approval based on a surrogate endpoint or, in the case of priority review, a shorter timeline for reviewing a marketing application. We may seek to take advantage of one or more of these expedited programs for tesetaxel or other product candidates in the future. However, even if a product candidate qualifies for one or more of these programs, the development or approval of the product candidate may not be shortened. The FDA may also later determine that a product candidate no longer meets the criteria for designation, and designation does not guarantee that the FDA will ultimately approve the product.
U.S. Patent Term Restoration
Depending on the timing, duration and specifics of FDA approval of the use of our product candidates, one of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to 5 years as compensation for patent term lost during product development and the FDA regulatory review process, provided the patent term restoration does not extend the remaining term of a patent beyond a total of 14 years from the product’s approval date. In the future, if available, we intend to apply for an extension of patent term for one of our currently owned patents beyond its current expiration date; however, there can be no assurance that any such extension will be granted to us.
U.S. Post-Approval Requirements
Once an approval is granted, the FDA may withdraw the approval for various reasons, such as non-compliance with regulatory requirements or significant safety and performance problems with the product. Later discovery of previously unknown problems with a product may result in recalls or restrictions on the product or even complete withdrawal of the product from the market. Holders of an approved NDA are required to report certain adverse reactions to the FDA and maintain pharmacovigilance programs to proactively look for these adverse events. Manufacturers are also required to comply with restrictions on the advertising and promotion of their products, including restrictions on “off-label” promotion for uses outside those described in the approved product labeling.
In addition, after a product candidate has been approved, the FDA may require that certain additional post-approval requirements be satisfied, including the conduct of additional clinical studies. Certain changes to an approved product, such as adding new indications, making certain manufacturing changes or making certain additional labeling claims are subject to further FDA review and approval. Before a company can market products for additional indications, it must obtain approval from the FDA of a new NDA or NDA supplement, which generally requires that additional clinical studies be conducted. A company cannot be sure that any additional approval for new indications for any product candidate will be approved on a timely basis, or at all.
Changes to the manufacturing process for a given drug are strictly regulated and, depending on the significance of the change, may require FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting and documentation requirements on us and any third-party manufacturers we use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance and are subject to periodic or for-cause inspection by the FDA and other regulatory authorities to ensure such compliance.
U.S. Reimbursement and Pricing
Significant uncertainty exists as to the coverage and reimbursement status of tesetaxel and any other products for which we may seek regulatory approval. Sales in the U.S. will depend in part on the availability of adequate financial coverage and reimbursement from third-party payors, which include government health programs such as Medicare, Medicaid, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our product candidates can be subject to challenge, reduction or denial by payors.
33
The process for determining whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list or formulary, which might not include all of the FDA-approved products for a particular indication. Also, third-party payors may refuse to include a particular branded drug on their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available. Medicare Part D, Medicare’s outpatient prescription drug benefit, contains protections to ensure coverage and reimbursement for oral oncology products, and all Part D prescription drug plans are required to cover substantially all oral anti-cancer agents. However, a payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be available.
Private payors often rely on the lead of the governmental payors in rendering coverage and reimbursement determinations. Sales of our product candidates will therefore depend substantially on the extent to which the costs of our products will be paid by third-party payors. Achieving favorable coverage and reimbursement from the Centers for Medicare and Medicaid Services (“CMS”) and/or the Medicare Administrative Contractors is typically a significant gating issue for successful introduction of a new product.
Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended to obtain regulatory approvals. Third-party payors may not consider our product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development.
U.S. Healthcare Fraud and Abuse Laws and Compliance Requirements
We are subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales and marketing programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:
|
|
• |
The federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. The term “remuneration” has been broadly interpreted to include anything of value, including for example gifts, cash payments, donations, the furnishing of supplies or equipment, waivers of payment, ownership interests, and providing any item, service or compensation for something other than fair market value. Federal false claims and civil monetary penalties laws, including the federal civil False Claims Act, which prohibits anyone from, among other things, knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services that are false or fraudulent. Although we may not submit claims directly to payors, manufacturers can be held liable under these laws in a variety of ways. These include: providing inaccurate billing or coding information to customers, improperly promoting a product’s off-label use, violating the Anti-Kickback Statute or misreporting pricing information to government programs. |
|
|
• |
Provisions of the federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which created new federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program or making false statements in connection with the delivery of or payment for healthcare benefits, items or services. |
34
|
|
• |
The federal Physician Payment Sunshine Act requirements, under the Patient Protection and Affordable Care Act, which require manufacturers of certain drugs and biologics to track and report to CMS payments and other transfers of value they make to U.S. physicians and teaching hospitals as well as physician ownership and investment interests in the manufacturer. |
|
|
• |
Provisions of HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information. |
|
|
• |
Section 1927 of the Social Security Act, which requires that manufacturers of drugs and biological products covered by Medicaid report pricing information to CMS on a monthly and quarterly basis, including the best price available to any customer of the manufacturer, with certain exceptions for government programs, and pay prescription rebates to state Medicaid programs based on a statutory formula derived from reported pricing information. State law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state transparency reporting and compliance laws; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and which may not have the same effect, thus complicating compliance efforts. |
European Government Regulation
In Europe, tesetaxel and any future products we may seek to develop and commercialize will also be subject to extensive regulatory requirements. As in the U.S., medicinal products can only be marketed if a marketing authorization from the competent regulatory authorities has been obtained.
Similar to the U.S., the various phases of nonclinical and clinical research in Europe are subject to significant regulatory controls. Although the EU Clinical Trials Directive 2001/20/EC (the “Directive”) has sought to harmonize the EU clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the EU, the EU Member States have transposed and applied the provisions of the Directive differently. This has led to significant variations in the member state regimes. Under the current regime, before a clinical study can be initiated, it must be approved in each of the EU countries where the study is to be conducted by two distinct bodies: The National Competent Authority (“NCA”) and one or more Ethics Committees (“EC”). Under the current regime, all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical study have to be reported to the NCA and ECs of the Member State where they occurred.
In 2014, a new Clinical Trials Regulation 536/2014 (the “Regulation”), which will replace the current Directive, was adopted. The new Regulation will become directly applicable in all EU Member States (without national implementation) once the EU Portal and Database are fully functional. Until that time, the Directive remains in force and continues to apply to clinical studies in the EU. It is expected that the Regulation will apply in 2021, although this timing may be further delayed. The new Regulation seeks to simplify and streamline the approval of clinical studies in the EU. For example, the sponsor shall submit a single application for approval of a clinical study via the EU Portal. As part of the application process, the sponsor shall propose a reporting Member State, which will coordinate the validation and evaluation of the application. The reporting Member State shall consult and coordinate with the other concerned Member States. If an application is rejected, it can be amended and resubmitted through the EU Portal. If an approval is issued, the sponsor can start the clinical study in all concerned Member States. However, a concerned Member State can, in limited circumstances, declare an “opt-out” from an approval. In such a case, the clinical study cannot be conducted in that Member State. The Regulation also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical study results to the EU Database.
35
European Drug Approval Process
In the European Economic Area (“EEA”), which is comprised of the 27 Member States of the EU plus Norway, Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization (“MA”). There are two types of marketing authorizations:
|
|
• |
The Centralized (or Community) MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use (“CHMP”), of the European Medicines Agency (“EMA”) and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of drugs, such as biotechnology medicinal drugs, orphan medicinal drugs and medicinal drugs containing a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for drugs containing a new active substance not yet authorized in the EEA, or for drugs that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. Under the Centralized Procedure in the EU, the maximum timeframe for the evaluation of a marketing authorization application is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP). Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, defined by three cumulative criteria: the seriousness of the disease (e.g., disabling or life-threatening diseases) to be treated; the absence or insufficiency of an appropriate alternative therapeutic approach; and anticipation of high therapeutic benefit. In this circumstance, EMA ensures that the opinion of the CHMP is given within 150 days, excluding clock stops. |
|
|
• |
National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for drugs not falling within the mandatory scope of the Centralized Procedure. Where a drug has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member States through the Mutual Recognition Procedure. If the drug has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure, an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State (“RMS”). Within 120 days after receipt of a valid application, the competent authority of the RMS prepares a draft assessment report, a draft summary of the drug characteristics (“SmPC”) and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Concerned Member States) for their approval. Within 90 days of receiving the reference member state’s assessment report and related materials, each concerned member state must decide whether to approve the assessment report and related materials. If the Concerned Member States raise no objections, based on a potential serious risk to public health, to the assessment, SmPC, labeling or packaging proposed by the RMS, the drug is subsequently granted a national MA in all the Member States (i.e., in the RMS and the Concerned Member States). |
Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the drug on the basis of scientific criteria concerning its quality, safety and efficacy.
Patent Term Extension in Europe
Similar to the patent term extensions available in the U.S., European patent law offers the possibility to apply for a supplementary protection certificate (“SPC”) in order to compensate patent holders for the regulatory delays caused by marketing authorization procedures for medicinal products. SPCs extend the patent term for a period that is equal to the time that elapsed between the filing date of the patent application and the date of the first marketing authorization in the EU, minus 5 years. The overall term of an SPC may not exceed 5 years. An SPC may afford a maximum patent duration of 25 years or, when calculated from the date of first marketing approval, an effective patent exclusivity period of 15 years after
36
first marketing authorization. Applications for SPCs must be filed and approved on a country-by-country basis.
Pharmaceutical Coverage, Reimbursement and Pricing in Europe
In Europe, similar political, economic and regulatory developments may affect our ability to profitably commercialize tesetaxel or any other products, if approved. European countries vary significantly in their approach to coverage, reimbursement and pricing assessments. Some countries allow drug products to be marketed only after a reimbursement price has been agreed to. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular drug candidate to currently available therapies, or so-called health technology assessments, in order to obtain reimbursement or pricing approval. The considerations in each country can also vary with respect to the value placed on unmet need, generic availability, dosing, administration, level of innovation and many other dynamics. In certain cases, these decisions are made sequentially and are often interdependent. Many also have multi-layered, decision-making bodies at the country, regional, local and even hospital level, with various responsibilities within the process.
For example, the United Kingdom typically bases reimbursement decision on a determination of cost effectiveness as defined by cost per quality-adjusted life year (“QALY”), as assessed by National Institute for Health and Care Excellence (“NICE”). Funding by the National Health Service is typically granted on an incremental cost-effectiveness ratio (“ICER”) of £30,000 or less per QALY. Unlike other countries, the United Kingdom does have a specific process for cancer therapies that do not gain NICE recommendation initially. Cancer therapies can enter into a conditional reimbursement agreement for no more than two years funded by the Cancer Drug Fund while clinical value continues to be assessed in order to inform the final guidance. At the end of this two-year period, recommendation may be granted for permanent reimbursement on fulfillment of the evidence commitment by the manufacturer.
Similarly, Germany also makes reimbursement decisions based on the determination of additional benefit. Unlike the ICER approach, an efficiency frontier of the total cost and total benefit of all available agents is employed as a cost-benefit methodology. Newly approved agents are compared in terms of cost-benefit ratio either against alternatives or within a specific indication.
France has its own system of therapeutic index to assess medicines for reimbursement and pricing. Reimbursement is determined through a Service Médical Rendu rating of clinical benefit (low, moderate, substantial), with the exception of hospital-only drugs that may be reimbursed at 100%. Pricing is negotiated based on an Amélioration du Service Médical Rendu rating of therapeutic improvement compared to available alternatives (negative (VI), no improvement (V), minor (IV), moderate (III), substantial (II), major (I)).
It is possible that we may be required to conduct cost-effectiveness studies of our product candidates relative to other available therapies in certain countries. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our financial results may suffer.
Japanese Government Regulation
Tesetaxel and any future products we may seek to develop and commercialize will also be subject to extensive regulatory requirements in Japan. As in the U.S., medicinal products can only be marketed if a marketing authorization from the competent regulatory authorities has been obtained. In Japan, the Ministry of Health, Labor and Welfare (“MHLW”) oversees the regulation and safety of pharmaceuticals, medical devices, cosmetics and food and is the organizational body responsible for approving or rejecting an NDA. Within MHLW, the Pharmaceuticals and Medical Devices Agency (“PMDA”) oversees regulatory affairs for drugs and medical devices and is the body responsible for regulatory review of NDAs.
37
Japanese Drug Approval Process
The drug approval process in Japan involves a series of activities, including nonclinical and clinical (Phase 1, 2 and 3) studies, bridging studies, submission of an NDA by the manufacturer and review of the NDA by the PMDA. MHLW and PMDA are the main regulatory authorities regulating clinical studies. To conduct a clinical study, a pharmaceutical company must register a protocol with MHLW. Prior to submitting a protocol to the MHLW, an applicant usually submits a Clinical Trial Notification to the PMDA. All documents must be translated into Japanese. The notification mainly consists of a description and product summary, nonclinical data, the clinical study protocol, analysis plan, SOPs, contact person and the names of participating research institution(s). Also, compliance with cGCPs often requires an IRB to review the clinical study protocol, provide written informed consent forms for participants and report adverse events.
In order to obtain marketing approval, an applicant must submit an NDA for drug marketing authorization to the PMDA for review. Once the PMDA has received the NDA, a team of reviewers evaluates the application data, including quality, pharmacology, pharmacokinetics, toxicology, clinical implications, biostatistics and cGCP on-site inspection. During the review process, the reviewers exchange opinions with external experts (expert meetings) to discuss important problems. A general review conference attended by team members, external experts and representatives of the applicant is held after the expert meeting. After the review, the PMDA makes a recommendation and sends the application to the MHLW. MHLW then obtains a recommendation from the Pharmaceutical Affairs and Food Sanitation Council before making a decision regarding approval or rejection of the application.
When data from clinical studies performed in foreign countries are used for an NDA in Japan, the data are first checked to assure that it complies with legal requirements in Japan. Following the legal assessment, an evaluation to determine whether or not the drug is apt to be affected by ethnic factors (intrinsic or extrinsic factors) is conducted. When necessary, a bridging study in Japanese patients is performed, and, when it is concluded that the clinical study outcome in a foreign population can be extrapolated to the Japanese population, the foreign data can be accepted. It is mandatory to conduct pharmacokinetic studies in Japanese people.
Drug approval reviews are normally processed in the order in which the application forms are received. However, orphan drugs and other drugs considered to be especially important from a medical standpoint, such as new drugs to treat serious diseases, may be designated for priority review.
Products for priority review are given priority at each stage of the review process as much as possible. For example, for products designated for priority review at the development stage, it is possible to obtain priority interview advice on indications and other items concerning the designated product. The target review period for priority review is 9 months, compared to 12 months for standard reviews.
Patent-term Extension in Japan
The term of a patent that covers an approved drug may be extended for the shorter of 5 years or the period during which the patent could not be exploited due to obtaining regulatory approval. This period is calculated from the later of the patent registration date (grant date) or the clinical study start date to the regulatory approval date. Unlike in the U.S., patent-term extension in Japan can be applied to more than one patent.
Pharmaceutical Coverage, Reimbursement and Pricing in Japan
In Japan, there is significant uncertainty as to the reimbursement and pricing status of tesetaxel and any other products for which we may seek regulatory approval. Japanese pricing of prescription pharmaceuticals is subject to tight government control. Drug prices are set both according to standardized formulas and through negotiations between government officials and applicant companies on a product-by-product basis. In those negotiations, the level of innovation, usefulness and marketability
38
are important determinants of price. With few exceptions, the Japanese MHLW sets the reimbursement prices for all newly launched prescription drugs in Japan.
There are currently three main pricing methodologies, which are dependent on the number of similar products available. The Cost Calculation Method applies to first-to-market products and is based on manufacturer cost inputs as well as international reference markets. Comparison Method I applies to products with less than three non-generic competitors and allows for premiums based on innovation, usefulness and marketability among others, plus an adjustment to international reference markets. Comparison Method II is reserved for products with three or more non-generic competitors and anchors price to the lowest competitor in the basket, with only downward adjustments possible to the international reference markets. Over 80% of products in Japan are priced through Comparison Method I.
In order to control the proportion of the country’s total healthcare expenditure that is devoted to drugs, the government mandates revisions in the prices of all prescription drugs every two years. However, pricing reform introduced in 2016 may have an impact on the commercial landscape in future years. There are three main changes in discussion, including annual pricing reviews, the addition of a cost-effectiveness analysis and the “huge sellers” provision to reduce budget risk for expensive drugs with significant budget impact. These went into effect in 2018, with additional proposals under consideration for later roll out, including annual reference pricing, indication expansion discounts and optimal use guidelines. These changes may impact the timeline for pricing negotiations as well as the result of these negotiations. The adoption of more restrictive pricing and reimbursement policies along with existing controls could limit our commercial revenue in the Japanese market.
Rest of the World Regulation
For other countries outside of the U.S., EU and Japan, such as Eastern Europe, Latin America, Asia and emerging markets, the requirements governing the conduct of clinical studies, drug licensing, pricing and reimbursement vary from country to country. In all cases, clinical studies must be conducted in accordance with cGCPs and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.
Implications of Being an Emerging Growth Company
We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under this act, an emerging growth company may take advantage of certain exemptions from various reporting requirements for up to 5 years that are otherwise applicable to public companies. These exemptions include, among others:
|
|
• |
an exemption from the auditor attestation requirement on the effectiveness of our system of internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002, as amended; |
|
|
• |
reduced disclosure about executive compensation arrangements; |
|
|
• |
an exemption from the requirement to seek non-binding advisory votes on executive compensation and golden parachute arrangements; and |
|
|
• |
an exemption from compliance with any new requirements adopted by the Public Company Accounting Oversight Board requiring a supplement to the auditor’s report in which the auditor would be required to provide additional information about the audit and the financial statements of the issuer. |
We have availed ourselves of certain of the exemptions in this Annual Report on Form 10-K, and we expect to continue to avail ourselves of certain of the exemptions available to emerging growth companies in future filings with the U.S. Securities and Exchange Commission (the “SEC”) as long as we are an emerging growth company. We will remain an emerging growth company until December 31, 2023 unless, prior to that time, we: (i) have more than $1.07 billion in annual gross revenue; (ii) have a market value for shares of our common stock held by non-affiliates of more than $700 million as of the last day of
39
our second quarter of any year; or (iii) issue more than $1.0 billion of non-convertible debt over a three-year period.
Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the U.S. Securities Act of 1933 for complying with new or revised accounting standards. An emerging growth company can therefore delay the adoption of certain new or revised accounting standards issued subsequent to the enactment of the JOBS Act until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
Human Capital
As of December 31, 2020, we had 153 employees, of which 137 were full-time employees. None of our employees are represented by labor unions or covered by collective bargaining agreements, and we consider our relations with our employees to be good. We also hire consultants and contract with third-parties, as needed, to provide additional resources to support our business activities.
Our key human capital management objectives are to identify, recruit, integrate, retain and motivate our new and existing employees. We believe that our compensation and benefit programs are appropriately designed to attract and retain qualified talent. Employees receive an annual base salary and are eligible to earn performance-based cash bonuses. To create and maintain a successful work environment, we offer a comprehensive package of additional benefits that support the physical and mental health and wellness of all of our employees and their families. Additionally, we grant equity awards in order to allow for directors, officers, employees and consultants of Odonate to share in the performance of the Company.
Corporate and Other Information
We are a Delaware corporation that was initially formed as a Delaware limited liability company in March 2013. On December 6, 2017, in anticipation of our initial public offering, we converted into a Delaware corporation. We currently operate in one segment.
Our principal executive offices are located at 3 East 28th Street, 10th Floor, New York, New York 10016, and our telephone number is (332) 206-0935. Our corporate website address is www.odonate.com. Information contained on or accessible through our website is not a part of this Annual Report on Form 10-K, and the inclusion of our website address in this Annual Report on Form 10-K is an inactive textual reference only.
We file electronically with the SEC our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934. We make available on our website at www.odonate.com, under “Corporate Resources,” free of charge, copies of these reports as soon as reasonably practicable after filing or furnishing these reports with the SEC. The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC.
40
Item 1A. Risk Factors
An investment in shares of our common stock involves a high degree of risk. You should carefully consider the material risks and uncertainties described below before deciding whether to purchase shares of our common stock. In assessing these risks, you should also refer to the other information contained in this Annual Report on Form 10-K, including our audited financial statements and related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Our business, financial condition, results of operations, cash flow, reputation and prospects could be materially and adversely affected by any of these risks and uncertainties, including risks and uncertainties not currently known to us or that we currently do not believe to be material. In any such case, the trading price of shares of our common stock could decline, and you could lose all or part of your investment.
Summary of Risk Factors
Below is a summary of the principal factors that make an investment in shares of our common stock speculative or risky. These factors, along with other general risk factors, are described in further detail under the heading “Risk Factors” below.
Risks Related to Our Business
|
|
• |
We are substantially dependent on our ability to successfully develop and commercialize tesetaxel. |
|
|
• |
Results from CONTESSA and any other clinical studies we may undertake may not be sufficient to obtain regulatory approvals to market our product candidates on a timely basis, if at all. |
|
|
• |
CONTESSA and other clinical studies that we may undertake may be delayed or halted. |
|
|
• |
Even if we obtain regulatory approval for tesetaxel or another product candidate, our products will remain subject to regulatory scrutiny. |
|
|
• |
The commercial adoption of tesetaxel and any other product candidates we develop will depend on the degree of their market acceptance. |
|
|
• |
If we are unable to achieve and maintain coverage and adequate levels of reimbursement for tesetaxel and other product candidates, if approved, their commercial success may be severely hindered. |
|
|
• |
We have only limited assets and will need to raise additional capital before we can expect to generate revenue or become profitable. |
|
|
• |
We have never generated any revenue and may never be profitable. |
|
|
• |
We currently have no sales, marketing or distribution capabilities. If we elect to commercialize tesetaxel ourselves and we are unable to establish effective sales, marketing or distribution capabilities or if we are unable to enter into agreements with third parties to commercialize tesetaxel or other product candidates that we may develop, we may not be able to effectively generate product revenues. |
|
|
• |
Because a number of companies compete with us, many of which have greater resources than we do, and because we face rapid changes in science in our industry, we cannot be certain that our products will be accepted in the marketplace or capture market share. |
|
|
• |
Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, reduce the commercial attractiveness of a prescribing label or result in significant negative consequences following regulatory approval, if approved. |
|
|
• |
We may not be successful in our efforts to identify, in-license or acquire, discover, develop or commercialize additional product candidates. |
41
|
|
• |
We will need to increase the size and capabilities of our organization, and we may experience difficulties in managing our growth. |
|
|
• |
Our future success depends on our ability to retain our key executives and to attract, retain and motivate qualified personnel. |
|
|
• |
We are a defendant in a putative class action lawsuit, which could divert the attention of management, result in negative press reports and, if adversely determined, have an adverse effect on our results of operations and financial condition. |
Risks Related to Our Industry
|
|
• |
Drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results. |
|
|
• |
The ongoing COVID-19 pandemic may disrupt our operations and affect our ability to successfully conduct clinical studies. |
|
|
• |
We will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy, security laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. |
|
|
• |
Current and future legislation may increase the difficulty and cost of obtaining regulatory approval, and the subsequent commercialization, of our product candidates, if approved, and may affect the prices we may obtain. |
|
|
• |
Governments outside the U.S. tend to impose strict price controls, which may adversely affect our revenues, if any. |
Risks Relating to Our Reliance on Third Parties
|
|
• |
We rely on contract development and manufacturing organizations (“CDMOs”) to manufacture our product candidates. If these CDMOs fail to produce our product candidates on a timely basis or comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the studies, regulatory submissions, regulatory approval or commercialization of our product candidates. |
|
|
• |
We rely on clinical sites to conduct our clinical studies. If these clinical sites do not enroll patients in a timely manner or comply with study protocols and regulations applicable to clinical study conduct, we may face delays in the studies, regulatory submissions, regulatory approval or commercialization of our product candidates. |
|
|
• |
We rely on third parties to provide certain services relating to our clinical studies and other activities. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may face delays in the studies, regulatory submissions, regulatory approval or commercialization of our product candidates. |
Risks Relating to Intellectual Property
|
|
• |
Our success in developing and marketing our product candidates depends significantly on our ability to obtain and maintain patent protection and operate without infringing on the rights of others. |
|
|
• |
The scope and terms of our patents may be insufficient to protect our product candidates for an adequate amount of time. |
|
|
• |
If the FDA or foreign regulatory authorities approve generic versions of any of our products that receive marketing approval or such authorities do not grant our products appropriate periods of |
42
|
|
exclusivity before approving generic versions of our products, the sales of our products could be adversely affected. |
|
|
• |
If we fail to comply with our obligations under our license, we may lose rights to critical patents that are important to the commercialization and revenue potential of tesetaxel. |
|
|
• |
If our product candidates infringe the rights of others, we could be subject to expensive litigation, become liable for substantial damages, be required to obtain licenses from others or be prohibited from selling our product candidates altogether. |
|
|
• |
Patent policy and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. |
|
|
• |
In addition to patent protection, we will need to successfully preserve our trade secrets. If we are unable to maintain effective proprietary rights for tesetaxel or any future product candidates, we may not be able to compete effectively in our markets. |
Risks Related to Ownership of Shares of Our Common Stock
|
|
• |
The price of shares of our common stock may be volatile, and you may lose all or part of your investment. |
|
|
• |
Because we do not expect to pay dividends in the foreseeable future, you must rely on price appreciation of shares of our common stock for return on your investment. |
|
|
• |
Our directors, executive officers and principal stockholders have substantial control over the Company, which could limit your ability to influence the outcome of key transactions, including a change of control. |
Risk Factors
Risks Related to Our Business
We are substantially dependent on our ability to successfully develop and commercialize tesetaxel.
Since our inception, we have invested substantially all of our capital resources in the development of tesetaxel, which we initially are developing for the treatment of metastatic breast cancer (“MBC”). Tesetaxel currently is the subject of three studies in MBC, including a multinational, multicenter, randomized, Phase 3 study in patients with MBC, known as CONTESSA. We cannot assure you that the U.S. Food and Drug Administration (“FDA”), the European Commission or any other regulatory authority will approve tesetaxel for marketing.
Our ability to generate revenue and our future success depend in large part on the success of CONTESSA, the approval of tesetaxel, the nature of any potential requirements for post-approval studies and the successful commercialization of tesetaxel, if approved. Delays in obtaining regulatory approval for tesetaxel would, among other consequences, require further development expenditures, delay the launch of tesetaxel and impact our ability to raise additional capital, all of which would have a material adverse effect on our business and financial condition.
Results from CONTESSA and any other clinical studies we may undertake may not be sufficient to obtain regulatory approvals to market our product candidates on a timely basis, if at all.
Pharmaceutical product candidates are subject to extensive government regulations related to development, clinical studies, manufacturing and commercialization. In order to sell any product that is under development, we must first receive regulatory approval. To obtain regulatory approval, we must conduct nonclinical and clinical studies that demonstrate that our product candidates are safe and effective. The process of obtaining FDA, European Commission and other regulatory authority approvals is costly, time-consuming, uncertain and subject to unanticipated delays.
43
The FDA, European Commission and other regulatory authorities have substantial discretion in the approval process and may not agree that we have demonstrated that our product candidates are safe and effective. If our product candidates are ultimately not found to be safe and effective, we would be unable to obtain regulatory approval to manufacture, market and sell them. We can provide no assurances that the FDA, European Commission or other regulatory authorities will approve our product candidates or, if approved, what the scope of the approved indication might be.
CONTESSA and other clinical studies that we may undertake may be delayed or halted.
CONTESSA and any other clinical studies of our product candidates that we may conduct in the future may be delayed or halted for various reasons, including:
|
|
• |
insufficient financial resources; |
|
|
• |
insufficient supplies of drug product to treat the patients in the studies; |
|
|
• |
failure of patients to enroll in the studies at the rate we expect; |
|
|
• |
ineffectiveness of our product candidates; |
|
|
• |
patients experiencing unexpected side effects or other safety concerns being raised during treatment; |
|
|
• |
changes in governmental regulations or administrative actions; |
|
|
• |
failure to conduct studies in accordance with required clinical practices; |
|
|
• |
inspection of clinical study operations or study sites by the FDA or other regulatory authorities, resulting in a clinical hold; |
|
|
• |
political unrest at foreign clinical sites; |
|
|
• |
a shutdown of the U.S. government, including the FDA; or |
|
|
• |
natural disasters, public health crises or other catastrophic events impacting any of our clinical sites. |
If studies are delayed or halted, we may incur significant additional expenses, and the potential approval of our product candidates may be delayed, which would have a material adverse effect on our business and financial condition.
Even if we obtain regulatory approval for tesetaxel or another product candidate, our products will remain subject to regulatory scrutiny.
If tesetaxel or other product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information.
Manufacturers and manufacturers’ facilities are required to comply with extensive FDA, EMA and other regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practices (“cGMPs”). As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMPs and adherence to commitments made in any New Drug Application (“NDA”), Market Authorization Application (“MAA”) or other marketing application. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.
Any regulatory approvals we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or
44
contain requirements for potentially costly post-marketing testing, including Phase 4 clinical studies, which must comply with applicable current Good Clinical Practice (“cGCPs”). We could also be asked to conduct post-marketing clinical studies to verify the safety and efficacy of our products in general or in specific patient subsets. If initial regulatory approval was obtained via the accelerated approval pathway, we could be required to conduct a successful post-marketing clinical study to confirm clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of regulatory approval. We will be required to report certain adverse reactions and production problems, if any, to the FDA, EMA and other regulatory authorities. Any new legislation addressing drug safety or approval issues could result in delays in product development or commercialization, or increased costs to assure compliance. We will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product’s approved label. As such, we may not promote our products for indications or uses for which they do not have approval. The holder of an approved NDA or MAA must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling or manufacturing process.
If a regulatory authority discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory authority may impose restrictions on that product or us. If we fail to comply with applicable regulatory requirements, a regulatory or enforcement authority may, among other things:
|
|
• |
issue warning or untitled letters; |
|
|
• |
impose civil or criminal penalties; |
|
|
• |
suspend or withdraw regulatory approval; |
|
|
• |
suspend any of our ongoing clinical studies; |
|
|
• |
refuse to approve pending applications or supplements to approved applications submitted by us; |
|
|
• |
impose restrictions on our and our contract manufacturers’ operations, including closing manufacturers’ facilities; |
|
|
• |
seize or detain products; or |
|
|
• |
require a product recall. |
Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, this would have a material adverse effect on our business and financial condition.
The commercial adoption of tesetaxel and any other product candidates we develop will depend on the degree of their market acceptance.
Even with the requisite approvals from the FDA, the European Commission and other regulatory authorities, the commercial adoption of tesetaxel and any other product candidates we develop will depend on the degree of their acceptance by physicians, patients, third-party payors and others in the medical community. The degree of market acceptance will depend on a number of factors, including:
|
|
• |
the safety and efficacy of the product as demonstrated in clinical studies; |
|
|
• |
the perception of physicians, patients, third-party payors and others in the medical community of the relative safety, efficacy, convenience, effect on quality-of-life and cost-effectiveness of the product, compared to those of other available treatments; |
45
|
|
• |
the product’s prescribing label, including the description of the product’s approved indication(s), the description of its efficacy, including the endpoints in which it showed an improvement, and the prevalence and severity of any side effects, including any limitations or warnings arising therefrom; |
|
|
• |
the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; |
|
|
• |
the strength of marketing and distribution support and timing of market introduction of competitive products; |
|
|
• |
the publicity concerning our products or competing products and treatments; |
|
|
• |
product liability litigation alleging injuries relating to our products or similar classes of drugs; |
|
|
• |
our ability to access third parties to manufacture or distribute our products on acceptable terms or at all; |
|
|
• |
any post-approval study requirements for our products and the results thereof; and |
|
|
• |
sufficient third-party insurance coverage and reimbursement. |
Even if a potential product such as tesetaxel displays a favorable efficacy and safety profile in nonclinical and clinical studies, market acceptance of the product is not fully known until after its commercial launch. Our efforts to educate physicians, patients, third-party payors and others in the medical community on the benefits of our product candidates may require significant resources and may never be successful. If tesetaxel or other product candidates are approved but fail to achieve an adequate level of acceptance by physicians, patients, third-party payors and others in the medical community, we will not be able to generate sufficient revenue to become or remain profitable.
If we are unable to achieve and maintain coverage and adequate levels of reimbursement for tesetaxel and other product candidates, if approved, their commercial success may be severely hindered.
Successful sales of tesetaxel and any other product candidates that may receive regulatory approval depend on the availability of coverage and adequate reimbursement from third-party payors. Patients who are prescribed medications for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Coverage decisions may depend on clinical and economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available. Assuming we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products.
The market for tesetaxel and any other product candidates that we attempt to commercialize will depend significantly on access to third-party payors’ drug formularies or lists of medications for which third-party payors provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical products. Also, third-party payors may refuse to include a particular branded drug in their formularies or otherwise restrict patient access through formulary controls or otherwise to a branded drug when a less costly generic equivalent or other alternative is available.
Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In addition, in the U.S., no uniform policy requirement for coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no
46
assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.
Third-party coverage and reimbursement for our product candidates for which we may receive regulatory approval may not be available or adequate in either the U.S. or international markets, which could have a material adverse effect on our business, results of operations, financial condition and prospects.
We have only limited assets and will need to raise additional capital before we can expect to generate revenue or become profitable.
As of December 31, 2020, we had no revenue, an accumulated deficit of $366.4 million and cash of $157.3 million. We believe that our existing cash will be sufficient to meet our anticipated cash requirements through at least one year from the date this Annual Report on Form 10-K is filed with the U.S. Securities and Exchange Commission (the “SEC”). However, to fund future operations to the point at which we are able to generate positive cash flow from sales of tesetaxel or other potential product candidates, we will need to raise significant additional capital. The amount and timing of future funding requirements will depend on many factors, including the timing and results of our ongoing development efforts, the potential expansion of our current development programs, potential new development programs and related general and administrative support. We anticipate that we will seek to fund our operations through public and private equity and debt financings or other sources, such as potential licenses or other collaboration agreements. We cannot assure you that anticipated additional financing will be available to us on favorable terms, or at all. Although we have been successful in obtaining financing through the issuance of our equity securities, we cannot assure you that we will be able to do so in the future. If we are unable to raise additional capital to fund our clinical development and commercialization of tesetaxel, if approved, and other business activities, we could be forced to abandon one or more programs and curtail or cease our operations.
We have never generated any revenue and may never be profitable.
We have no products approved for marketing, have never generated any revenue from product sales and have incurred losses in each year since our inception. Our ability to generate revenue and achieve profitability depends on our ability, alone or with marketing partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, tesetaxel. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase as we continue to develop tesetaxel. Our ability to generate revenue from product sales depends heavily on our success in many areas, including but not limited to:
|
|
• |
successfully completing the development of tesetaxel; |
|
|
• |
obtaining regulatory approvals to market tesetaxel; |
|
|
• |
successfully managing third-party service providers involved in the manufacturing and development of tesetaxel; |
|
|
• |
successfully commercializing tesetaxel, either independently or with marketing partners; |
|
|
• |
obtaining market acceptance of tesetaxel, including garnering market share from existing and future treatment alternatives; |
|
|
• |
negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter; |
|
|
• |
maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and |
|
|
• |
attracting, hiring and retaining qualified personnel. |
47
If tesetaxel or any other product candidates we may develop are approved for marketing, we anticipate incurring significant commercialization costs. Our expenses could increase beyond our current expectations if we are required by the FDA, the European Medicines Agency (“EMA”) or other regulatory authorities to change our manufacturing processes or quality procedures or perform additional or unanticipated nonclinical, clinical or other studies. In cases where we are successful in obtaining regulatory approvals to market tesetaxel or other product candidates, our revenue will be dependent, in part, on the size of the markets in the territories for which we gain regulatory approval, the acceptance of the price of the product in those markets and the ability to obtain reimbursement at any price. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. If we are not able to generate revenue from the sale of approved products, we may never become profitable.
We currently have no sales, marketing or distribution capabilities. If we elect to commercialize tesetaxel ourselves and we are unable to establish effective sales, marketing or distribution capabilities or if we are unable to enter into agreements with third parties to commercialize tesetaxel or other product candidates that we may develop, we may not be able to effectively generate product revenues.
We currently do not have sales, marketing or distribution capabilities. In order to commercialize tesetaxel, if approved, or any other product candidates that we may develop, we must build marketing, sales and distribution capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If tesetaxel receives regulatory approval and we decide to commercialize tesetaxel ourselves, building the requisite sales, marketing or distribution capabilities will be expensive and time-consuming and will require significant attention of our leadership team to manage. Any failure or delay in the development of our sales, marketing or distribution capabilities would adversely affect the commercialization of any product. The competition for talented individuals experienced in selling and marketing pharmaceutical products is intense, and we cannot assure you that we can assemble an effective team. Additionally, we may choose to collaborate, either globally or on a territory-by-territory basis, with third parties on the commercialization of tesetaxel or any other product candidates that we may develop. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval or any such commercialization may experience delays or limitations.
We may be subject to additional risks related to operating in foreign countries either ourselves or through a third-party, including:
|
|
• |
differing regulatory requirements in foreign countries; |
|
|
• |
international trade relations, including unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; |
|
|
• |
economic weakness, including inflation or political instability in particular foreign economies and markets; |
|
|
• |
compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; |
|
|
• |
foreign taxes, including withholding of payroll taxes; |
|
|
• |
foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country; |
|
|
• |
difficulties staffing and managing foreign operations; |
|
|
• |
workforce uncertainty in countries where labor unrest is more common than in the U.S.; |
|
|
• |
potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations; |
48
|
|
• |
challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the U.S.; |
|
|
• |
production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and |
|
|
• |
business interruptions resulting from geopolitical actions, including war and terrorism, as well as natural disasters, public health crises or other catastrophic events. |
If we are not successful in commercializing tesetaxel or other product candidates, our future product revenue will suffer and we may incur significant additional losses.
Because a number of companies compete with us, many of which have greater resources than we do, and because we face rapid changes in science in our industry, we cannot be certain that our products will be accepted in the marketplace or capture market share.
Competition from other biotechnology and pharmaceutical companies is intense and is expected to increase. A number of companies are pursuing the development of pharmaceuticals in oncology, our area of focus. Many of these companies are very large and have financial, technical, sales and distribution and other resources substantially greater than ours. The greater resources of these competitors may enable them to develop, obtain regulatory approval for or market competing products more quickly or effectively, making it extremely difficult for us to capture a share of the market for our products. Additionally, the biotechnology and pharmaceutical industries are subject to rapid changes in science, and our competitors may develop and market products with improved therapeutic profiles relative to our product candidates that would render our product candidates noncompetitive.
Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, reduce the commercial attractiveness of a prescribing label or result in significant negative consequences following regulatory approval, if approved.
Clinical studies of tesetaxel or other product candidates we may develop could reveal a high and unacceptable incidence and severity of undesirable side effects. Undesirable side effects could adversely affect patient enrollment in clinical studies, cause us or regulatory authorities to interrupt, delay or halt clinical studies or result in the delay, denial or withdrawal of regulatory approval by the FDA, the European Commission or other regulatory authorities. For example, in 2007, tesetaxel was placed on clinical hold by the FDA while in development by the original sponsor due to the occurrence of several fatalities in the setting of severe neutropenia (a low level of neutrophils, a type of white blood cell) in patients with advanced cancer. While this clinical hold was lifted in 2008, and tesetaxel has since been evaluated in multiple clinical studies in more than 1,000 patients without any interruption due to safety issues, we cannot assure you that safety-related interruptions in tesetaxel’s clinical development will not occur again in the future. Any such recurrence could potentially delay or prevent the ultimate approval of our product candidate. Undesirable or adverse side effects also could result in regulatory authorities mandating a more restrictive prescribing label for the product, which, in turn, could limit the market acceptance of the product even if approved for marketing and commercialization. In patients treated with tesetaxel plus capecitabine in CONTESSA, the rate of Grade ≥3 neutropenia was 70.9%, and the rate of febrile neutropenia was 13.1%.
49
Drug-related side effects could result in potential product liability claims. We carry product liability insurance in the amount of $10.0 million in the aggregate. We believe that our product liability insurance coverage is sufficient in light of our clinical programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts or maintain coverage at all to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations, business and financial condition. In addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, withdrawal of clinical study participants, costs due to related litigation, distraction of management’s attention from our primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our product candidates and decreased demand for our product candidates, if approved for marketing.
Additionally, if one or more of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including but not limited to:
|
|
• |
the withdrawal of approvals by regulatory authorities; |
|
|
• |
the requirement of additional warnings on the prescribing label; |
|
|
• |
the requirement of a Risk Evaluation and Mitigation Strategy plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use; |
|
|
• |
litigation and the potential to be held liable for harm caused to patients; and |
|
|
• |
an adverse effect on our reputation. |
Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate and could significantly harm our business, results of operations, financial condition and prospects.
We may not be successful in our efforts to identify, in-license or acquire, discover, develop or commercialize additional product candidates.
Although a substantial amount of our effort will focus on the development and potential commercialization of tesetaxel, we also may seek to identify, in-license or acquire, discover, develop and commercialize additional product candidates in the oncology field. We cannot assure you that our efforts to in-license or acquire additional product candidates will be successful. Even if we are successful in in-licensing or acquiring additional product candidates, their requisite development activities may require substantial resources, and we cannot assure you that these development activities will result in regulatory approvals.
We will need to increase the size and capabilities of our organization, and we may experience difficulties in managing our growth.
Odonate was formed in 2013 and had 153 employees as of December 31, 2020. As we advance the development of tesetaxel, we must continue to grow the size of the organization. Future growth will impose significant added responsibilities on members of management, including:
|
|
• |
identifying, recruiting, integrating, retaining and motivating additional employees; |
|
|
• |
effectively managing our development efforts, including the clinical development and FDA, EMA or other regulatory authority review processes for our product candidates; |
|
|
• |
effectively managing our third-party service providers involved in the development and manufacture of our product candidates; and |
50
|
|
• |
improving our operational, financial and management controls, reporting systems and procedures. |
Our future financial performance and our ability to successfully develop and commercialize our product candidates will depend, in part, on our ability to effectively and efficiently manage any future growth. Our management will have to dedicate a significant amount of its attention to managing these growth activities. In addition, we expect to incur additional costs in hiring, training and retaining such additional personnel.
If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully execute the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.
Our future success depends on our ability to retain our key executives and to attract, retain and motivate qualified personnel.
We are highly dependent on the principal members of our management and scientific teams. We do not maintain “key person” insurance for any of our executives or other employees. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.
To induce valuable employees to remain at our company, in addition to salary and cash incentives, we grant equity awards that vest over time. The value to employees of these equity awards that vest over time may be significantly affected by changes in the price of shares of our common stock that are beyond our control, and may at any time be insufficient to retain employees who receive more lucrative offers from other companies. Any of our employees could leave our employment at any time, with or without notice.
Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel or consultants will also be critical to our success. We rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our discovery, development and commercialization strategies. The loss of the services of any of our executive officers, key employees or consultants could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy.
Replacing executive officers, key employees or consultants may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel or consultants on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel.
We may hire part-time employees or use consultants. As a result, certain of our employees, officers, directors or consultants may not devote all of their time to our business, and may from time to time serve as employees, officers, directors and consultants of other companies.
We are a defendant in a putative class action lawsuit, which could divert the attention of management, result in negative press reports and, if adversely determined, have an adverse effect on our results of operations and financial condition.
As described in Note 4 to our audited financial statements included in Item 8 of this Annual Report on Form 10-K, a putative class action lawsuit has been filed against us and certain of our current and former officers. The lawsuit seeks damages allegedly sustained by the class and an award of plaintiffs’ costs and attorney fees. While we believe that the complaint is without merit and that we have substantive defenses to the claims of liability and damages, this lawsuit, like any lawsuit, is subject to inherent uncertainties,
51
and we might not prevail. This lawsuit could divert the attention of management, result in negative press reports and, if adversely determined, have an adverse effect on our results of operations and financial condition.
Risks Related to Our Industry
Drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results.
Clinical testing is expensive, can take many years to complete and its outcome is inherently uncertain. Failure can occur at any time during the clinical study process. The results of nonclinical studies and early clinical studies of our product candidates may not be predictive of the results of later-stage clinical studies. Product candidates that have shown promising results in early-stage clinical studies may still suffer significant setbacks in subsequent clinical studies. For example, the safety or efficacy results generated to date in our clinical studies do not ensure that later clinical studies will demonstrate similar results. There is a high failure rate for pharmaceutical product candidates proceeding through clinical studies, and product candidates in later stages of clinical studies may fail to show the desired safety and efficacy, despite having progressed through nonclinical studies and initial clinical studies.
A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical studies due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies. Moreover, nonclinical and clinical data often are susceptible to varying interpretations and analyses. We do not know whether any clinical studies we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain regulatory approval to market our product candidates.
The ongoing COVID-19 pandemic may disrupt our operations and affect our ability to successfully conduct clinical studies.
We are unable to accurately predict the full impact that the ongoing Coronavirus Disease 2019 (“COVID-19”) pandemic will have on our results from operations, financial condition and clinical studies due to numerous factors that are not within our control, including its duration and severity. Stay-at-home orders, business closures, travel restrictions, supply chain disruptions and employee illness or quarantines could result in disruptions to our operations, which could adversely impact our results from operations and financial condition. In addition, the COVID-19 pandemic has resulted in ongoing volatility in financial markets. If our access to capital is restricted or associated borrowing costs increase as a result of developments in financial markets relating to the COVID-19 pandemic, our operations and financial condition could be adversely impacted.
We will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy, security laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
Our operations may be directly, or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act and physician sunshine laws and regulations. These laws will impact, among other things, our clinical development, proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The U.S. laws that will affect our ability to operate include:
|
|
• |
the federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; |
|
|
• |
federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims |
52
|
|
for payment or approval from Medicare, Medicaid or other third-party payors that are false or fraudulent; |
|
|
• |
federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters; |
|
|
• |
HIPAA, as amended by the federal Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; |
|
|
• |
the federal physician sunshine requirements under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, (collectively, the “PPACA”), which require manufacturers of drugs, devices, biologics and medical supplies to report annually to the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians, other healthcare providers and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations; and |
|
|
• |
state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. |
Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available thereunder, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent healthcare reform legislation has strengthened these laws. For example, the PPACA, among other things, amended the previous intent requirement of the federal Anti-Kickback Statute and criminal healthcare fraud statutes. Now, a person or entity does not have to have actual knowledge of the statutes or specific intent to violate them. The PPACA also provides that the federal government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.
If our operations are found to be in violation of any of these laws or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, imprisonment, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if a person becomes subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.
Current and future legislation may increase the difficulty and cost of obtaining regulatory approval, and the subsequent commercialization, of our product candidates, if approved, and may affect the prices we may obtain.
In the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay regulatory approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain regulatory approval.
53
For example, in 2010, President Obama signed into law the PPACA, which contains provisions, among others, that may impact our potential product candidates, including:
|
|
• |
an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; |
|
|
• |
an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; |
|
|
• |
expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance; |
|
|
• |
a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices; |
|
|
• |
extension of manufacturers’ Medicaid rebate liability; |
|
|
• |
expansion of eligibility criteria for Medicaid programs; |
|
|
• |
requirements to report financial arrangements with physicians and teaching hospitals; |
|
|
• |
a requirement to annually report drug samples that manufacturers and distributors provide to physicians; |
|
|
• |
a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; |
|
|
• |
the Independent Payment Advisory Board, which, if created, would have authority to recommend certain changes to the Medicare program that could result in reduced payments for prescription drugs; and |
|
|
• |
a Center for Medicare Innovation at the Centers for Medicare & Medicaid Services to test innovative payment and service delivery models to lower Medicare and Medicaid spending. |
Other legislative changes have been proposed and adopted since the PPACA was enacted. These changes included aggregate reductions of Medicare payments to providers of up to two percent per year. Additionally, the American Taxpayer Relief Act of 2012 reduced Medicare payments to certain providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. There have been judicial, Congressional and Executive Branch challenges to certain aspects of the PPACA, and we expect there will be additional challenges and/or amendments to the PPACA in the future. Further, it is possible that additional regulatory changes, as well as the repeal (in whole or in part) of the PPACA, could negatively affect insurance coverage and/or drug prices. These new laws also may result in additional reductions in Medicare and other healthcare funding as well as insurance coverage and payments.
We expect that the PPACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the reimbursement received for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.
Moreover, there recently has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Individual states in the U.S. have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing,
54
including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects.
Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. Additionally, legislation has been introduced to repeal the PPACA. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the regulatory approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA’s approval process may significantly delay or prevent regulatory approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.
Governments outside the U.S. tend to impose strict price controls, which may adversely affect our revenues, if any.
In some countries, particularly certain countries of the European Union (“EU”), the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of regulatory approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical study that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.
Risks Relating to Our Reliance on Third Parties
We rely on CDMOs to manufacture our product candidates. If these CDMOs fail to produce our product candidates on a timely basis or comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the studies, regulatory submissions, regulatory approval or commercialization of our product candidates.
We contract with CDMOs to manufacture our product candidates, and we would expect to rely on these CDMOs to produce commercial quantities of tesetaxel. The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical products often encounter difficulties in production, which include difficulties with production costs and yields, supply chain issues, quality control and assurance and shortages of qualified personnel, as well as compliance with strictly enforced governmental regulations, including cGMPs. The CDMOs we contract with may not perform as agreed or may terminate their agreements with us.
In addition to product approval, any facilities in which our product candidates are manufactured or tested for their ability to meet required specifications must be inspected and approved by regulatory authorities before a commercial product can be manufactured. Failure of such a facility to be approved could delay the approval of one or more of our product candidates.
Any of these factors could cause us to delay or suspend any clinical studies, regulatory submissions, required approvals or commercialization of one or more of our product candidates, entail higher costs and result in our being unable to effectively commercialize products.
55
We rely on clinical sites to conduct our clinical studies. If these clinical sites do not enroll patients in a timely manner or comply with study protocols and regulations applicable to clinical study conduct, we may face delays in the studies, regulatory submissions, regulatory approval or commercialization of our product candidates.
We rely on clinical sites to enroll patients in our clinical studies. The rate of enrollment of patients into our clinical studies at these clinical sites is dependent on a number of factors, including the number of eligible patients and the interest level of investigators, study staff and patients in our clinical studies relative to other enrolling studies. If the clinical sites participating in our clinical studies do not enroll patients in a timely manner, we may face delays in the studies, regulatory submissions, regulatory approval or commercialization of our product candidates.
We rely on clinical sites to comply with study protocols and regulations applicable to clinical study conduct. We and these clinical sites are required to comply with cGCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for products in clinical development. Regulatory authorities enforce these cGCPs through periodic inspections of study sponsors, principal investigators and clinical sites. If we, the investigators or the clinical sites fail to comply with applicable cGCPs, the clinical data generated in our clinical studies may be deemed unreliable and the regulatory authorities may require us to perform additional clinical studies before approving our marketing applications, which would delay or compromise the regulatory approval process.
We rely on third parties to provide certain services relating to our clinical studies and other activities. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may face delays in the studies, regulatory submissions, regulatory approval or commercialization of our product candidates.
We have agreements with third parties to provide legal representation and regulatory reporting for our clinical programs. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the work they perform is compromised due to the failure to adhere to regulatory requirements or for other reasons, we may face delays in the studies, regulatory submissions, regulatory approval or commercialization of our product candidates.
We have agreements with other third parties that provide various services in connection with our development and business activities. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the work they perform is compromised, we may face delays in the studies, regulatory submissions, regulatory approval or commercialization of our product candidates.
Risks Relating to Intellectual Property
Our success in developing and marketing our product candidates depends significantly on our ability to obtain and maintain patent protection and operate without infringing on the rights of others.
We depend on patents and other intellectual property rights to prevent others from improperly benefiting from products or inventions that we developed or acquired. For details about our intellectual property portfolio protecting our tesetaxel program, see the section titled “Business—Patent and Proprietary Rights.”
56
The patent position of pharmaceutical firms like ours is highly uncertain and involves complex legal and factual questions. We intend to continue to file patent applications because we believe it is appropriate to seek to obtain patents covering our products and their manufacture and use. There can be no assurance, however, that any additional patents will issue, that the scope of any patent that has issued or may issue will be sufficient to protect our product candidates, or that any current or future issued patent will not be held invalid if challenged. Additionally, we may have to incur significant expense and expend management time defending or enforcing our patents. If we cannot obtain and maintain effective patent rights and/or regulatory exclusivity for our product candidates, we may not be able to compete effectively, and our business and results of operations would be harmed.
The scope and terms of our patents may be insufficient to protect our product candidates for an adequate amount of time.
In the U.S., the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours.
Patents may be eligible for limited patent term extension in the U.S. under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. Similar patent extensions exist in the EU and Japan. The Hatch-Waxman Act permits a patent term extension of up to 5 years for a patent covering a qualified approved product as compensation for patent term that elapsed during product development and the FDA regulatory review process, provided the extension does not extend the total patent term beyond a total of 14 years from the product’s approval date, and only one patent per approved product is extended. We may not receive an extension if we fail to apply within applicable deadlines or fail to apply prior to expiration of relevant patents. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner, impacting our revenue.
If the FDA or foreign regulatory authorities approve generic versions of any of our products that receive marketing approval or such authorities do not grant our products appropriate periods of exclusivity before approving generic versions of our products, the sales of our products could be adversely affected.
NDA applicants are required to list with the FDA each patent with claims covering the applicant’s product or method of using the product for which approval is sought. Upon approval of a drug, each of the patents listed in the application for the drug that cover the drug or an approved use of the drug is then published in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic or 505(b)(2) NDA applicants in support of approval of an Abbreviated New Drug Application (“ANDA”) or a 505(b)(2) NDA. An ANDA is a streamlined way to seek approval for marketing a drug product that has the same active ingredient in the same strength and dosage form as the listed drug and has been shown to be bioequivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct or submit results of nonclinical or clinical studies to prove the safety or effectiveness of their drug product. Drugs approved in this way can often be substituted by pharmacists under prescriptions written for the original listed drug.
Both ANDA and 505(b)(2) NDA applicants are required to make a certification to the FDA concerning any patents listed for the approved NDA product in the FDA’s Orange Book. Specifically, ANDA and 505(b)(2) NDA applicants must certify that: (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed patent is invalid or will not be infringed by the
57
new product. The ANDA applicant may also elect to submit a statement certifying that its proposed ANDA labeling does not contain (or carves out) any language regarding patented methods-of-use rather than certify to a listed method-of-use patent. If the applicant does not challenge the listed patents, the submitted application will not be approved until all the listed patents claiming the referenced product have expired.
A certification that the proposed product will not infringe the already approved product’s listed patents, or that such patents are invalid or unenforceable, is called a “paragraph IV” certification. If the applicant has provided a “paragraph IV” certification to the FDA, the applicant must also notify each patent holder and the NDA holder of the “paragraph IV” certification within 20 days after the postmark on the FDA letter acknowledging receipt of the ANDA or 505(b)(2) NDA. The patent holder and the NDA holder may then initiate patent infringement lawsuits in response to the notice of the ”paragraph IV” certification. The filing of a patent infringement lawsuit within 45 days after receipt of the notice of a “paragraph IV” certification automatically prevents the FDA from approving the ANDA or 505(b)(2) NDA until the earliest of 30 months, expiration of the relevant patent(s), settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant or 505(b)(2) applicant.
In addition to the protections from competitors that may be afforded by patents, pharmaceutical products may also be eligible for regulatory exclusivity, such as the exclusivity that may be granted to New Chemical Entities (“NCEs”). While we believe that tesetaxel will qualify as an NCE, such determination is only made at, or after, the time of approval. Accordingly, we do not have any agreement with the FDA, EMA or other regulatory body that tesetaxel will in fact be regarded as an NCE, and there can be no assurance that it will be treated as such at the time of approval (if approval is granted).
Competition that our products may face from generic versions of our products could materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates.
If we fail to comply with our obligations under our license, we may lose rights to critical patents that are important to the commercialization and revenue potential of tesetaxel.
We have licensed patent rights covering tesetaxel from Daiichi Sankyo. If, for any reason, our license agreement with Daiichi Sankyo is terminated or we otherwise lose those rights, it would materially and adversely affect our business. Our license agreement with Daiichi Sankyo imposes, and any future collaboration agreements or license agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us. Failure to fulfill these obligations could pose a material risk to our patent protection for tesetaxel and any future product candidates.
If our product candidates infringe the rights of others, we could be subject to expensive litigation, become liable for substantial damages, be required to obtain licenses from others or be prohibited from selling our product candidates altogether.
Our competitors or others may have patent rights that they choose to assert against us or our licensors, licensees, suppliers, customers or potential marketing partners. Moreover, we may not know about patents or patent applications that our products would infringe. Because patent applications do not publish for at least 18 months, if at all, and can take many years to issue, there may be currently pending applications unknown to us that may later result in issued patents that our product candidates would infringe. In addition, if third parties file patent applications or obtain patents claiming inventions also claimed by us or our licensors in issued patents or pending applications, we may have to participate in interference proceedings in the U.S. Patent and Trademark Office (“USPTO”) to determine priority of invention. If third parties file oppositions in foreign countries, we may also have to participate in opposition proceedings in foreign tribunals to defend the patentability of claims in our foreign patent applications.
58
If a third party claims that we infringe its proprietary rights, any of the following may occur:
|
|
• |
we may become involved in time-consuming and expensive litigation, even if the claim is without merit; |
|
|
• |
we may become liable for substantial damages for past infringement if a court decides that we have infringed a competitor’s patent; |
|
|
• |
a court may prohibit us from selling or licensing our product without a license from the patent holder, which may not be available on commercially acceptable terms, if at all, or which may require us to pay substantial royalties or grant cross-licenses to our patents; or |
|
|
• |
we may have to redesign our product candidates so that they do not infringe patent rights of others, which may not be possible or commercially feasible and may require new regulatory approvals. |
Any of these events would have a material adverse effect on our business, results of operations and financial condition.
Patent policy and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.
Changes in either the patent laws or interpretation of the patent laws in the U.S. or other countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. We therefore cannot be certain that we or our licensors were the first to make the inventions claimed in our owned and licensed patents or pending applications, or that we or our licensor were the first to file for patent protection of such inventions.
Assuming the other requirements for patentability are met, in the U.S., prior to March 15, 2013, the first to make the claimed invention is entitled to the patent, while, outside the U.S., the first to file a patent application is entitled to the patent. After March 15, 2013, under the Leahy-Smith America Invents Act (“Leahy-Smith Act”), enacted on September 16, 2011, the U.S. has moved to a first-to-file system. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and may also affect patent litigation. In general, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, results of operations and financial condition.
Among some of the other changes introduced by the Leahy-Smith Act are changes that limit where a patentee may file a patent infringement suit and provide new opportunities for third parties to challenge issued patents in the USPTO. We may be subject to the risk of third-party prior art submissions on pending applications or become a party to opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patents for tesetaxel. There is a lower standard of evidence necessary to invalidate a patent claim in a USPTO proceeding relative to the standard in U.S. federal courts. This could lead third parties to challenge and successfully invalidate our patents that would not otherwise be invalidated if challenged through the court system.
In addition to patent protection, we will need to successfully preserve our trade secrets. If we are unable to maintain effective proprietary rights for tesetaxel or any future product candidates, we may not be able to compete effectively in our markets.
In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate
59
discovery and development processes that involve information or know-how that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary science and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. Our agreements and security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. For instance, the FDA has introduced its Transparency Initiative and is currently considering whether to publicly disclose additional information from drug sponsors; in such case, we cannot guarantee that our trade secrets will not be disclosed.
Although we expect all of our employees and consultants to assign their inventions to us and we expect all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, science or information to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed, that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets.
Risks Related to Ownership of Shares of Our Common Stock
The price of shares of our common stock may be volatile, and you may lose all or part of your investment.
The market price of shares of our common stock could fluctuate significantly, and you may not be able to resell your shares near, at or above the price that you purchased them. Those fluctuations could be based on various factors in addition to those otherwise described in this Annual Report on Form 10-K, including those described throughout the section titled “Risk Factors” and the following:
|
|
• |
unfavorable developments relating to the regulatory status of our product candidates, such as the FDA refusing to accept for filing our NDA or issuing a complete response letter, or a delay in the regulatory review process; |
|
|
• |
adverse actions taken by regulatory authorities with respect to our clinical studies, manufacturing supply chain or future sales and marketing activities; |
|
|
• |
unfavorable results from our clinical studies, including lack of efficacy or unfavorable safety results; |
|
|
• |
delays in the initiation or completion of our clinical studies; |
|
|
• |
poor commercial adoption of our product candidates; |
|
|
• |
higher-than-expected expenses related to our development programs or overall corporate operations; |
|
|
• |
an inability to raise additional capital; |
|
|
• |
an inability to become profitable; |
|
|
• |
a change in competitive landscape that is unfavorable to our product candidates; |
|
|
• |
departures of our key executives; |
|
|
• |
an adverse determination in a class action lawsuit; |
|
|
• |
adverse developments at third-party service providers on which we are dependent, including our CDMOs; |
|
|
• |
actual or threatened intellectual property litigation that involves our product candidates; |
60
|
|
• |
adverse developments concerning the pharmaceutical industry in general; |
|
|
• |
financial results that are not in line with analyst expectations or our projections; |
|
|
• |
changes in analyst estimates, ratings and price targets; |
|
|
• |
press reports or other negative publicity, whether or not true, about our business; |
|
|
• |
release or expiry of lock-up or other transfer restrictions on our outstanding shares of common stock; |
|
|
• |
sales or perceived potential sales of additional shares of common stock; |
|
|
• |
sales of shares of our common stock by us, our executive officers and directors or our stockholders in the future; |
|
|
• |
fluctuations in the stock prices of pharmaceutical and biotechnology stocks; and |
|
|
• |
general economic and market conditions and overall fluctuations in the U.S. equity markets. |
Any of these factors may result in large and sudden changes in the volume and trading price of shares of our common stock. In addition, the Nasdaq Global Select Market, in general, and the stocks of small pharmaceutical and biotechnology companies, in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of shares of our common stock, regardless of our actual operating performance. Further, a decline in the financial markets and related factors beyond our control may cause the market price of shares of our common stock to decline rapidly and unexpectedly.
Because we do not expect to pay dividends in the foreseeable future, you must rely on price appreciation of shares of our common stock for return on your investment.
We intend to retain most, if not all, of our available funds and earnings to fund the development and growth of our business. As a result, we do not expect to pay any cash dividends in the foreseeable future. Therefore, you should not rely on an investment in shares of our common stock as a source for any future dividend income.
Our board of directors (“Board”) has significant discretion as to whether to distribute dividends and in what amounts. Even if our Board decides to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on, among other things, our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our Board.
Our directors, executive officers and principal stockholders have substantial control over the Company, which could limit your ability to influence the outcome of key transactions, including a change of control.
Our current directors, officers and stockholders who own greater than 5% of our outstanding shares of common stock, together with their affiliates, beneficially own, in the aggregate, approximately 75% of our outstanding shares of common stock, based on the number of shares outstanding as of February 8, 2021. As a result, these current directors, officers and stockholders, if they act, will be able to influence or control matters requiring approval by our stockholders, including the election of directors and the approval of mergers, acquisitions or other extraordinary transactions. In addition, our current directors, officers and stockholders, acting together, would have the ability to control the management and affairs of our company. They may also have interests that differ from yours and may vote in a way with which you disagree and that may be adverse to your interests. This concentration of ownership may have the effect of delaying, preventing or deterring a change of control of our company, could deprive our stockholders of an opportunity to receive a premium for their shares of common stock as part of a sale of our company and could affect the market price of shares of our common stock.
61
General Risk Factors
Future sales of shares of our common stock, or the perception that such sales may occur, could depress the market price of shares of our common stock.
We will need additional capital in the future to continue our planned operations. Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, could depress the market price of shares of our common stock. All of our outstanding shares are freely tradable except for any shares held or acquired by persons who may be deemed to be our affiliates. Shares of our common stock held by our affiliates continue to be subject to the volume and other restrictions of Rule 144 under the U.S. Securities Act of 1933 (the “Securities Act”). Sales of a substantial number of such shares, or the perception that such sales may occur, could cause our market price to fall or make it more difficult for you to sell your shares of common stock at a time and price that you deem appropriate.
Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
We are subject to the periodic reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC.
Disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.
These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.
62
Our business and operations may be materially adversely affected in the event of computer system failures or security breaches.
Despite the implementation of security measures, our internal computer systems, and those of other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, cyber-attacks, natural disasters, fire, terrorism, war and telecommunication and electrical failures. If such an event were to occur and interrupt our operations, it could result in a material disruption of our development programs. For example, the loss of data from ongoing or planned clinical studies could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, loss of trade secrets or inappropriate disclosure of confidential or proprietary information, including protected health information or personal data of employees or former employees, access to our clinical data or disruption of the manufacturing process, we could incur liability and the further development of our product candidates could be delayed. We may also be vulnerable to cyber-attacks or other malfeasance by hackers, employees and others. This type of breach of our cybersecurity may compromise our confidential information or our financial information and adversely affect our business or result in legal proceedings.
We are an emerging growth company, as defined in the Securities Act, and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make shares of our common stock less attractive to investors.
We are an emerging growth company, as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and we may take advantage of certain exemptions from various reporting requirements that are otherwise applicable to public companies, including, among others, an exemption from the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended; reduced disclosure about executive compensation arrangements in our registration statements, periodic reports and proxy statements; and an exemption from the requirement to seek non-binding advisory votes on executive compensation and golden parachute arrangements. As a result, our stockholders may not have access to certain information that they may deem important. We will remain an emerging growth company until December 31, 2023 unless, prior to that time, we: (i) have more than $1.07 billion in annual gross revenue; (ii) have a market value for shares of our common stock held by non-affiliates of more than $700 million as of the last day of our second quarter of any year; or (iii) issue more than $1.0 billion of non-convertible debt over a three-year period.
Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. An emerging growth company can therefore delay the adoption of certain new or revised accounting standards issued subsequent to the enactment of the JOBS Act until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
We cannot predict if investors will find shares of our common stock less attractive because we may rely on these exemptions. If some investors find shares of our common stock less attractive as a result, there may be a less active trading market for shares of our common stock and our stock price may be more volatile.
63
Item 1B. Unresolved Staff Comments
Not applicable.
Item 2. Properties
Our principal executive offices are located at 3 East 28th Street, 10th Floor, New York, New York 10016. We also maintain offices at 4747 Executive Drive, Suite 210, San Diego, California 92121. We lease approximately 5,575 square feet of office space in New York and approximately 8,441 square feet of office space in San Diego.
Item 3. Legal Proceedings
See Note 4 to the audited financial statements included in Item 8 of this Annual Report on Form 10-K.
Item 4. Mine Safety Disclosures
Not applicable.
64
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Information
Shares of our common stock began trading on the Nasdaq Global Select Market on December 7, 2017 under the symbol “ODT.” Prior to that time, there was no public market for shares of our common stock.
Holders of Record
As of February 8, 2021, we had 2 holders of record of shares of our common stock. Certain shares of common stock are held in “street” name, and accordingly, the number of beneficial owners of such shares of common stock is not known or included in the foregoing number. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.
Dividend Policy
We have never declared or paid any cash dividends on shares of our common stock and do not currently intend to do so for the foreseeable future. Any determination to pay dividends to holders of shares of our common stock will be at the discretion of our board of directors (“Board”) and will depend on many factors, including our financial condition, results of operations, projections, liquidity, earnings, legal requirements, restrictions in the agreements governing any indebtedness we may enter into and other factors that our Board deems relevant.
Item 6. Selected Financial Data
We are a smaller reporting company, as defined by Rule 12b-2 under the Securities and Exchange Act of 1934 and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.
65
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations together with our audited financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, include forward-looking statements that involve risks and uncertainties. You should review the “Risk Factors” set forth in this Annual Report on Form 10-K for a discussion of important factors that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Company Overview
We are a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several properties that make it unique among taxanes, including:
|
|
• |
oral administration with a low pill burden; |
|
|
• |
a long (~8-day) terminal plasma half-life in humans, enabling the maintenance of adequate drug levels with relatively infrequent dosing; |
|
|
• |
no history of hypersensitivity (allergic) reactions; and |
|
|
• |
significant activity against chemotherapy-resistant tumors. |
In patients with metastatic breast cancer (“MBC”), tesetaxel was shown to have significant, single-agent antitumor activity in two multicenter, Phase 2 studies. Tesetaxel currently is the subject of three studies in breast cancer, including a multinational, multicenter, randomized, Phase 3 study in patients with MBC, known as CONTESSA. Positive results of CONTESSA were presented at the 2020 San Antonio Breast Cancer Symposium. We plan to submit a New Drug Application for tesetaxel to the U.S. Food and Drug Administration in mid-2021. Our goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
Results of Operations
The following table summarizes our results of operations for each of the periods below (in thousands):
|
|
|
Year Ended |
|
|||||
|
|
|
December 31, |
|
|||||
|
|
|
2020 |
|
|
2019 |
|
||
|
Research and development expense |
|
$ |
117,041 |
|
|
$ |
104,034 |
|
|
General and administrative expense |
|
$ |
10,392 |
|
|
$ |
10,896 |
|
|
Other income, net |
|
$ |
1,083 |
|
|
$ |
3,105 |
|
Research and Development Expense
Research and development expense consists of expense associated with the development of tesetaxel and includes non-personnel-related and personnel-related expense. Non-personnel-related expense includes expense related to: (i) clinical study site payments; (ii) acquiring clinical study materials and the clinical study supply chain; (iii) manufacturing development and scale-up, including manufacturing registration and validation batches of tesetaxel; (iv) clinical and quality systems; and (v) regulatory submissions. Personnel-related expense includes expense related to salaries, benefits and equity-based compensation for personnel engaged in research and development functions.
66
Research and development expense is charged to operations as incurred when the expenditures relate to our research and development efforts and have no alternative future use. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.
All of our research and development expense incurred to date has been incurred in connection with the development of tesetaxel. We do not expect our research and development expense to change significantly in the near term.
The following table summarizes our research and development expense for each of the periods below (in thousands):
|
|
|
Year Ended |
|
|||||
|
|
|
December 31, |
|
|||||
|
|
|
2020 |
|
|
2019 |
|
||
|
Non-personnel expense: |
|
|
|
|
|
|
|
|
|
Clinical development |
|
$ |
72,697 |
|
|
$ |
63,748 |
|
|
Other |
|
|
1,966 |
|
|
|
2,209 |
|
|
Total non-personnel expense |
|
|
74,663 |
|
|
|
65,957 |
|
|
Personnel expense: |
|
|
|
|
|
|
|
|
|
Salaries, bonuses and benefits |
|
|
33,673 |
|
|
|
28,137 |
|
|
Equity-based compensation expense |
|
|
8,705 |
|
|
|
9,940 |
|
|
Total personnel expense |
|
|
42,378 |
|
|
|
38,077 |
|
|
Total research and development expense |
|
$ |
117,041 |
|
|
$ |
104,034 |
|
Research and development expense was $117.0 million and $104.0 million for the years ended December 31, 2020 and 2019, respectively. The increase in research and development expense of $13.0 million was due primarily to increased activities and headcount in connection with our tesetaxel clinical development program.
General and Administrative Expense
General and administrative expense includes non-personnel and personnel-related expense. Non-personnel-related expense includes expense related to: (i) professional fees for legal, patent, consulting, accounting and audit services; (ii) insurance; and (iii) facilities and information technology. Personnel-related expense includes expense related to salaries, benefits and equity-based compensation for personnel engaged in finance and administrative functions. We do not expect our general and administrative expense to change significantly in the near term.
The following table summarizes our general and administrative expense for each of the periods below (in thousands):
|
|
|
Year Ended |
|
|||||
|
|
|
December 31, |
|
|||||
|
|
|
2020 |
|
|
2019 |
|
||
|
Non-personnel expense |
|
$ |
5,256 |
|
|
$ |
5,199 |
|
|
Personnel expense: |
|
|
|
|
|
|
|
|
|
Salaries, bonuses and benefits |
|
|
4,013 |
|
|
|
4,193 |
|
|
Equity-based compensation expense |
|
|
1,123 |
|
|
|
1,504 |
|
|
Total personnel expense |
|
|
5,136 |
|
|
|
5,697 |
|
|
Total general and administrative expense |
|
$ |
10,392 |
|
|
$ |
10,896 |
|
General and administrative expense of $10.4 million for the year ended December 31, 2020 remained consistent compared to $10.9 million for the year ended December 31, 2019.
67
Other Income, Net
Other income, net consists primarily of interest income generated from cash held in savings accounts. Other income, net also includes losses on disposal of property and equipment and gains and losses on foreign currency transactions.
Other income, net was $1.1 million and $3.1 million for the years ended December 31, 2020 and December 31, 2019, respectively. The decrease in other income, net was due primarily to decreased interest income as a result of lower interest rates during the year ended December 31, 2020.
Liquidity and Capital Resources
As of December 31, 2020 and 2019, we had cash in the amount of $157.3 million and $180.5 million, respectively. We believe that our existing cash will be sufficient to meet our anticipated cash requirements through at least one year from the date this Annual Report on Form 10-K is filed with the U.S. Securities and Exchange Commission.
We have incurred losses in each year since our inception. Our net loss was $126.4 million and $111.8 million for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020 and 2019, we had an accumulated deficit of $366.4 million and $240.1 million, respectively. Substantially all of our operating losses resulted from expenses incurred in connection with advancing tesetaxel through development activities and general and administrative costs associated with our operations.
To date, we have funded our operations through the sale of equity securities. For a discussion of the underwritten public offerings closed during the years ended December 31, 2020 and 2019, see Note 5 to our audited financial statements included in Item 8 of this Annual Report on Form 10-K. Since our inception, we have raised $467.4 million in net proceeds from the sale of equity securities.
The following table summarizes our net cash flow activity for each of the periods below (in thousands):
|
|
|
Year Ended |
|
|||||
|
|
|
December 31, |
|
|||||
|
|
|
2020 |
|
|
2019 |
|
||
|
Net cash (used in) provided by: |
|
|
|
|
|
|
|
|
|
Operating activities |
|
$ |
(113,130 |
) |
|
$ |
(96,638 |
) |
|
Investing activities |
|
|
(432 |
) |
|
|
(166 |
) |
|
Financing activities |
|
|
90,367 |
|
|
|
138,677 |
|
|
Net (decrease) increase in cash and restricted cash |
|
$ |
(23,195 |
) |
|
$ |
41,873 |
|
Net cash used in operating activities was $113.1 million and $96.6 million for the years ended December 31, 2020 and 2019, respectively. Net cash used in operating activities was primarily the result of our net loss and change in working capital, partially offset by equity-based compensation expense, depreciation and amortization expense and non-cash lease expense.
Net cash used in investing activities was $0.4 million and $0.2 million for the years ended December 31, 2020 and 2019, respectively. Net cash used in investing activities was the result of purchases of property and equipment.
Net cash provided by financing activities was $90.4 million and $138.7 million for the years ended December 31, 2020 and 2019, respectively. Net cash provided by financing activities was primarily the result of net proceeds from the sale of common stock in underwritten public offerings.
Until such time as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic partnerships and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the
68
terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic partnerships or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, associated intellectual property, our other technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidate even if we would otherwise prefer to develop and market such product candidate ourselves.
Impact of the COVID-19 Pandemic
Although the ongoing Coronavirus Disease 2019 (“COVID-19”) pandemic did not have a material impact on our results of operations, financial condition or clinical studies during the year ended December 31, 2020, we are unable to accurately predict the full impact that the COVID-19 pandemic will have on our business in the future due to numerous factors that are not within our control, including its duration and severity.
Contractual Obligations and Commitments
In February 2018, we entered into an agreement to lease office space in New York, New York (the “New York Lease”) with aggregate payments of approximately $2.8 million over the 7-year term of the lease. We have an option to extend the New York Lease for an additional three years at the end of the initial term. Further, we provided a standby letter of credit of $0.3 million in lieu of a security deposit during the term of the lease, subject to a reduction 3.5 years after the lease commencement. As of December 31, 2020, $0.3 million was pledged as collateral for the letter of credit and was recorded as restricted cash.
In March 2018, we entered into an agreement to lease office space in San Diego, California (the “San Diego Lease”) with aggregate payments of approximately $0.8 million over the term of the lease. The San Diego Lease originally provided for expiration on December 31, 2019. In August 2019, we entered into a First Amendment to the San Diego Lease to extend the term of the lease through the commencement of the New San Diego Lease (defined below).
In October 2019, we entered into an agreement to lease office space in San Diego, California (the “New San Diego Lease”) with aggregate payments of approximately $4.1 million over the 7.5-year term of the lease. The New San Diego Lease commenced in July 2020. We have an option to extend the New San Diego Lease for an additional 5 years at the end of the initial term. Further, we provided a standby letter of credit of $0.5 million as a security deposit during the term of the lease, subject to certain reductions beginning 4 years after the lease commencement. As of December 31, 2020, $0.5 million was pledged as collateral for the letter of credit and recorded as restricted cash.
We enter into contracts in the normal course of business with contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments.
69
In 2013, we licensed rights to tesetaxel in all major markets from Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), the original inventor of the product. Under the Daiichi Sankyo license agreement, we are obligated to use commercially reasonable efforts to develop and commercialize tesetaxel in the following countries: France, Germany, Italy, Spain, the United Kingdom and the U.S. We are required to make aggregate future milestone payments of up to $31.0 million, contingent on attainment of certain regulatory milestones. Additionally, we are obligated to pay Daiichi Sankyo a tiered royalty that ranges from the low to high single digits, depending on annual net sales of tesetaxel.
Off–Balance Sheet Arrangements
During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under the rules of the SEC.
Jumpstart Our Business Startups Act
We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under this act, an emerging growth company can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. However, we intend to rely on other exemptions provided by the JOBS Act, including without limitation, an exemption from the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended. We will remain an emerging growth company until December 31, 2023 unless, prior to that time, we: (i) have more than $1.07 billion in annual gross revenue; (ii) have a market value for shares of our common stock held by non-affiliates of more than $700 million as of the last day of our second quarter of any year; or (iii) issue more than $1.0 billion of non-convertible debt over a three-year period.
Critical Accounting Policies and Significant Judgments and Estimates
Our management’s discussion and analysis of financial condition and results of operations is based on our audited financial statements, which have been prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses during the reporting periods. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ materially from these estimates under different assumptions or conditions.
While our significant accounting policies are more fully described in the notes to our audited financial statements elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies related to accrued expenses and equity-based compensation are most critical to understanding and evaluating our reported financial results.
Accrued Expenses
As part of the process of preparing our financial statements, we are required to estimate our accrued expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for
70
services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of estimated accrued expenses include costs associated with conducting our development and regulatory activities, including fees paid to third-party professional consultants and service providers, and costs to develop and manufacture clinical study materials.
We base our accrued expenses on our estimates of the services received and efforts expended pursuant to our contractual arrangements. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our service providers will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepayment accordingly.
Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differs from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. To date, there have been no material differences from our estimates to the amount actually incurred.
Equity-based Compensation Expense
We issue stock options and had historically issued incentive units, considered “profits interests” within the meaning of U.S. federal and state tax rules, to directors, officers, employees and consultants. Equity-based compensation expense represents the estimated fair value of equity awards, which are comprised of stock options and incentive units, expected to vest. We estimate the fair value of each equity award on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the use of estimates and assumptions, including expected volatility of our stock price, expected term of the equity awards, the risk-free interest rate, expected dividend yield and estimated forfeiture rate. We recognize equity-based compensation expense over the requisite service period of the equity awards (usually the vesting period) on a straight-line basis. For stock options with a performance condition, we recognize expense in accordance with Financial Accounting Standards Board Accounting Standards Codification 718-10-25-20.
Recent Accounting Pronouncements
See Note 2 to the audited financial statements included in Item 8 of this Annual Report on Form 10-K.
Item 7A. Quantitative and Qualitative Disclosures about Market Risk
We are a smaller reporting company, as defined by Rule 12b-2 under the Securities and Exchange Act of 1934 and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.
Item 8. Financial Statements and Supplementary Data
Our financial statements, together with the report of our independent registered public accounting firm, appear in this Annual Report on Form 10-K beginning on page F-1.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
71
Item 9A. Controls and Procedures
Management’s Evaluation of our Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures. Based on that evaluation of our disclosure controls and procedures as of December 31, 2020, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Management’s Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the U.S.
As of December 31, 2020, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (“2013 Framework”). Based on this assessment, our management concluded that our internal control over financial reporting was effective as of December 31, 2020.
This Annual Report on Form 10-K does not include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. Our auditors will not be required to opine on the effectiveness of our internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002 until we are no longer an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting that occurred during our most recent quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Item 9B. Other Information
None.
72
PART III
Item 10. Directors, Executive Officers and Corporate Governance
Directors and Executive Officers
The following table sets forth certain information regarding members of our Board of Directors (the “Board”) and our executive officers as of the date of this Annual Report on Form 10-K. There are no family relationships among any of our directors or executive officers.
|
Name |
|
Age |
|
Position |
|
Kevin Tang |
|
53 |
|
Chairman and Chief Executive Officer |
|
Aaron Davis(1)(2)(3) |
|
42 |
|
Director |
|
Craig Johnson(1)(2)(3) |
|
59 |
|
Director |
|
Laura Johnson(1) |
|
56 |
|
Director |
|
Robert Rosen |
|
65 |
|
Director |
|
Joseph O’Connell, M.D. |
|
66 |
|
Chief Medical Officer |
|
Michael Hearne |
|
58 |
|
Chief Financial Officer |
|
(1) |
Member of the Audit Committee |
|
(2) |
Member of the Compensation Committee |
|
(3) |
Member of the Nominating and Corporate Governance Committee |
Each of our directors stands for election at each annual meeting of stockholders and, if elected, will serve from the time of election and qualification until the next annual meeting. Each director’s term continues until the election and qualification of his or her successor, or his or her earlier death, resignation or removal. Each of our executive officers was appointed to serve until such officer’s resignation or removal.
The following is a biographical summary of the experience of our directors and executive officers:
Kevin Tang
Mr. Tang has served as our Chairman and Chief Executive Officer since the Company’s inception in 2013. He also serves as President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002 and an affiliate of the Company. Since 2014, Mr. Tang has served as a director and Chairman of La Jolla Pharmaceutical Company. From 2009 to 2020, he served as a director of Heron Therapeutics, Inc. and, from 2012 to 2020, served as Chairman. From 2009 through its acquisition by Endo Pharmaceuticals, Inc. in 2010, Mr. Tang served as a director of Penwest Pharmaceuticals Co. In 2006, he co-founded Ardea Biosciences, Inc. and served as a director from inception through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, Mr. Tang served as a director of Trimeris, Inc. From 1993 to 2001, he held various positions at Deutsche Banc Alex Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm’s Life Sciences research group. Mr. Tang received a B.S. degree from Duke University. The Board has concluded that Mr. Tang should serve as a director based on his experience forming and building biotechnology companies, serving as a director of biotechnology companies and serving as a manager of funds specializing in the area of life sciences.
Aaron Davis
Mr. Davis has served as a director since 2016. Since 2012, he has served as Chief Executive Officer of Boxer Capital, the healthcare arm of Tavistock Group. Mr. Davis co-founded Boxer Capital in 2005 and, prior to being appointed Chief Executive Officer, served as Portfolio Manager. Since 2020, he has also served as Chief Executive Officer and a director of BCTG Acquisition Corp., a special purpose acquisition company. Mr. Davis serves as Chairman of CiVi Biopharma, Inc., a director of Sojournix, Inc., a director of Mirati Therapeutics, Inc. and a director of iTeos Therapeutics, Inc. From 2006 to 2008, Mr. Davis served as a director of Kalypsys, Inc. From 2000 to 2004, he worked in the Global Healthcare Investment Banking and Private Equity Group at UBS Warburg, LLC. Mr. Davis received an M.A. degree
73
in biotechnology from Columbia University and a B.B.A. degree in finance from Emory University. The Board has concluded that Mr. Davis should serve as a director based on his experience serving as a director of biotechnology companies and serving as a manager of funds specializing in the area of life sciences.
Craig Johnson
Mr. Johnson has served as a director since 2017. He also serves as a director of Heron Therapeutics, Inc., a director of La Jolla Pharmaceutical Company and a director of Mirati Therapeutics, Inc. From 2015 to 2018, Mr. Johnson served as a director of Decipher Biosciences, Inc. From 2011 to 2014, he served as a director of Adamis Pharmaceuticals Corporation, and, from 2008 until its acquisition by AstraZeneca PLC in 2012, Mr. Johnson served as a director of Ardea Biosciences, Inc. From 2011 to 2012, he served as Chief Financial Officer of PURE Bioscience, Inc., and, from 2010 to 2011, Mr. Johnson served as Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. From 2004 through its acquisition by Raptor Pharmaceuticals Corp. in 2009, he served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. and, from 2009 to 2010, Mr. Johnson served as Vice President of a wholly owned subsidiary of Raptor Pharmaceuticals Corp. From 1994 to 2004, he held various positions at MitoKor, Inc., most recently serving as Chief Financial Officer and Senior Vice President of Operations. Mr. Johnson practiced as a Certified Public Accountant with Price Waterhouse, and he received a B.B.A. degree in accounting from the University of Michigan-Dearborn. The Board has concluded that Mr. Johnson should serve as a director based on his experience serving as a director of biotechnology companies and his expertise in financial management.
Laura Johnson
Ms. Johnson has served as a director since 2018. She serves as President and Chief Executive Officer of Next Generation Clinical Research Consulting, Inc., a contract research organization servicing the pharmaceutical industry that she founded in 1999. Additionally, Ms. Johnson serves as the President and Chief Executive Officer of Eufaeria Biosciences, Inc., a biotechnology company that she founded in 2016. Since 2013, she has served as a director of La Jolla Pharmaceutical Company, and since 2020, Ms. Johnson has served as a director of Kintara Therapeutics, Inc. She is also a founder, and from 2007 to 2019 served as a director, of Sb Bancorp, Inc. and Settlers Bank, Inc. Ms. Johnson received a nursing degree from The University of the State of New York-Albany. The Board has concluded that Ms. Johnson should serve as a director based on her substantial operating experience and expertise in clinical study management.
Robert Rosen
Mr. Rosen has served as a director since 2017. Since 2014, he has served as a director of La Jolla Pharmaceutical Company. From 2013 to 2019, Mr. Rosen served as President and as a director of Heron Therapeutics, Inc. and, from 2012 to 2013, served as Senior Vice President and Chief Commercial Officer of Heron Therapeutics, Inc. From 2014 to 2015, he served as a director of Conkwest, Inc. (now NantKwest, Inc.). In 2012, Mr. Rosen served as Managing Partner of Scotia Nordic LLC, a life sciences advisory firm. From 2011 to 2012, he served as Senior Vice President of Global Commercial Operations at Dendreon Corporation. From 2005 to 2011, Mr. Rosen served as Global Head of Oncology at Bayer HealthCare Pharmaceuticals. From 2002 to 2005, he served as Vice President of the Oncology Business Unit at Sanofi-Synthèlabo Inc. Mr. Rosen received a B.S. degree in pharmacy from Northeastern University. The Board has concluded that Mr. Rosen should serve as a director based on his leadership experience in the biotechnology and pharmaceutical industries and expertise in commercializing pharmaceutical products.
Joseph O’Connell, M.D.
Dr. O’Connell has served as our Chief Medical Officer since 2017. From 2015 to 2017, he served as Vice President, Medical and Scientific Affairs, Hematology and Oncology at inVentiv Health Clinical, LLC. From 2007 to 2015, Dr. O’Connell held various positions at Pfizer Inc., most recently serving as Senior
74
Director and Asset Global Clinical Lead for Oncology. Prior to 2007, he practiced adult medical oncology for more than 15 years, including at the Yale Cancer Center. Dr. O’Connell received a B.S. degree in biology from Fordham University and an M.D. degree from the State University of New York and completed his Oncology Fellowship at Memorial Sloan Kettering Cancer Center.
Michael Hearne
Mr. Hearne has served as our Chief Financial Officer since 2018 and previously as Vice President of Finance and Accounting from 2015 to 2018. Since 2015, he has served as Chief Financial Officer of Tang Capital Management, LLC, a life sciences-focused investment company and an affiliate of the Company. Since 2020, Mr. Hearne has also served as Chief Financial Officer of La Jolla Pharmaceutical Company, a biopharmaceutical company. From 2014 to 2015, he served as a partner at Weaver & Tidwell, LLP. Mr. Hearne started his career in public accounting at Coopers & Lybrand. Mr. Hearne received a B.S. degree in accounting and a masters of accountancy, taxation from Brigham Young University and is a Certified Public Accountant (inactive) in the state of California.
Code of Conduct
We have adopted a Code of Conduct that applies to all of our directors, officers and employees, including our principal executive officer and principal financial and accounting officer. Our Code of Conduct is posted on our website located at www.odonate.com. We intend to disclose any material future amendments to, or waivers of, provisions of the Code of Conduct on our website within 4 business days after the date of the amendment or waiver.
Audit Committee and Audit Committee Financial Expert
We have a separately-designated standing audit committee (“Audit Committee”) established in accordance with Section 3(a)(58)(A) of the Exchange Act. The Audit Committee is comprised of Messrs. Davis and Johnson and Ms. Johnson, each of whom qualify as an independent director, as defined under applicable Nasdaq qualification standards. Additionally, Mr. Johnson qualifies as an “audit committee financial expert” as that term is defined in the rules and regulations established by the SEC.
75
Item 11. Executive Compensation
Summary Compensation Table
The following table summarizes information for the years ended December 31, 2020 and 2019 concerning the compensation paid or awarded to our principal executive officer and the two other most highly compensated executive officers as of December 31, 2020 (the “Named Executive Officers” or “NEOs”):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-Equity |
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
Option |
|
|
Incentive Plan |
|
|
All Other |
|
|
|
|
|
|
||||||
|
Name and Principal Position |
|
Year |
|
Salary |
|
|
Awards(1) |
|
|
Compensation(2) |
|
|
Compensation(3) |
|
|
Total |
|
||||||||||
|
Kevin Tang(4) |
|
2020 |
|
$ |
|
1 |
|
|
$ |
|
- |
|
|
$ |
|
- |
|
|
$ |
|
- |
|
|
$ |
|
1 |
|
|
Chairman and Chief Executive Officer |
|
2019 |
|
$ |
|
1 |
|
|
$ |
|
- |
|
|
$ |
|
- |
|
|
$ |
|
- |
|
|
$ |
|
1 |
|
|
Joseph O’Connell, M.D. |
|
2020 |
|
$ |
|
374,800 |
|
|
$ |
|
828,858 |
|
|
$ |
|
142,400 |
|
|
$ |
|
26,194 |
|
|
$ |
|
1,372,252 |
|
|
Chief Medical Officer |
|
2019 |
|
$ |
|
363,900 |
|
|
$ |
|
1,434,630 |
|
|
$ |
|
152,800 |
|
|
$ |
|
29,238 |
|
|
$ |
|
1,980,568 |
|
|
Michael Hearne(5) |
|
2020 |
|
$ |
|
191,781 |
|
|
$ |
|
320,945 |
|
|
$ |
|
51,400 |
|
|
$ |
|
8,045 |
|
|
$ |
|
572,172 |
|
|
Chief Financial Officer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
The amounts reported in this column reflect the grant-date fair values of stock options granted to each NEO, calculated in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, Compensation-Stock Compensation. For a discussion of the assumptions used to calculate the value of our stock options, see Note 6 to our audited financial statements included in Item 8 of this Annual Report on Form 10-K. |
|
(2) |
The amounts reported in this column reflect each NEO’s performance-based cash bonus paid. |
|
(3) |
The amounts reported in this column reflect the Company’s annual and matching contributions to each NEO’s 401(k) plan account, life insurance premiums and tax gross-up payments related to expense reimbursements. |
|
(4) |
Mr. Tang has elected to receive an annual salary of $1.00 and to not receive any bonuses, option awards or other compensation. |
|
(5) |
Mr. Hearne’s compensation reflects the portion of his time dedicated to the Company. Mr. Hearne’s compensation for 2019 is omitted, as he was not an NEO for that year. |
Outstanding Option Awards as of December 31, 2020
The following table presents information regarding the outstanding option awards held by each of the NEOs as of December 31, 2020:
|
|
|
|
|
|
|
Option Awards |
|||||||||||||
|
|
|
|
|
|
|
Number |
|
|
Number |
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
of Securities |
|
|
of Securities |
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
Underlying |
|
|
Underlying |
|
|
Option |
|
|
Option |
||||
|
|
|
|
|
Vesting |
|
Unexercised |
|
|
Unexercised |
|
|
Award |
|
|
Award |
||||
|
|
|
Award |
|
Commencement |
|
Option Awards (#) |
|
|
Option Awards (#) |
|
|
Exercise |
|
|
Expiration |
||||
|
Name |
|
Type |
|
Date |
|
Exercisable |
|
|
Unexercisable(1) |
|
|
Price ($) |
|
|
Date(2) |
||||
|
Kevin Tang(3) |
|
- |
|
- |
|
|
- |
|
|
|
- |
|
|
$ |
|
- |
|
|
- |
|
Joseph O’Connell, M.D. |
|
Incentive Unit |
|
9/9/2017 |
|
|
156,960 |
|
|
|
36,222 |
|
|
$ |
|
14.89 |
|
|
- |
|
|
|
Stock Option |
|
1/2/2018 |
|
|
8,214 |
|
|
|
3,051 |
|
|
$ |
|
24.73 |
|
|
1/2/2028 |
|
|
|
Stock Option |
|
4/13/2018 |
|
|
10 |
|
|
|
5 |
|
|
$ |
|
21.65 |
|
|
4/13/2028 |
|
|
|
Stock Option |
|
4/30/2018 |
|
|
12 |
|
|
|
5 |
|
|
$ |
|
21.08 |
|
|
4/30/2028 |
|
|
|
Stock Option |
|
5/15/2018 |
|
|
10 |
|
|
|
5 |
|
|
$ |
|
23.17 |
|
|
5/15/2028 |
|
|
|
Stock Option |
|
5/31/2018 |
|
|
9 |
|
|
|
5 |
|
|
$ |
|
23.99 |
|
|
5/31/2028 |
|
|
|
Stock Option |
|
6/15/2018 |
|
|
9 |
|
|
|
4 |
|
|
$ |
|
26.52 |
|
|
6/15/2028 |
|
|
|
Stock Option |
|
6/29/2018 |
|
|
10 |
|
|
|
6 |
|
|
$ |
|
22.08 |
|
|
6/29/2028 |
|
|
|
Stock Option |
|
7/13/2018 |
|
|
9 |
|
|
|
6 |
|
|
$ |
|
23.95 |
|
|
7/13/2028 |
|
|
|
Stock Option |
|
7/31/2018 |
|
|
11 |
|
|
|
6 |
|
|
$ |
|
19.77 |
|
|
7/31/2028 |
|
|
|
Stock Option |
|
8/15/2018 |
|
|
11 |
|
|
|
8 |
|
|
$ |
|
18.74 |
|
|
8/15/2028 |
|
|
|
Stock Option |
|
8/31/2018 |
|
|
11 |
|
|
|
7 |
|
|
$ |
|
19.19 |
|
|
8/31/2028 |
|
|
|
Stock Option |
|
9/14/2018 |
|
|
10 |
|
|
|
8 |
|
|
$ |
|
19.13 |
|
|
9/14/2028 |
76
|
|
|
Stock Option |
|
9/28/2018 |
|
|
10 |
|
|
|
8 |
|
|
$ |
|
19.41 |
|
|
9/28/2028 |
|
|
|
Stock Option |
|
10/15/2018 |
|
|
35 |
|
|
|
29 |
|
|
$ |
|
16.09 |
|
|
10/15/2028 |
|
|
|
Stock Option |
|
10/31/2018 |
|
|
39 |
|
|
|
33 |
|
|
$ |
|
14.50 |
|
|
10/31/2028 |
|
|
|
Stock Option |
|
11/15/2018 |
|
|
33 |
|
|
|
30 |
|
|
$ |
|
16.52 |
|
|
11/15/2028 |
|
|
|
Stock Option |
|
11/30/2018 |
|
|
35 |
|
|
|
31 |
|
|
$ |
|
15.76 |
|
|
11/30/2028 |
|
|
|
Stock Option |
|
12/14/2018 |
|
|
34 |
|
|
|
34 |
|
|
$ |
|
15.12 |
|
|
12/14/2028 |
|
|
|
Stock Option |
|
12/31/2018 |
|
|
40,037 |
|
|
|
40,037 |
|
|
$ |
|
14.08 |
|
|
12/31/2028 |
|
|
|
Stock Option |
|
1/15/2019 |
|
|
32 |
|
|
|
34 |
|
|
$ |
|
16.29 |
|
|
1/15/2029 |
|
|
|
Stock Option |
|
1/31/2019 |
|
|
31 |
|
|
|
33 |
|
|
$ |
|
16.57 |
|
|
1/31/2029 |
|
|
|
Stock Option |
|
2/15/2019 |
|
|
30 |
|
|
|
35 |
|
|
$ |
|
16.52 |
|
|
2/15/2029 |
|
|
|
Stock Option |
|
2/28/2019 |
|
|
30 |
|
|
|
35 |
|
|
$ |
|
16.48 |
|
|
2/28/2029 |
|
|
|
Stock Option |
|
3/15/2019 |
|
|
20 |
|
|
|
25 |
|
|
$ |
|
23.75 |
|
|
3/15/2029 |
|
|
|
Stock Option |
|
3/29/2019 |
|
|
21 |
|
|
|
27 |
|
|
$ |
|
22.11 |
|
|
3/29/2029 |
|
|
|
Stock Option |
|
4/15/2019 |
|
|
18 |
|
|
|
25 |
|
|
$ |
|
24.99 |
|
|
4/15/2029 |
|
|
|
Stock Option |
|
4/30/2019 |
|
|
23 |
|
|
|
32 |
|
|
$ |
|
19.66 |
|
|
4/30/2029 |
|
|
|
Stock Option |
|
5/15/2019 |
|
|
19 |
|
|
|
29 |
|
|
$ |
|
22.20 |
|
|
5/15/2029 |
|
|
|
Stock Option |
|
5/31/2019 |
|
|
20 |
|
|
|
30 |
|
|
$ |
|
21.49 |
|
|
5/31/2029 |
|
|
|
Stock Option |
|
6/14/2019 |
|
|
16 |
|
|
|
27 |
|
|
$ |
|
25.00 |
|
|
6/14/2029 |
|
|
|
Stock Option |
|
6/28/2019 |
|
|
- |
|
|
|
29 |
|
|
$ |
|
36.69 |
|
|
6/28/2029 |
|
|
|
Stock Option |
|
7/15/2019 |
|
|
- |
|
|
|
30 |
|
|
$ |
|
35.17 |
|
|
7/15/2029 |
|
|
|
Stock Option |
|
7/31/2019 |
|
|
- |
|
|
|
26 |
|
|
$ |
|
40.75 |
|
|
7/31/2029 |
|
|
|
Stock Option |
|
8/15/2019 |
|
|
- |
|
|
|
33 |
|
|
$ |
|
33.44 |
|
|
8/15/2029 |
|
|
|
Stock Option |
|
8/30/2019 |
|
|
- |
|
|
|
34 |
|
|
$ |
|
30.81 |
|
|
8/30/2029 |
|
|
|
Stock Option |
|
9/13/2019 |
|
|
- |
|
|
|
38 |
|
|
$ |
|
28.36 |
|
|
9/13/2029 |
|
|
|
Stock Option |
|
9/30/2019 |
|
|
- |
|
|
|
41 |
|
|
$ |
|
26.03 |
|
|
9/30/2029 |
|
|
|
Stock Option |
|
10/15/2019 |
|
|
- |
|
|
|
38 |
|
|
$ |
|
28.50 |
|
|
10/15/2029 |
|
|
|
Stock Option |
|
10/31/2019 |
|
|
- |
|
|
|
33 |
|
|
$ |
|
31.76 |
|
|
10/31/2029 |
|
|
|
Stock Option |
|
11/15/2019 |
|
|
- |
|
|
|
33 |
|
|
$ |
|
33.10 |
|
|
11/15/2029 |
|
|
|
Stock Option |
|
11/29/2019 |
|
|
- |
|
|
|
31 |
|
|
$ |
|
34.38 |
|
|
11/29/2029 |
|
|
|
Stock Option |
|
12/10/2019 |
|
|
- |
|
|
|
57,198 |
|
|
$ |
|
30.51 |
|
|
12/10/2029 |
|
|
|
Stock Option |
|
12/13/2019 |
|
|
- |
|
|
|
37 |
|
|
$ |
|
28.97 |
|
|
12/13/2029 |
|
|
|
Stock Option |
|
12/31/2019 |
|
|
- |
|
|
|
33 |
|
|
$ |
|
32.45 |
|
|
12/31/2029 |
|
|
|
Stock Option |
|
1/15/2020 |
|
|
- |
|
|
|
40 |
|
|
$ |
|
27.23 |
|
|
1/15/2030 |
|
|
|
Stock Option |
|
1/31/2020 |
|
|
- |
|
|
|
38 |
|
|
$ |
|
29.20 |
|
|
1/31/2030 |
|
|
|
Stock Option |
|
2/14/2020 |
|
|
- |
|
|
|
35 |
|
|
$ |
|
31.45 |
|
|
2/14/2030 |
|
|
|
Stock Option |
|
2/28/2020 |
|
|
- |
|
|
|
37 |
|
|
$ |
|
29.59 |
|
|
2/28/2030 |
|
|
|
Stock Option |
|
3/13/2020 |
|
|
- |
|
|
|
48 |
|
|
$ |
|
23.05 |
|
|
3/13/2030 |
|
|
|
Stock Option |
|
3/31/2020 |
|
|
- |
|
|
|
40 |
|
|
$ |
|
27.61 |
|
|
3/31/2030 |
|
|
|
Stock Option |
|
4/15/2020 |
|
|
- |
|
|
|
41 |
|
|
$ |
|
26.85 |
|
|
4/15/2030 |
|
|
|
Stock Option |
|
4/30/2020 |
|
|
- |
|
|
|
39 |
|
|
$ |
|
28.15 |
|
|
4/30/2030 |
|
|
|
Stock Option |
|
5/15/2020 |
|
|
- |
|
|
|
39 |
|
|
$ |
|
28.24 |
|
|
5/15/2030 |
|
|
|
Stock Option |
|
5/29/2020 |
|
|
- |
|
|
|
34 |
|
|
$ |
|
32.67 |
|
|
5/29/2030 |
|
|
|
Stock Option |
|
6/15/2020 |
|
|
- |
|
|
|
27 |
|
|
$ |
|
40.25 |
|
|
6/15/2030 |
|
|
|
Stock Option |
|
6/30/2020 |
|
|
- |
|
|
|
26 |
|
|
$ |
|
42.34 |
|
|
6/30/2030 |
|
|
|
Stock Option |
|
7/15/2020 |
|
|
- |
|
|
|
27 |
|
|
$ |
|
41.17 |
|
|
7/15/2030 |
|
|
|
Stock Option |
|
7/31/2020 |
|
|
- |
|
|
|
30 |
|
|
$ |
|
36.37 |
|
|
7/31/2030 |
|
|
|
Stock Option |
|
8/14/2020 |
|
|
- |
|
|
|
31 |
|
|
$ |
|
36.13 |
|
|
8/14/2030 |
|
|
|
Stock Option |
|
8/31/2020 |
|
|
- |
|
|
|
69 |
|
|
$ |
|
16.15 |
|
|
8/31/2030 |
|
|
|
Stock Option |
|
9/15/2020 |
|
|
- |
|
|
|
72 |
|
|
$ |
|
15.37 |
|
|
9/15/2030 |
|
|
|
Stock Option |
|
9/30/2020 |
|
|
- |
|
|
|
82 |
|
|
$ |
|
13.43 |
|
|
9/30/2030 |
|
|
|
Stock Option |
|
10/15/2020 |
|
|
- |
|
|
|
117 |
|
|
$ |
|
15.70 |
|
|
10/15/2030 |
|
|
|
Stock Option |
|
10/30/2020 |
|
|
- |
|
|
|
127 |
|
|
$ |
|
14.41 |
|
|
10/30/2030 |
77
|
|
|
Stock Option |
|
11/13/2020 |
|
|
- |
|
|
|
128 |
|
|
$ |
|
14.35 |
|
|
11/13/2030 |
|
|
|
Stock Option |
|
11/30/2020 |
|
|
- |
|
|
|
122 |
|
|
$ |
|
15.02 |
|
|
11/30/2030 |
|
|
|
Stock Option |
|
12/8/2020 |
|
|
- |
|
|
|
60,373 |
|
|
$ |
|
16.52 |
|
|
12/8/2030 |
|
|
|
Stock Option |
|
12/15/2020 |
|
|
- |
|
|
|
121 |
|
|
$ |
|
15.19 |
|
|
12/15/2030 |
|
|
|
Stock Option |
|
12/31/2020 |
|
|
- |
|
|
|
169 |
|
|
$ |
|
19.20 |
|
|
12/31/2030 |
|
Michael Hearne |
|
Stock Option |
|
4/13/2018 |
|
|
39 |
|
|
|
19 |
|
|
$ |
|
21.65 |
|
|
4/13/2028 |
|
|
|
Stock Option |
|
4/30/2018 |
|
|
40 |
|
|
|
20 |
|
|
$ |
|
21.08 |
|
|
4/30/2028 |
|
|
|
Stock Option |
|
5/15/2018 |
|
|
36 |
|
|
|
19 |
|
|
$ |
|
23.17 |
|
|
5/15/2028 |
|
|
|
Stock Option |
|
5/31/2018 |
|
|
35 |
|
|
|
18 |
|
|
$ |
|
23.99 |
|
|
5/31/2028 |
|
|
|
Stock Option |
|
6/15/2018 |
|
|
15 |
|
|
|
8 |
|
|
$ |
|
26.52 |
|
|
6/15/2028 |
|
|
|
Stock Option |
|
6/29/2018 |
|
|
19 |
|
|
|
10 |
|
|
$ |
|
22.08 |
|
|
6/29/2028 |
|
|
|
Stock Option |
|
7/13/2018 |
|
|
16 |
|
|
|
11 |
|
|
$ |
|
23.95 |
|
|
7/13/2028 |
|
|
|
Stock Option |
|
7/31/2018 |
|
|
19 |
|
|
|
13 |
|
|
$ |
|
19.77 |
|
|
7/31/2028 |
|
|
|
Stock Option |
|
8/15/2018 |
|
|
20 |
|
|
|
14 |
|
|
$ |
|
18.74 |
|
|
8/15/2028 |
|
|
|
Stock Option |
|
8/31/2018 |
|
|
20 |
|
|
|
13 |
|
|
$ |
|
19.19 |
|
|
8/31/2028 |
|
|
|
Stock Option |
|
9/14/2018 |
|
|
19 |
|
|
|
14 |
|
|
$ |
|
19.13 |
|
|
9/14/2028 |
|
|
|
Stock Option |
|
9/28/2018 |
|
|
18 |
|
|
|
14 |
|
|
$ |
|
19.41 |
|
|
9/28/2028 |
|
|
|
Stock Option |
|
10/15/2018 |
|
|
22 |
|
|
|
18 |
|
|
$ |
|
16.09 |
|
|
10/15/2028 |
|
|
|
Stock Option |
|
10/31/2018 |
|
|
24 |
|
|
|
20 |
|
|
$ |
|
14.50 |
|
|
10/31/2028 |
|
|
|
Stock Option |
|
11/15/2018 |
|
|
20 |
|
|
|
18 |
|
|
$ |
|
16.52 |
|
|
11/15/2028 |
|
|
|
Stock Option |
|
11/30/2018 |
|
|
21 |
|
|
|
19 |
|
|
$ |
|
15.76 |
|
|
11/30/2028 |
|
|
|
Stock Option |
|
12/14/2018 |
|
|
21 |
|
|
|
21 |
|
|
$ |
|
15.12 |
|
|
12/14/2028 |
|
|
|
Stock Option |
|
12/31/2018 |
|
|
22,523 |
|
|
|
22,522 |
|
|
$ |
|
14.08 |
|
|
12/31/2028 |
|
|
|
Stock Option |
|
1/15/2019 |
|
|
19 |
|
|
|
21 |
|
|
$ |
|
16.29 |
|
|
1/15/2029 |
|
|
|
Stock Option |
|
1/31/2019 |
|
|
19 |
|
|
|
19 |
|
|
$ |
|
16.57 |
|
|
1/31/2029 |
|
|
|
Stock Option |
|
2/15/2019 |
|
|
18 |
|
|
|
21 |
|
|
$ |
|
16.52 |
|
|
2/15/2029 |
|
|
|
Stock Option |
|
2/28/2019 |
|
|
18 |
|
|
|
21 |
|
|
$ |
|
16.48 |
|
|
2/28/2029 |
|
|
|
Stock Option |
|
3/15/2019 |
|
|
12 |
|
|
|
15 |
|
|
$ |
|
23.75 |
|
|
3/15/2029 |
|
|
|
Stock Option |
|
3/29/2019 |
|
|
13 |
|
|
|
16 |
|
|
$ |
|
22.11 |
|
|
3/29/2029 |
|
|
|
Stock Option |
|
4/15/2019 |
|
|
11 |
|
|
|
15 |
|
|
$ |
|
24.99 |
|
|
4/15/2029 |
|
|
|
Stock Option |
|
4/30/2019 |
|
|
14 |
|
|
|
19 |
|
|
$ |
|
19.66 |
|
|
4/30/2029 |
|
|
|
Stock Option |
|
5/15/2019 |
|
|
12 |
|
|
|
17 |
|
|
$ |
|
22.20 |
|
|
5/15/2029 |
|
|
|
Stock Option |
|
5/31/2019 |
|
|
12 |
|
|
|
18 |
|
|
$ |
|
21.49 |
|
|
5/31/2029 |
|
|
|
Stock Option |
|
6/14/2019 |
|
|
10 |
|
|
|
16 |
|
|
$ |
|
25.00 |
|
|
6/14/2029 |
|
|
|
Stock Option |
|
6/28/2019 |
|
|
- |
|
|
|
17 |
|
|
$ |
|
36.69 |
|
|
6/28/2029 |
|
|
|
Stock Option |
|
7/15/2019 |
|
|
- |
|
|
|
18 |
|
|
$ |
|
35.17 |
|
|
7/15/2029 |
|
|
|
Stock Option |
|
7/31/2019 |
|
|
- |
|
|
|
16 |
|
|
$ |
|
40.75 |
|
|
7/31/2029 |
|
|
|
Stock Option |
|
8/15/2019 |
|
|
- |
|
|
|
19 |
|
|
$ |
|
33.44 |
|
|
8/15/2029 |
|
|
|
Stock Option |
|
8/30/2019 |
|
|
- |
|
|
|
21 |
|
|
$ |
|
30.81 |
|
|
8/30/2029 |
|
|
|
Stock Option |
|
9/13/2019 |
|
|
- |
|
|
|
23 |
|
|
$ |
|
28.36 |
|
|
9/13/2029 |
|
|
|
Stock Option |
|
9/30/2019 |
|
|
- |
|
|
|
25 |
|
|
$ |
|
26.03 |
|
|
9/30/2029 |
|
|
|
Stock Option |
|
10/15/2019 |
|
|
- |
|
|
|
22 |
|
|
$ |
|
28.50 |
|
|
10/15/2029 |
|
|
|
Stock Option |
|
10/31/2019 |
|
|
- |
|
|
|
21 |
|
|
$ |
|
31.76 |
|
|
10/31/2029 |
|
|
|
Stock Option |
|
11/15/2019 |
|
|
- |
|
|
|
19 |
|
|
$ |
|
33.10 |
|
|
11/15/2029 |
|
|
|
Stock Option |
|
11/29/2019 |
|
|
- |
|
|
|
19 |
|
|
$ |
|
34.38 |
|
|
11/29/2029 |
|
|
|
Stock Option |
|
12/10/2019 |
|
|
- |
|
|
|
32,173 |
|
|
$ |
|
30.51 |
|
|
12/10/2029 |
|
|
|
Stock Option |
|
12/13/2019 |
|
|
- |
|
|
|
22 |
|
|
$ |
|
28.97 |
|
|
12/13/2029 |
|
|
|
Stock Option |
|
12/31/2019 |
|
|
- |
|
|
|
20 |
|
|
$ |
|
32.45 |
|
|
12/31/2029 |
|
|
|
Stock Option |
|
1/15/2020 |
|
|
- |
|
|
|
24 |
|
|
$ |
|
27.23 |
|
|
1/15/2030 |
|
|
|
Stock Option |
|
1/31/2020 |
|
|
- |
|
|
|
23 |
|
|
$ |
|
29.20 |
|
|
1/31/2030 |
|
|
|
Stock Option |
|
2/14/2020 |
|
|
- |
|
|
|
21 |
|
|
$ |
|
31.45 |
|
|
2/14/2030 |
|
|
|
Stock Option |
|
2/28/2020 |
|
|
- |
|
|
|
22 |
|
|
$ |
|
29.59 |
|
|
2/28/2030 |
78
|
|
|
Stock Option |
|
3/13/2020 |
|
|
- |
|
|
|
29 |
|
|
$ |
|
23.05 |
|
|
3/13/2030 |
|
|
|
Stock Option |
|
3/31/2020 |
|
|
- |
|
|
|
24 |
|
|
$ |
|
27.61 |
|
|
3/31/2030 |
|
|
|
Stock Option |
|
4/15/2020 |
|
|
- |
|
|
|
50 |
|
|
$ |
|
26.85 |
|
|
4/15/2030 |
|
|
|
Stock Option |
|
4/30/2020 |
|
|
- |
|
|
|
47 |
|
|
$ |
|
28.15 |
|
|
4/30/2030 |
|
|
|
Stock Option |
|
5/15/2020 |
|
|
- |
|
|
|
47 |
|
|
$ |
|
28.24 |
|
|
5/15/2030 |
|
|
|
Stock Option |
|
5/29/2020 |
|
|
- |
|
|
|
40 |
|
|
$ |
|
32.67 |
|
|
5/29/2030 |
|
|
|
Stock Option |
|
6/15/2020 |
|
|
- |
|
|
|
17 |
|
|
$ |
|
40.25 |
|
|
6/15/2030 |
|
|
|
Stock Option |
|
6/30/2020 |
|
|
- |
|
|
|
15 |
|
|
$ |
|
42.34 |
|
|
6/30/2030 |
|
|
|
Stock Option |
|
7/15/2020 |
|
|
- |
|
|
|
17 |
|
|
$ |
|
41.17 |
|
|
7/15/2030 |
|
|
|
Stock Option |
|
7/31/2020 |
|
|
- |
|
|
|
18 |
|
|
$ |
|
36.37 |
|
|
7/31/2030 |
|
|
|
Stock Option |
|
8/14/2020 |
|
|
- |
|
|
|
18 |
|
|
$ |
|
36.13 |
|
|
8/14/2030 |
|
|
|
Stock Option |
|
8/31/2020 |
|
|
- |
|
|
|
42 |
|
|
$ |
|
16.15 |
|
|
8/31/2030 |
|
|
|
Stock Option |
|
9/15/2020 |
|
|
- |
|
|
|
43 |
|
|
$ |
|
15.37 |
|
|
9/15/2030 |
|
|
|
Stock Option |
|
9/30/2020 |
|
|
- |
|
|
|
50 |
|
|
$ |
|
13.43 |
|
|
9/30/2030 |
|
|
|
Stock Option |
|
10/15/2020 |
|
|
- |
|
|
|
42 |
|
|
$ |
|
15.70 |
|
|
10/15/2030 |
|
|
|
Stock Option |
|
10/30/2020 |
|
|
- |
|
|
|
46 |
|
|
$ |
|
14.41 |
|
|
10/30/2030 |
|
|
|
Stock Option |
|
11/13/2020 |
|
|
- |
|
|
|
46 |
|
|
$ |
|
14.35 |
|
|
11/13/2030 |
|
|
|
Stock Option |
|
11/30/2020 |
|
|
- |
|
|
|
45 |
|
|
$ |
|
15.02 |
|
|
11/30/2030 |
|
|
|
Stock Option |
|
12/8/2020 |
|
|
- |
|
|
|
22,639 |
|
|
$ |
|
16.52 |
|
|
12/8/2030 |
|
|
|
Stock Option |
|
12/15/2020 |
|
|
- |
|
|
|
43 |
|
|
$ |
|
15.19 |
|
|
12/15/2030 |
|
|
|
Stock Option |
|
12/31/2020 |
|
|
- |
|
|
|
350 |
|
|
$ |
|
19.20 |
|
|
12/31/2030 |
|
(1) |
The incentive units and stock options granted prior to July 2019 vest with respect to 25% of the underlying shares of common stock on the first anniversary of the vesting commencement date, with the remaining shares of common stock vesting in equal monthly installments over the following three years. The stock options granted in July 2019 and later vest as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the NEO’s continued service to the Company through each vesting date. |
|
(2) |
The incentive units do not expire. |
|
(3) |
Mr. Tang has elected to receive an annual salary of $1.00 and to not receive any bonuses, option awards or other compensation. Accordingly, there were no option awards held by Mr. Tang as of December 31, 2020. |
Outstanding option awards held by the NEOs as of December 31, 2020 are comprised of incentive units issued under the Odonate Management Holdings Equity Incentive Plan (the “Management Plan”) and stock options issued under the Odonate Therapeutics, Inc. 2017 Stock Option Plan (the “2017 Plan”). The Management Plan and the 2017 Plan were adopted in order to allow for directors, officers, employees and consultants of Odonate (the “Management Plan Participants” and the “2017 Plan Participants”) to share in the performance of the Company. The incentive units issued under the Management Plan were issued to Odonate Management Holdings, LLC, which issued incentive units to the Management Plan Participants on the same terms and conditions. The incentive units generally vest over a 4-year period from either the date of grant or the commencement of service and are subject to continued service requirements. Generally, on termination of services, unvested incentive units are forfeited. The vested incentive units may be exercised by the Management Plan Participants, with the value received by the Management Plan Participants in the form of cash or shares of common stock equal to the fair market value on the date of exercise less the exercise price of the incentive unit. Following our initial public offering in December 2017, we have not granted, and will no longer grant, any incentive units. Recipients of stock options are eligible to purchase shares of our common stock at an exercise price equal to the fair market value of such stock on the date of grant. The maximum term of options granted under the 2017 Plan is 10 years. Stock options granted prior to July 2019 generally vest over a 4-year period from either the date of grant or the commencement of service and are subject to continued service requirements. Beginning in July 2019, stock options granted generally include a performance condition related to our development program.
79
Compensation Arrangements with Named Executive Officers
All compensation arrangements with NEOs constitute “at-will” employment, meaning the NEO can terminate employment at any time, for any reason or for no reason. Similarly, the Company is free to terminate an NEO at any time, for any reason or for no reason. NEOs receive an annual base salary and are eligible to earn an annual performance-based cash bonus. In determining the annual performance-based cash bonus for each NEO, the NEO’s annual base salary is multiplied by his target bonus percentage, and the resulting amount is then multiplied by the corporate performance percentage approved by the board of directors (the “Board”), which is dependent on the achievement of corporate performance goals. NEOs are also eligible to receive an equity interest in the Company in the form of option awards. Option awards granted prior to July 2019 generally vest over a 4-year period from either the date of grant or the commencement of service and are subject to continued service requirements. Beginning in July 2019, stock options granted generally include a performance condition related to our development program. Option awards are subject to accelerated vesting in the event of an NEO’s termination of employment by reason of death or disability or by the Company without cause within 24 months after the occurrence of a change in control. Compensation arrangements with NEOs do not provide for severance benefits.
Defined Contribution Plan
In 2016, we adopted a defined contribution 401(k) plan available to eligible employees, including NEOs. Employee contributions are voluntary, determined on an individual basis and limited to the maximum amount allowable under U.S. federal tax regulations. We make a mandatory annual contribution of 3% of the eligible employees’ compensation to the 401(k) plan. In addition, we make matching contributions of up to 6% of the eligible employees’ compensation to the 401(k) plan.
CEO Pay Ratio
We determined the ratio of the annual total compensation of our Chief Executive Officer to the annual total compensation of our median employee (the “CEO Pay Ratio”) in accordance with Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(u) of Regulation S-K.
For the year ended December 31, 2020:
|
|
• |
the annual total compensation of Kevin Tang, our Chief Executive Officer, was $1.00; |
|
|
• |
the annual total compensation of our median employee was $335,654; and |
|
|
• |
the CEO Pay Ratio was 0.000003:1. |
We identified our median employee as of December 31, 2020 based on a consistently applied compensation measure defined as the sum of: (i) annual base salary; (ii) annual target performance-based cash bonus; and (iii) grant-date fair value of option awards granted in 2020. We then calculated the annual total compensation of our median employee using the same methodology used for our NEOs in the Summary Compensation Table above.
Director Compensation
We adopted a director compensation plan whereby we pay an annual retainer of $50,000 per year to each non-employee director, with an additional $15,000 annual fee for service as chairperson of the Audit Committee and $10,000 annual fee for service as chairperson of the Compensation Committee. Such cash fees are generally paid quarterly in the last month of the quarter in which services are provided. We also may periodically grant option awards to such directors, but we have no current commitments to do so. We reimburse our directors for their reasonable out-of-pocket expenses incurred in performing services, including expenses for attending board and committee meetings.
80
The following table shows the compensation earned in 2020 by the directors who served on the Board during any portion of the year ended December 31, 2020:
|
|
|
Fees Earned or |
|
|
Option |
|
|
|
|
|
|
||||
|
Name |
|
Paid in Cash |
|
|
Awards(1) |
|
|
Total |
|
||||||
|
Kevin Tang(2) |
|
$ |
|
- |
|
|
$ |
|
- |
|
|
$ |
|
- |
|
|
Aaron Davis(2) |
|
$ |
|
- |
|
|
$ |
|
- |
|
|
$ |
|
- |
|
|
Craig Johnson |
|
$ |
|
75,000 |
|
|
$ |
|
199,442 |
|
|
$ |
|
274,442 |
|
|
Laura Johnson |
|
$ |
|
50,000 |
|
|
$ |
|
199,442 |
|
|
$ |
|
249,442 |
|
|
Robert Rosen |
|
$ |
|
50,000 |
|
|
$ |
|
199,442 |
|
|
$ |
|
249,442 |
|
|
(1) |
The amounts reported in this column reflect the grant-date fair values of stock options granted to the directors calculated in accordance with FASB ASC Topic 718, Compensation-Stock Compensation. For a discussion of the assumptions used to calculate the value of our stock options, see Note 6 to our audited financial statements included in Item 8 of this Annual Report on Form 10-K. The aggregate number of option awards outstanding for Mr. Johnson, Ms. Johnson and Mr. Rosen as of December 31, 2020 was 131,030, 75,000 and 131,030, respectively. There were no option awards held by Messrs. Tang and Davis as of December 31, 2020. |
|
(2) |
Messrs. Tang and Davis have waived all compensation for their services on the Board. |
81
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters
The following table presents information regarding beneficial ownership of our equity interests as of February 8, 2021 by:
|
|
• |
each stockholder or group of stockholders known by us to be the beneficial owner of more than 5% of any class of our voting securities; |
|
|
• |
our Named Executive Officers (“NEOs”); |
|
|
• |
each of our directors; and |
|
|
• |
all of our executive officers and directors as a group. |
The percentage ownership information shown in the column titled “Percentage of Shares Beneficially Owned” in the table below is based on 38,603,588 shares of common stock outstanding as of February 8, 2021.
Beneficial ownership is determined in accordance with the rules of the U.S. Securities and Exchange Commission (the “SEC”) and, thus, represents voting or investment power with respect to our securities as of February 8, 2021. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all equity interests beneficially owned, subject to community property laws where applicable. Unless otherwise indicated, the address of each individual listed in this table is 4747 Executive Drive, Suite 210, San Diego, California 92121.
|
|
|
Number of Shares |
|
|
Percentage of Shares |
||||
|
Name and Address of Beneficial Owner |
|
Beneficially Owned |
|
|
Beneficially Owned(1) |
||||
|
Greater than 5% Holders |
|
|
|
|
|
|
|
|
|
|
Tang Capital Partners, LP(2) |
|
|
16,031,893 |
|
|
|
41.5 |
|
% |
|
Affiliates of Boxer Capital(3) |
|
|
6,252,842 |
|
|
|
16.2 |
|
% |
|
Wellington Management Group LLP(4) |
|
|
3,771,744 |
|
|
|
9.8 |
|
% |
|
Janus Henderson Group plc(5) |
|
|
2,723,248 |
|
|
|
7.1 |
|
% |
|
Named Executive Officers and Directors |
|
|
|
|
|
|
|
|
|
|
Kevin Tang(2) |
|
|
16,031,893 |
|
|
|
41.5 |
|
% |
|
Aaron Davis(3) |
|
|
645,756 |
|
|
|
1.7 |
|
% |
|
Joseph O'Connell, M.D.(6) |
|
|
231,229 |
|
|
* |
|
% |
|
|
Craig Johnson(7) |
|
|
99,986 |
|
|
* |
|
% |
|
|
Robert Rosen(8) |
|
|
96,986 |
|
|
* |
|
% |
|
|
Laura Johnson(9) |
|
|
32,917 |
|
|
* |
|
% |
|
|
Michael Hearne(10) |
|
|
28,484 |
|
|
* |
|
% |
|
|
All executive officers and directors as a group (7 persons)(11) |
|
|
17,167,251 |
|
|
|
44.3 |
|
% |
|
* |
Indicates ownership of less than one percent. |
|
(1) |
Shares of common stock underlying stock options exercisable within 60 days after February 8, 2021 are deemed outstanding for the purpose of computing the percentage ownership of the person holding the stock options but are not deemed outstanding for the purpose of computing the percentage ownership of any other person. |
|
(2) |
These securities are beneficially owned by Tang Capital Partners, LP ("TCP"). TCP shares voting and dispositive power over such shares of common stock with Tang Capital Management, LLC (“TCM”) and Kevin Tang. TCM, as the general partner of TCP, and Mr. Tang, as the manager of TCM, may be deemed to beneficially own the shares of the common stock owned by TCP. Mr. Tang is Chairman and Chief Executive Officer of the Company. Additionally, these securities include a total of 671,631 shares of common stock that are held of record by Odonate Holdings, LLC (“Odonate Holdings”). Odonate Holdings has granted a proxy to TCP giving TCP the authority to vote 154,285 shares of common stock. Odonate Holdings has also granted a proxy to the Company giving the Company the authority to vote 1,245,685 shares of common stock in the same proportion as the votes cast by all other stockholders of the Company. Of the 1,245,685 shares of common stock, TCP controls the voting of 517,346 shares of common stock based on its proportional ownership in the Company. The address of the foregoing entities is 4747 Executive Drive, Suite 210, San Diego, California 92121. |
|
(3) |
Based on the Form 4 filed with the SEC on December 30, 2020. Affiliates of Boxer Capital consist of Boxer Capital, LLC (“Boxer Capital”), which is the beneficial owner of 5,607,086 shares of common stock, and Aaron Davis, Chief Executive Officer of Boxer Capital and a director of the Company, who is the beneficial owner of 645,756 shares of common stock. Boxer Asset |
82
|
Management Inc. (“Boxer Management”) is the majority owner of Boxer Capital. Joe Lewis, a natural person, is the sole indirect beneficial owner of and controls Boxer Management. Mr. Davis is not deemed to be the beneficial owner of the shares of common stock held by Boxer Capital. The address for the Affiliates of Boxer Capital is 12860 El Camino Real, Suite 300, San Diego, California 92130. |
|
(4) |
Based on the Schedule 13G/A filed with the SEC on February 4, 2021. These securities are beneficially owned by clients of the Wellington Investment Advisers. Wellington Management Group LLP is the parent holding company of certain holding companies and the Wellington Investment Advisers. The address of the foregoing entities is 280 Congress Street, Boston, Massachusetts 02210. |
|
(5) |
Based on the Schedule 13G filed with the SEC on February 12, 2021. Janus Henderson Group plc has a 100% ownership stake in Janus Capital Management LLC (“JCM”). JCM is an investment adviser or sub-adviser to various fund, individual and/or institutional clients (collectively, “Managed Portfolios”). JCM may be deemed to be the beneficial owner of these securities held by such Managed Portfolios, but JCM does not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaims any ownership associated with such rights. The address of Janus Henderson Group plc is 201 Bishopsgate, London EC2M 3AE, United Kingdom. |
|
(6) |
Includes 173,059 shares of common stock underlying incentive units and 54,825 shares of common stock underlying stock options exercisable by Dr. O’Connell within 60 days after February 8, 2021. |
|
(7) |
Includes 71,986 shares of common stock underlying incentive units and 25,000 shares of common stock underlying stock options exercisable by Mr. Johnson within 60 days after February 8, 2021. |
|
(8) |
Includes 71,986 shares of common stock underlying incentive units and 25,000 shares of common stock underlying stock options exercisable by Mr. Rosen within 60 days after February 8, 2021. |
|
(9) |
Includes 32,917 shares of common stock underlying stock options exercisable by Ms. Johnson within 60 days after February 8, 2021. |
|
(10) |
Includes 25,963 shares of common stock underlying stock options exercisable by Mr. Hearne within 60 days after February 8, 2021. Additionally, Mr. Hearne is Chief Financial Officer of the Company, as well as Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in a portion of the shares beneficially held by TCP. |
|
(11) |
Includes 317,031 shares of common stock underlying incentive units and 163,705 shares of common stock underlying stock options exercisable within 60 days after February 8, 2021 referred to in footnotes (6), (7), (8), (9) and (10). |
Equity Plan Compensation Information
The following table provides certain information regarding our equity compensation plans in effect as of December 31, 2020:
|
|
|
|
|
|
|
|
|
|
|
|
Number of |
|
|
|
|
|
Number of |
|
|
|
|
|
|
|
Securities Remaining |
|
||
|
|
|
Securities to Be |
|
|
Weighted-average |
|
|
Available for Future |
|
||||
|
|
|
Issued upon Exercise |
|
|
Exercise Price |
|
|
Issuance under Equity |
|
||||
|
|
|
of Outstanding |
|
|
of Outstanding |
|
|
Compensation Plans, |
|
||||
|
|
|
Options, Warrants |
|
|
Options, Warrants |
|
|
excluding Securities |
|
||||
|
|
|
and Rights |
|
|
and Rights |
|
|
Reflected in Column (1) |
|
||||
|
Plan Category |
|
(1) |
|
|
(2) |
|
|
(3) |
|
||||
|
Equity compensation plans approved by security holders(1) |
|
|
7,229,526 |
|
|
$ |
|
18.16 |
|
|
|
471,136 |
|
|
Equity compensation plans not approved by security holders |
|
|
- |
|
|
$ |
|
- |
|
|
|
- |
|
|
Total |
|
|
7,229,526 |
|
|
$ |
|
18.16 |
|
|
|
471,136 |
|
|
(1) |
Includes the Odonate Therapeutics, Inc. 2017 Stock Option Plan, Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan and Odonate Management Holdings Equity Incentive Plan. |
83
Item 13. Certain Relationships and Related Transactions, and Director Independence
We have described below each transaction or series of similar transactions since January 1, 2019, or any currently proposed transaction, to which we were or are a party in which:
|
|
• |
the amount involved exceeded or exceeds $120,000; and |
|
|
• |
any of our directors or executive officers, any beneficial owner of more than 5% of any class of our voting securities or any member of their immediate family had or will have a direct or indirect material interest. |
Beneficial ownership is determined in accordance with the rules of the U.S. Securities and Exchange Commission and generally includes voting or investment power with respect to such securities.
Related Party Transactions
On September 1, 2020, we closed an underwritten public offering of 5,614,036 shares of common stock at a public offering price of $14.25 per share (collectively with the underwriters’ option, the “September 2020 Offering”). The underwriters exercised in full their option to purchase 842,105 additional shares of common stock. In the September 2020 Offering, Tang Capital Partners, LP (“TCP”), which is beneficially owned by Mr. Tang, our Chairman and Chief Executive Officer, purchased 1,052,631 shares of common stock through the underwriters at the public offering price for an aggregate purchase price of $15.0 million. Boxer Capital, where Mr. Davis, one of our directors, is Chief Executive Officer, purchased 1,403,509 shares of common stock through the underwriters at the public offering price for an aggregate purchase price of $20.0 million. Wellington Management Group LLP, a beneficial owner of more than 5% of any class of our voting securities, purchased 1,600,000 shares of common stock through the underwriters at the public offering price for an aggregate purchase price of $22.8 million. Janus Capital Management LLC, an indirect subsidiary of Janus Henderson Group plc, which is a beneficial owner of more than 5% of any class of our voting securities, purchased 950,000 shares of common stock through the underwriters at the public offering price for an aggregate purchase price of $13.5 million.
On June 28, 2019, we closed an underwritten public offering of 4,750,000 shares of common stock at a public offering price of $26.00 per share (collectively with the underwriters’ option, the “June 2019 Offering”). On July 2, 2019, the underwriters exercised in full their option to purchase 712,500 additional shares of common stock. In the June 2019 Offering, TCP purchased 769,231 shares of common stock through the underwriters at the public offering price for an aggregate purchase price of $20.0 million. Boxer Capital purchased 384,615 shares of common stock through the underwriters at the public offering price for an aggregate purchase price of $10.0 million. Wellington Management Group LLP purchased 1,830,282 shares of common stock through the underwriters at the public offering price for an aggregate purchase price of $47.6 million. Jeff Vacirca, M.D., a director at the time of the June 2019 Offering, purchased 19,231 shares of common stock through the underwriters at the public offering price for an aggregate purchase price of $0.5 million.
Director Independence
Our Board has reviewed the independence of all directors in light of each director’s (or any family member’s, if applicable) affiliations with the Company and members of management, as well as significant holdings of the Company’s securities. The Board uses the definition of independence from the Nasdaq Stock Market listing standards to assess independence of our directors (the “Nasdaq Independence Rules”). The Nasdaq Independence Rules have objective tests and a subjective test for determining who is an “independent director.” The subjective test states that an independent director must be a person who lacks a relationship that, in the opinion of the board of directors (the “Board”), would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The Board has not established categorical standards or guidelines to make these subjective determinations but considers all relevant facts and circumstances. After considering the foregoing factors, our Board has determined that Messrs. Davis and Johnson and Ms. Johnson qualify as “independent directors,” as defined by the Nasdaq Independence Rules. Mr. Tang is deemed not to be independent
84
under the Nasdaq Independence Rules due to his current employment with the Company. Mr. Rosen is deemed not to be independent due to Mr. Tang’s prior service on the compensation committee of Heron Therapeutics, Inc.
The members of our Audit Committee must satisfy the independence criteria set forth in Rule 10A-3 under the Exchange Act (“Rule 10A-3”). In order to be considered independent for purposes of Rule 10A-3, no member of the Audit Committee may, other than in his or her capacity as a member of the Audit Committee, the Board or any other committee of the Board: (i) accept, directly or indirectly, any consulting, advisory or other compensatory fee from us or any of our subsidiaries; or (ii) directly, or indirectly through one or more intermediaries, control, be controlled by or be under common control with us or any of our subsidiaries.
Item 14. Principal Accountant Fees and Services
The following table represents aggregate fees billed to us by Squar Milner LLP (which, effective as of November 1, 2020, merged with Baker Tilly US, LLP), our principal accountant, for each of the periods below:
|
|
|
Year Ended |
|
|||||||
|
|
|
December 31, |
|
|||||||
|
|
|
2020 |
|
|
2019 |
|
||||
|
Audit Fees(1) |
|
$ |
|
140,904 |
|
|
$ |
|
145,161 |
|
|
Audit-related Fees |
|
|
|
- |
|
|
|
|
- |
|
|
Tax Fees |
|
|
|
- |
|
|
|
|
- |
|
|
All Other Fees |
|
|
|
- |
|
|
|
|
- |
|
|
Total |
|
$ |
|
140,904 |
|
|
$ |
|
145,161 |
|
|
(1) |
“Audit Fees” consists of fees for professional services provided in connection with: (i) the audit of our annual financial statements; (ii) the reviews of our quarterly financial statements; and (iii) the consents and other services related to U.S. Securities and Exchange Commission filings. |
Our Audit Committee approves in advance all services provided by our independent registered public accounting firm. All engagements of our independent registered public accounting firm for the years ended December 31, 2020 and 2019 were approved by the Audit Committee.
85
PART IV
Item 15. Exhibits and Financial Statement Schedules
(a)(1) Financial Statements
The response to this portion of Item 15 is set forth under Item 8 hereof.
(a)(2) Financial Statement Schedules
No financial statement schedules are provided because the information called for is not required or is shown in the financial statements or the notes thereto.
(a)(3) Exhibits
86
|
Exhibit
|
|
Description |
|
|
|
|
|
3.1 |
|
|
|
|
|
|
|
3.2 |
|
|
|
|
|
|
|
4.1* |
|
|
|
|
|
|
|
10.1+ |
|
|
|
|
|
|
|
10.2+ |
|
|
|
|
|
|
|
10.3+ |
|
|
|
|
|
|
|
10.4+ |
|
|
|
|
|
|
|
10.5† |
|
|
|
|
|
|
|
10.6+ |
|
|
|
|
|
|
|
16.1 |
|
|
|
|
|
|
|
24.1 |
|
|
|
|
|
|
|
31.1* |
|
|
|
|
|
|
|
31.2* |
|
|
|
|
|
|
|
32.1# |
|
|
|
|
|
|
|
101.INS* |
|
Inline XBRL Instance Document |
|
|
|
|
|
101.SCH* |
|
Inline XBRL Taxonomy Extension Schema Document |
|
|
|
|
|
101.CAL* |
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
|
|
|
|
|
101.DEF* |
|
Inline XBRL Taxonomy Extension Definition Linkbase Document |
|
|
|
|
|
101.LAB* |
|
Inline XBRL Taxonomy Extension Label Linkbase Document |
|
|
|
|
|
101.PRE* |
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
|
|
|
|
|
104 |
|
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
|
* |
Filed herewith |
|
† |
Confidential treatment has been granted with respect to certain portions (indicated by asterisks) of this exhibit. Omitted portions have been filed separately with the SEC. |
|
+ |
Indicates a management contract or compensatory plan or arrangement |
87
|
# |
Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act |
Item 16. Form 10-K Summary
None.
88
SIGNATURES
Pursuant to the requirements of Section 13 of 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
ODONATE THERAPEUTICS, INC. |
||
|
|
|
|
|
|
Date: February 23, 2021 |
By: |
|
/s/ Kevin Tang |
|
|
|
|
Kevin Tang |
|
|
|
|
Chairman and Chief Executive Officer |
89
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below hereby constitutes and appoints Kevin Tang and Michael Hearne, and each of them, the true and lawful attorneys-in-fact and agents of the undersigned, with full power of substitution and resubstitution, for and in the name, place and stead of the undersigned, to sign in any and all capacities (including, without limitation, the capacities listed below), with respect to this Annual Report on Form 10-K, and any and all amendments thereto, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the U.S. Securities and Exchange Commission (the “SEC”), and hereby grants to such attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and anything necessary to be done to enable Odonate Therapeutics, Inc. to comply with the provisions of the Securities Exchange Act of 1934 (the “Exchange Act”) and all the requirements of the SEC, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitute, or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Exchange Act, this report has been signed by the following persons in the capacities set forth opposite their names and on the dates indicated below.
|
Signature |
|
Title |
|
Date |
|
|
|
|
|
|
|
/s/ Kevin Tang Kevin Tang |
|
Chairman and Chief Executive Officer (principal executive officer) |
|
February 23, 2021 |
|
|
|
|
|
|
|
/s/ Michael Hearne Michael Hearne |
|
Chief Financial Officer (principal financial and accounting officer) |
|
February 23, 2021 |
|
|
|
|
|
|
|
/s/ Aaron Davis Aaron Davis |
|
Director |
|
February 23, 2021 |
|
|
|
|
|
|
|
/s/ Craig Johnson Craig Johnson |
|
Director |
|
February 23, 2021 |
|
|
|
|
|
|
|
/s/ Laura Johnson Laura Johnson |
|
Director |
|
February 23, 2021 |
|
|
|
|
|
|
|
/s/ Robert Rosen Robert Rosen |
|
Director |
|
February 23, 2021 |
90
ODONATE THERAPEUTICS, INC.
INDEX TO FINANCIAL STATEMENTS
F-1
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and the Board of Directors of
Odonate Therapeutics, Inc.
Opinion on the Financial Statements
We have audited the accompanying balance sheets of Odonate Therapeutics, Inc. (the Company) as of December 31, 2020 and 2019, the related statements of operations, stockholders’ equity and cash flows for the years then ended, and the related notes to the financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ Baker Tilly US, LLP
We have served as the Company's auditor since 2017.
San Diego, California
February 23, 2021
F-2
ODONATE THERAPEUTICS, INC.
Balance Sheets
(in thousands, except par value and share amounts)
|
|
|
December 31, |
|
|
December 31, |
|
||
|
|
|
2020 |
|
|
2019 |
|
||
|
Assets |
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
|
Cash |
|
$ |
157,265 |
|
|
$ |
180,460 |
|
|
Prepaid expenses and other current assets |
|
|
2,607 |
|
|
|
3,468 |
|
|
Total current assets |
|
|
159,872 |
|
|
|
183,928 |
|
|
Property and equipment, net |
|
|
2,286 |
|
|
|
1,663 |
|
|
Right-of-use lease assets |
|
|
4,017 |
|
|
|
1,581 |
|
|
Restricted cash |
|
|
714 |
|
|
|
714 |
|
|
Other |
|
|
997 |
|
|
|
941 |
|
|
Total assets |
|
$ |
167,886 |
|
|
$ |
188,827 |
|
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
14,168 |
|
|
$ |
15,583 |
|
|
Accrued expenses |
|
|
12,247 |
|
|
|
8,881 |
|
|
Lease liabilities, current portion |
|
|
658 |
|
|
|
315 |
|
|
Total current liabilities |
|
|
27,073 |
|
|
|
24,779 |
|
|
Lease liabilities, less current portion |
|
|
4,668 |
|
|
|
1,748 |
|
|
Total liabilities |
|
|
31,741 |
|
|
|
26,527 |
|
|
Commitments and contingencies (Note 4) |
|
|
|
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
|
|
|
|
|
Common stock, $0.01 par value—100,000,000 shares authorized; 38,562,281 and 32,050,906 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively |
|
|
367 |
|
|
|
300 |
|
|
Additional paid-in capital |
|
|
502,205 |
|
|
|
402,077 |
|
|
Accumulated deficit |
|
|
(366,427 |
) |
|
|
(240,077 |
) |
|
Total stockholders' equity |
|
|
136,145 |
|
|
|
162,300 |
|
|
Total liabilities and stockholders' equity |
|
$ |
167,886 |
|
|
$ |
188,827 |
|
See accompanying notes.
F-3
ODONATE THERAPEUTICS, INC.
Statements of Operations
(in thousands, except share and per share amounts)
|
|
|
Year Ended |
|
|||||
|
|
|
December 31, |
|
|||||
|
|
|
2020 |
|
|
2019 |
|
||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
Research and development |
|
$ |
117,041 |
|
|
$ |
104,034 |
|
|
General and administrative |
|
|
10,392 |
|
|
|
10,896 |
|
|
Total operating expenses |
|
|
127,433 |
|
|
|
114,930 |
|
|
Loss from operations |
|
|
(127,433 |
) |
|
|
(114,930 |
) |
|
Other income, net |
|
|
1,083 |
|
|
|
3,105 |
|
|
Net loss |
|
$ |
(126,350 |
) |
|
$ |
(111,825 |
) |
|
Net loss per share: |
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
$ |
(3.84 |
) |
|
$ |
(4.05 |
) |
|
Weighted-average shares outstanding: |
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
|
32,862,552 |
|
|
|
27,625,468 |
|
See accompanying notes.
F-4
ODONATE THERAPEUTICS, INC.
Statements of Stockholders’ Equity
(in thousands, except share amounts)
|
|
|
Common Stock |
|
|
Additional Paid-in |
|
|
Accumulated |
|
|
Total Stockholders' |
|
||||||||
|
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
|
Equity |
|
|||||
|
Balance at December 31, 2018 |
|
|
26,747,438 |
|
|
$ |
244 |
|
|
$ |
252,012 |
|
|
$ |
(128,252 |
) |
|
$ |
124,004 |
|
|
Issuance of common stock, net of issuance costs |
|
|
5,462,500 |
|
|
|
55 |
|
|
|
135,041 |
|
|
|
- |
|
|
|
135,096 |
|
|
Issuance of common stock under employee stock plans |
|
|
150,694 |
|
|
|
1 |
|
|
|
3,580 |
|
|
|
- |
|
|
|
3,581 |
|
|
Forfeiture of common stock underlying incentive units |
|
|
(309,726 |
) |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
Equity-based compensation expense |
|
|
- |
|
|
|
- |
|
|
|
11,444 |
|
|
|
- |
|
|
|
11,444 |
|
|
Net loss |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(111,825 |
) |
|
|
(111,825 |
) |
|
Balance at December 31, 2019 |
|
|
32,050,906 |
|
|
|
300 |
|
|
|
402,077 |
|
|
|
(240,077 |
) |
|
|
162,300 |
|
|
Issuance of common stock, net of issuance costs |
|
|
6,456,141 |
|
|
|
65 |
|
|
|
87,318 |
|
|
|
- |
|
|
|
87,383 |
|
|
Issuance of common stock under employee stock plans |
|
|
172,705 |
|
|
|
2 |
|
|
|
2,982 |
|
|
|
- |
|
|
|
2,984 |
|
|
Forfeiture of common stock underlying incentive units |
|
|
(117,471 |
) |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
Equity-based compensation expense |
|
|
- |
|
|
|
- |
|
|
|
9,828 |
|
|
|
- |
|
|
|
9,828 |
|
|
Net loss |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(126,350 |
) |
|
|
(126,350 |
) |
|
Balance at December 31, 2020 |
|
|
38,562,281 |
|
|
$ |
367 |
|
|
$ |
502,205 |
|
|
$ |
(366,427 |
) |
|
$ |
136,145 |
|
See accompanying notes.
F-5
ODONATE THERAPEUTICS, INC.
Statements of Cash Flows
(in thousands)
|
|
|
Year Ended |
|
|||||
|
|
|
December 31, |
|
|||||
|
|
|
2020 |
|
|
2019 |
|
||
|
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(126,350 |
) |
|
$ |
(111,825 |
) |
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
|
Equity-based compensation expense |
|
|
9,828 |
|
|
|
11,444 |
|
|
Depreciation and amortization |
|
|
445 |
|
|
|
426 |
|
|
Non-cash lease expense |
|
|
425 |
|
|
|
634 |
|
|
Loss on disposal of property and equipment |
|
|
83 |
|
|
|
- |
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
Prepaid expenses and other assets |
|
|
763 |
|
|
|
(2,936 |
) |
|
Accounts payable |
|
|
(1,415 |
) |
|
|
4,782 |
|
|
Accrued expenses |
|
|
3,366 |
|
|
|
1,516 |
|
|
Lease liabilities |
|
|
(275 |
) |
|
|
(679 |
) |
|
Net cash used in operating activities |
|
|
(113,130 |
) |
|
|
(96,638 |
) |
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(432 |
) |
|
|
(166 |
) |
|
Net cash used in investing activities |
|
|
(432 |
) |
|
|
(166 |
) |
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|
Proceeds from issuance of common stock, net of issuance costs |
|
|
87,383 |
|
|
|
135,096 |
|
|
Proceeds from issuance of common stock under employee stock plans |
|
|
2,984 |
|
|
|
3,581 |
|
|
Net cash provided by financing activities |
|
|
90,367 |
|
|
|
138,677 |
|
|
Net (decrease) increase in cash and restricted cash |
|
|
(23,195 |
) |
|
|
41,873 |
|
|
Cash and restricted cash, beginning of period |
|
|
181,174 |
|
|
|
139,301 |
|
|
Cash and restricted cash, end of period |
|
$ |
157,979 |
|
|
$ |
181,174 |
|
|
Supplemental disclosure of cash flow information: |
|
|
|
|
|
|
|
|
|
Initial recognition of right-of-use lease assets |
|
$ |
2,861 |
|
|
$ |
2,215 |
|
|
Tenant improvement allowance |
|
$ |
719 |
|
|
$ |
- |
|
|
Property and equipment purchases included in accounts payable |
|
$ |
1 |
|
|
$ |
24 |
|
See accompanying notes.
F-6
ODONATE THERAPEUTICS, INC.
Notes to Financial Statements
1. Business
Odonate Therapeutics, Inc. (“Odonate” or the “Company”) is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. The Company’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several properties that make it unique among taxanes, including:
|
|
• |
oral administration with a low pill burden; |
|
|
• |
a long (~8-day) terminal plasma half-life in humans, enabling the maintenance of adequate drug levels with relatively infrequent dosing; |
|
|
• |
no history of hypersensitivity (allergic) reactions; and |
|
|
• |
significant activity against chemotherapy-resistant tumors. |
In patients with metastatic breast cancer (“MBC”), tesetaxel was shown to have significant, single-agent antitumor activity in two multicenter, Phase 2 studies. Tesetaxel currently is the subject of three studies in breast cancer, including a multinational, multicenter, randomized, Phase 3 study in patients with MBC, known as CONTESSA. Positive results of CONTESSA were presented at the 2020 San Antonio Breast Cancer Symposium. The Company’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
As of December 31, 2020, the Company had $157.3 million in cash. The Company has incurred operating losses and negative cash flows from operations since inception. Management believes that the Company’s existing cash will be sufficient to meet the Company’s anticipated cash requirements through at least one year from the date this Annual Report on Form 10-K is filed with the U.S. Securities and Exchange Commission (the “SEC”).
2. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Use of Estimates
The Company’s financial statements are prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”). The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s financial statements relate to accrued expenses and equity-based compensation expense. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.
Segment Reporting
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.
F-7
ODONATE THERAPEUTICS, INC.
Notes to Financial Statements
Fair Value Measurements
The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
Level 1: Observable inputs such as quoted prices in active markets.
Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.
Level 3: Unobservable inputs for which there are little or no market data, which require the reporting entity to develop its own assumptions.
The carrying amounts of the Company’s cash, prepaid expenses and other current assets, accounts payable and accrued expenses are considered to be representative of their respective fair values because of the short-term nature of those instruments. As of December 31, 2020 and 2019, the Company had no financial assets or liabilities measured at fair value on a recurring basis.
Cash and Restricted Cash
The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. The Company maintains its cash in checking and savings accounts. Income generated from cash held in savings accounts is recorded as interest income. As of December 31, 2020 and 2019, the Company held no cash equivalents. Cash is classified as restricted cash when it is reserved for a specific purpose and, therefore, is not available for immediate or general business use.
Concentrations of Risk
Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.
Property and Equipment
Property and equipment consists of office equipment, software, furniture and fixtures and leasehold improvements. Office equipment, software and furniture and fixtures are stated at cost and depreciated on a straight-line basis over the estimated useful life of the related assets, which generally ranges from three to five years. Leasehold improvements are amortized over the lesser of the estimated useful life or the remaining term of the lease.
Impairment of Long-lived Assets
The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment is assessed by comparing an estimate of undiscounted future cash flows produced by the long-lived asset, including its eventual residual value, to the carrying value of the asset. When such cash flows are less than the carrying value, the asset is written down to its estimated fair value. No impairments were recorded for the years ended December 31, 2020 and 2019.
F-8
ODONATE THERAPEUTICS, INC.
Notes to Financial Statements
Leases
At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date.
After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.
Research and Development Expense
Research and development expense consists of expense associated with the development of tesetaxel and includes non-personnel-related and personnel-related expense. Non-personnel-related expense includes expense related to: (i) clinical study site payments; (ii) acquiring clinical study materials and the clinical study supply chain; (iii) manufacturing development and scale-up, including manufacturing registration and validation batches of tesetaxel; (iv) clinical and quality systems; and (v) regulatory submissions. Personnel-related expense includes expense related to salaries, benefits and equity-based compensation for personnel engaged in research and development functions.
Research and development expense is charged to operations as incurred when the expenditures relate to the Company’s research and development efforts and have no alternative future uses. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.
Patent Costs
Costs related to filing and pursuing patent applications are recorded as general and administrative expense and are expensed as incurred, since recoverability of such expenditures is uncertain.
Equity-based Compensation Expense
The Company issues stock options and had historically issued incentive units, considered “profits interests” within the meaning of U.S. federal and state tax rules, to directors, officers, employees and consultants. Equity-based compensation expense represents the estimated fair value of equity awards, which are comprised of stock options and incentive units, expected to vest. The Company estimates the fair value of each equity award on the date of grant using the Black-Scholes option-pricing model and recognizes equity-based compensation expense over the requisite service period of the equity awards (usually the vesting period) on a straight-line basis. For stock options with a performance condition, the Company recognizes expense in accordance with Financial Accounting Standards Board Accounting Standards Codification 718-10-25-20.
Income Taxes
Income taxes are accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective
F-9
ODONATE THERAPEUTICS, INC.
Notes to Financial Statements
tax bases, net operating losses incurred and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those assets or liabilities are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period of enactment. A valuation allowance against deferred tax assets is recorded if, based on the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. For uncertain tax positions that meet a “more likely than not” threshold, the Company recognizes the benefit of uncertain tax positions in the financial statements. The Company records interest and penalties, if any, related to uncertain tax positions as a component of income tax expense.
Comprehensive Loss
Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. There have been no items qualifying as other comprehensive loss, and, therefore, for all periods presented, the Company’s comprehensive loss was the same as its reported net loss.
Net Loss per Share
Basic net loss per share is calculated by dividing net loss by the weighted-average common shares outstanding during the period, without consideration of common stock equivalents. The basic net loss per share calculation excludes 1,245,685 and 1,454,577 outstanding shares of common stock held by Odonate Holdings, LLC (“Odonate Holdings”) as of December 31, 2020 and 2019, respectively, to be used to settle incentive units previously issued under the Odonate Management Holdings Equity Incentive Plan (the “Management Plan”). These shares of common stock are subject to transfer to the Company and cancellation until such incentive units are vested and exercised and, as such, are considered common stock equivalents. Therefore, the shares of common stock held by Odonate Holdings are excluded from the basic net loss per share calculation until the incentive units are exercised.
Diluted net loss per share is calculated by adjusting the weighted-average common shares outstanding for the dilutive effect of common stock equivalents outstanding for the period. Common stock equivalents, which consist of shares of common stock underlying incentive units and vested stock options, were excluded from the calculation of diluted net loss per share because they were anti-dilutive.
Recent Accounting Pronouncements
The Company has considered all recently issued accounting pronouncements and has concluded that there are no recently issued accounting pronouncements that may have a material impact on its results of operations, financial condition or cash flows based on current information.
3. Balance Sheet Details
Property and equipment consisted of the following (in thousands):
|
|
|
December 31, |
|
|
December 31, |
|
||
|
|
|
2020 |
|
|
2019 |
|
||
|
Leasehold improvements |
|
$ |
1,955 |
|
|
$ |
1,113 |
|
|
Office equipment |
|
|
791 |
|
|
|
698 |
|
|
Furniture and fixtures |
|
|
514 |
|
|
|
420 |
|
|
Software |
|
|
130 |
|
|
|
130 |
|
|
Total gross property and equipment |
|
|
3,390 |
|
|
|
2,361 |
|
|
Less accumulated depreciation and amortization |
|
|
(1,104 |
) |
|
|
(698 |
) |
|
Property and equipment, net |
|
$ |
2,286 |
|
|
$ |
1,663 |
|
F-10
ODONATE THERAPEUTICS, INC.
Notes to Financial Statements
Depreciation and amortization expense was $0.4 million for both the years ended December 31, 2020 and 2019.
Accrued expenses consisted of the following (in thousands):
|
|
|
December 31, |
|
|
December 31, |
|
||
|
|
|
2020 |
|
|
2019 |
|
||
|
Accrued clinical development costs |
|
$ |
9,537 |
|
|
$ |
6,667 |
|
|
Accrued compensation and related expenses |
|
|
2,658 |
|
|
|
2,122 |
|
|
Other accrued expenses |
|
|
52 |
|
|
|
92 |
|
|
Total accrued expenses |
|
$ |
12,247 |
|
|
$ |
8,881 |
|
4. Commitments and Contingencies
Lease Commitments
In February 2018, the Company entered into an agreement to lease office space in New York, New York (the “New York Lease”) with aggregate payments of approximately $2.8 million over the 7-year term of the lease. The Company has an option to extend the New York Lease for an additional three years at the end of the initial term. Further, the Company provided a standby letter of credit of $0.3 million in lieu of a security deposit during the term of the lease, subject to a reduction 3.5 years after the lease commencement. As of December 31, 2020, $0.3 million was pledged as collateral for the letter of credit and recorded as restricted cash. The New York lease is classified as an operating lease.
In March 2018, the Company entered into an agreement to lease office space in San Diego, California (the “San Diego Lease”) with aggregate payments of approximately $0.8 million over the term of the lease. The San Diego Lease originally provided for expiration on December 31, 2019. In August 2019, the Company entered into a First Amendment to the San Diego Lease to extend the term of the lease through the commencement of the New San Diego Lease (defined below). The San Diego Lease is classified as an operating lease.
In October 2019, the Company entered into an agreement to lease office space in San Diego, California (the “New San Diego Lease”) with aggregate payments of approximately $4.1 million over the 7.5-year term of the lease. The New San Diego Lease commenced in July 2020. The Company has an option to extend the New San Diego Lease for an additional 5 years at the end of the initial term. Further, the Company provided a standby letter of credit of $0.5 million in lieu of a security deposit during the term of the lease, subject to certain reductions beginning 4 years after the lease commencement. As of December 31, 2020, $0.5 million was pledged as collateral for the letter of credit and recorded as restricted cash. The New San Diego Lease is classified as an operating lease.
The Company recorded lease liabilities and right-of-use lease assets for the operating leases based on the present value of lease payments over the expected lease term, discounted using the Company’s incremental borrowing rate. The options to extend the operating leases were not recognized as part of the Company’s lease liabilities and right-of-use lease assets. As of December 31, 2020, the weighted-average remaining lease term and the weighted-average discount rate for the operating leases was 6.3 years and 4.0%, respectively. Rent expense under leases was $0.8 million for both the years ended December 31, 2020 and 2019. Cash paid for amounts included in the measurement of lease liabilities was $0.6 million for both the years ended December 31, 2020 and 2019.
F-11
ODONATE THERAPEUTICS, INC.
Notes to Financial Statements
Future minimum lease payments under operating leases as of December 31, 2020 are as follows (in thousands):
|
2021 |
|
$ |
859 |
|
|
2022 |
|
|
935 |
|
|
2023 |
|
|
980 |
|
|
2024 |
|
|
1,010 |
|
|
2025 |
|
|
953 |
|
|
Thereafter |
|
|
1,299 |
|
|
Total future minimum lease payments |
|
|
6,036 |
|
|
Less discount |
|
|
(710 |
) |
|
Total lease liabilities |
|
$ |
5,326 |
|
Other Commitments
The Company enters into contracts in the normal course of business with contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments.
Contingencies
From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. Other than as described below, the Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation.
On September 16, 2020, a putative class action lawsuit was filed against the Company, the Company’s Chief Executive Officer and the Company’s current and former Chief Financial Officers. The complaint was filed in the United States District Court for the Southern District of California and alleges that the Company made material misrepresentations and omissions regarding the safety and tolerability of tesetaxel in the Company’s public statements in violation of federal securities laws. The lawsuit seeks damages allegedly sustained by the class and an award of plaintiffs’ costs and attorney fees. The Company believes that the complaint is without merit and that it has substantive defenses to the claims of liability and damages. The Company plans to respond accordingly. Due to the early stage of this matter, the Company is unable to estimate the possible loss or range of loss, if any, that may result from this matter.
5. Stockholders’ Equity
On September 1, 2020, the Company closed an underwritten public offering of 5,614,036 shares of common stock at a public offering price of $14.25 per share (collectively with the underwriters’ option, the “September 2020 Offering”). The underwriters exercised in full their option to purchase 842,105 additional shares of common stock. The aggregate gross proceeds from the September 2020 Offering were $92.0 million, and the net proceeds were $87.4 million after deducting underwriting discounts and commissions and offering costs.
F-12
ODONATE THERAPEUTICS, INC.
Notes to Financial Statements
On June 28, 2019, the Company closed an underwritten public offering of 4,750,000 shares of common stock at a public offering price of $26.00 per share (collectively with the underwriters’ option, the “June 2019 Offering”). On July 2, 2019, the underwriters exercised in full their option to purchase 712,500 additional shares of common stock. The aggregate gross proceeds from the June 2019 Offering were $142.0 million, and the net proceeds were $135.1 million after deducting underwriting discounts and commissions and offering costs.
6. Equity Incentive Plans
2017 Stock Option Plan
In November 2017, the Company adopted the Odonate Therapeutics, Inc. 2017 Stock Option Plan (the “2017 Plan”) in order to grant stock options to directors, officers, employees and consultants of the Company. Recipients of stock options are eligible to purchase shares of the Company’s common stock at an exercise price equal to the fair market value of such stock on the date of grant. The maximum term of options granted under the 2017 Plan is 10 years. Stock options granted prior to July 2019 generally vest over a 4-year period from either the date of grant or the commencement of service and are subject to continued service requirements. Beginning in July 2019, stock options granted generally include a performance condition related to the Company’s development program.
A total of 6,300,000 shares of common stock have been reserved for issuance under the 2017 Plan. As of December 31, 2020, 59,638 shares of common stock remained available for future grants under the 2017 Plan.
2017 Employee Stock Purchase Plan
In November 2017, the Company adopted the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan (the “ESPP”) in order to provide a means for eligible employees to accumulate shares of the Company’s common stock over time through regular payroll deductions. Under the ESPP, eligible employees may purchase shares of the Company’s common stock twice per month at a price equal to 85% of the closing price of shares of the Company’s common stock on the date of each purchase. Eligible employees purchasing shares under the ESPP are subject to an annual cap equal to the lesser of $25,000 or 10% of the employee’s annual cash compensation. Shares purchased under the ESPP cannot be sold for a period of one year following the purchase date (or such shorter period of time if the participating employee’s employment terminates before this one-year anniversary).
A total of 500,000 shares of common stock have been reserved for issuance under the ESPP. As of December 31, 2020, 411,498 shares of common stock remained available for future grants under the ESPP.
Management Plan
In August 2016, the Company adopted the Management Plan in order to allow for directors, officers, employees and consultants of Odonate (the “Management Plan Participants”) to share in the performance of the Company. The incentive units issued under the Management Plan were issued to Odonate Management Holdings, LLC, which issued incentive units to the Management Plan Participants on the same terms and conditions. The incentive units generally vest over a 4-year period from either the date of grant or the commencement of service and are subject to continued service requirements. Generally, on termination of services, unvested incentive units are forfeited. The vested incentive units may be exercised by the Management Plan Participants, with the value received by the Management Plan Participants in the form of cash or shares of common stock equal to the fair market value on the date of exercise less the exercise price of the incentive unit.
The Company issued an aggregate of 2,931,402 incentive units under the Management Plan. Following the Company’s initial public offering in December 2017, the Company has not granted, and will no longer grant, any incentive units. As of December 31, 2020, 1,245,685 outstanding shares of common stock were held by Odonate Holdings to be used to settle incentive units previously issued under the Management Plan.
F-13
ODONATE THERAPEUTICS, INC.
Notes to Financial Statements
Equity Awards
The activity related to equity awards, which are comprised of stock options and incentive units, during the year ended December 31, 2020 is summarized as follows:
|
|
|
Equity Awards |
|
|
Weighted-average Exercise Price per Share |
|
|
Weighted-average Remaining Contractual Term(1) (years) |
|
|
Aggregate Intrinsic Value(2) (millions) |
|
||||
|
Outstanding at December 31, 2019 |
|
|
5,972,765 |
|
|
$ |
18.46 |
|
|
|
|
|
|
|
|
|
|
Granted |
|
|
2,222,814 |
|
|
$ |
18.21 |
|
|
|
|
|
|
|
|
|
|
Exercised |
|
|
(268,752 |
) |
|
$ |
14.48 |
|
|
|
|
|
|
|
|
|
|
Cancelled/forfeited |
|
|
(697,301 |
) |
|
$ |
22.32 |
|
|
|
|
|
|
|
|
|
|
Outstanding at December 31, 2020 |
|
|
7,229,526 |
|
|
$ |
18.16 |
|
|
|
8.7 |
|
|
$ |
31.0 |
|
|
Exercisable at December 31, 2020 |
|
|
2,494,031 |
|
|
$ |
11.69 |
|
|
|
7.5 |
|
|
$ |
21.4 |
|
|
(1) |
Represents the weighted-average remaining contractual term of stock options. The incentive units do not expire. |
|
(2) |
Aggregate intrinsic value represents the product of the number of equity awards outstanding or equity awards exercisable multiplied by the difference between the Company’s closing stock price per share on the last trading day of the period, which was $19.20 as of December 31, 2020, and the exercise price. |
The total intrinsic value of equity awards exercised during the years ended December 31, 2020 and 2019 was $4.7 million and $7.9 million, respectively. The total fair value of equity awards vested during the years ended December 31, 2020 and 2019 was $11.8 million and $14.8 million, respectively.
Equity-based Compensation Expense
For the years ended December 31, 2020 and 2019, the weighted average grant-date fair value per share was $14.66 and $22.83, respectively. The Company estimated the fair value of each stock option on the date of grant using the Black-Scholes option-pricing model with the following assumptions:
|
|
|
Year Ended |
||
|
|
|
December 31, |
||
|
|
|
2020 |
|
2019 |
|
Expected volatility |
|
80–82% |
|
73–80% |
|
Expected term |
|
10 years |
|
6–10 years |
|
Risk-free interest rate |
|
0.6–1.9% |
|
1.7–2.5% |
|
Expected dividend yield |
|
0% |
|
0% |
Expected Volatility. Due to the lack of Company-specific historical or implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar public companies in the life sciences industry. The Company selected the peer group based on comparable characteristics, including development stage, product pipeline and enterprise value. The Company computed historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the equity awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own share price becomes available.
Expected Term. The expected term represents the period that the equity awards are expected to be outstanding. For stock options with service conditions, it is based on the “simplified method” for developing the estimate of the expected term. Under this approach, the expected term is presumed to be the midpoint between the average vesting date and the end of the contractual term. For stock options with a performance condition, it is based on the contractual term.
Risk-free Interest Rate. The Company bases the risk-free interest rate assumption on U.S. Treasury constant maturities with maturities similar to those of the expected term of the equity award being valued.
F-14
ODONATE THERAPEUTICS, INC.
Notes to Financial Statements
Expected Dividend Yield. The Company bases the expected dividend yield assumption on the fact that it has never paid dividends and does not expect to pay dividends in the foreseeable future.
In addition to assumptions used in the Black-Scholes option-pricing model, the Company estimates a forfeiture rate to calculate the equity-based compensation expense for equity awards. The forfeiture rate is based on an analysis of actual and estimated forfeitures.
Under the ESPP, eligible employees may purchase shares of the Company’s common stock twice per month at a price equal to 85% of the closing price of shares of the Company’s common stock on the date of each purchase. The benefit received by the employees, which is equal to a 15% discount on the shares of the Company’s common stock purchased, is recognized as equity-based compensation expense on the date of each purchase.
The classification of equity-based compensation expense is summarized as follows (in thousands):
|
|
|
Year Ended |
|
|||||
|
|
|
December 31, |
|
|||||
|
|
|
2020 |
|
|
2019 |
|
||
|
Equity-based compensation expense: |
|
|
|
|
|
|
|
|
|
Research and development |
|
$ |
8,705 |
|
|
$ |
9,940 |
|
|
General and administrative |
|
|
1,123 |
|
|
|
1,504 |
|
|
Total equity-based compensation expense |
|
$ |
9,828 |
|
|
$ |
11,444 |
|
As of December 31, 2020, total unrecognized compensation cost related to unvested equity awards was $73.4 million, which is estimated to be recognized over a weighted average period of 2.7 years. As of December 31, 2020, there was no unrecognized compensation cost related to shares of common stock issued under the ESPP.
7. Income Taxes
For the years ended December 31, 2020 and 2019, the Company did not recognize a provision for income taxes due to having recorded a full valuation allowance against its deferred tax assets.
The difference between income taxes computed using the U.S. federal income effective tax rate and the provision for income taxes is as follows (in thousands):
|
|
|
Year Ended |
|
|||||
|
|
|
December 31, |
|
|||||
|
|
|
2020 |
|
|
2019 |
|
||
|
Federal statutory rate |
|
$ |
(26,533 |
) |
|
$ |
(23,483 |
) |
|
State taxes, net of federal benefit |
|
|
(8,824 |
) |
|
|
(7,809 |
) |
|
Research and development credits |
|
|
(3,302 |
) |
|
|
(3,333 |
) |
|
Change in valuation allowance |
|
|
37,170 |
|
|
|
33,232 |
|
|
Equity-based compensation expense |
|
|
1,461 |
|
|
|
1,688 |
|
|
Other permanent differences |
|
|
28 |
|
|
|
(295 |
) |
|
Income tax provision |
|
$ |
- |
|
|
$ |
- |
|
F-15
ODONATE THERAPEUTICS, INC.
Notes to Financial Statements
Deferred tax assets are as follows (in thousands):
|
|
|
December 31, |
|
|
December 31, |
|
||
|
|
|
2020 |
|
|
2019 |
|
||
|
Deferred tax assets: |
|
|
|
|
|
|
|
|
|
Net operating loss carryforwards |
|
$ |
82,598 |
|
|
$ |
50,760 |
|
|
Capitalized research and development |
|
|
11,838 |
|
|
|
7,748 |
|
|
Equity-based compensation expense |
|
|
3,201 |
|
|
|
2,276 |
|
|
Other accrued expenses |
|
|
586 |
|
|
|
224 |
|
|
Depreciation and amortization |
|
|
511 |
|
|
|
556 |
|
|
Total gross deferred tax assets |
|
|
98,734 |
|
|
|
61,564 |
|
|
Less valuation allowance |
|
|
(98,734 |
) |
|
|
(61,564 |
) |
|
Total deferred tax assets |
|
$ |
- |
|
|
$ |
- |
|
As of December 31, 2020 and 2019, the Company established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.
As of December 31, 2020 and 2019, the Company had federal net operating loss carryforwards of $293.1 million and $180.1 million, respectively, and state net operating loss carryforwards of $301.4 million and $185.4 million, respectively. Federal and state net operating loss carryforwards recorded before January 1, 2018 will begin to expire in 2037, unless utilized. Federal net operating loss carryforwards recorded after January 1, 2018 will carry forward indefinitely, unless utilized, and state net operating loss carryforwards recorded after January 1, 2018 will begin to expire in 2037, unless utilized.
As of December 31, 2020 and 2019, the Company had federal research and development credit carryforwards of $10.4 million and $6.9 million, respectively, and state research development credit carryforwards of $1.8 million and $1.1 million, respectively. The federal research and development credit carryforwards will begin to expire in 2037, unless utilized, and the state research and development credit carryforwards will carry forward indefinitely, unless utilized.
Pursuant to Section 382 and 383 of the Internal Revenue Code (“IRC”), utilization of the Company’s federal net operating loss carryforwards and research and development credit carryforwards may be subject to annual limitations in the event of any significant changes in its ownership structure. These annual limitations may result in the expiration of net operating loss carryforwards and research and development credit carryforwards prior to utilization. The Company has not completed an IRC Section 382 and 383 analysis regarding the limitation of net operating loss carryforwards and research and development credit carryforwards.
As of December 31, 2020 and 2019, the Company had no unrecognized tax benefits. The Company does not anticipate there will be a significant change in unrecognized tax benefits within the next 12 months.
The Company had no accrual for interest or penalties on the balance sheets as of December 31, 2020 and 2019 and has not recognized interest or penalties in the statements of operations for the years ended December 31, 2020 and 2019.
The Company is subject to taxation in the U.S. and various state jurisdictions. The Company’s tax returns for the tax years 2017 through 2019 are open and are subject to examination by federal and state taxing authorities. The Company is not currently undergoing a tax audit in any federal or state jurisdiction.
8. License Agreement
In 2013, the Company licensed rights to tesetaxel in all major markets from Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), the original inventor of the product. Under the Daiichi Sankyo license agreement, the Company is obligated to use commercially reasonable efforts to develop and
F-16
ODONATE THERAPEUTICS, INC.
Notes to Financial Statements
commercialize tesetaxel in the following countries: France, Germany, Italy, Spain, the United Kingdom and the U.S. The Company is required to make aggregate future milestone payments of up to $31.0 million, contingent on attainment of certain regulatory milestones. Additionally, the Company is obligated to pay Daiichi Sankyo a tiered royalty that ranges from the low to high single digits, depending on annual net sales of tesetaxel. To date, no payments have been made to Daiichi Sankyo under the license agreement. The license agreement and accompanying royalty obligation terminate on a country-by-country basis on the last-to-expire patent in each such country, which the Company expects will be between 2026 and 2031 in the U.S., 2025 and 2030 in European countries and 2025 and 2030 in Japan, depending on the availability and application of patent term extensions.
9. 401(k) Plan
In 2016, the Company adopted a defined contribution 401(k) plan available to eligible employees. Employee contributions are voluntary, determined on an individual basis and limited to the maximum amount allowable under U.S. federal tax regulations. The Company makes a mandatory annual contribution of 3% of the eligible employees’ compensation to the 401(k) plan. In addition, the Company makes matching contributions of up to 6% of the eligible employees’ compensation to the 401(k) plan. For the years ended December 31, 2020 and 2019, the Company incurred costs of $1.2 million and $1.4 million, respectively, related to the 401(k) plan.
F-17